Investigating the Colonisation of Voice Prostheses by Candida albicans Following Total Laryngectomy by Pentland, Daniel
Kent Academic Repository
Full text document (pdf)
Copyright & reuse
Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all
content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions 
for further reuse of content should be sought from the publisher, author or other copyright holder. 
Versions of research
The version in the Kent Academic Repository may differ from the final published version. 
Users are advised to check http://kar.kent.ac.uk for the status of the paper. Users should always cite the 
published version of record.
Enquiries
For any further enquiries regarding the licence status of this document, please contact: 
researchsupport@kent.ac.uk
If you believe this document infringes copyright then please contact the KAR admin team with the take-down 
information provided at http://kar.kent.ac.uk/contact.html
Citation for published version
Pentland, Daniel  (2019) Investigating the Colonisation of Voice Prostheses by Candida albicans
Following Total Laryngectomy.   Doctor of Philosophy (PhD) thesis, University of Kent,.
DOI











Investigating the Colonisation of Voice Prostheses by 
Candida albicans Following Total Laryngectomy  
 
 








No part of this thesis has been submitted in support of an application for any degree or other 
qualification at the University of Kent, or any other University or Institution of learning. 
 
 















I would like to thank Dr. Campbell Gourlay and Prof. Fritz Mühlschlegel for the opportunity to 
work on this PhD project and for their outstanding support and guidance. Dr. Campbell 
Gourlay has been an excellent mentor throughout my PhD; he has offered an enormous 
amount of insight, patience and encouragement. I would like to express my gratitude to him 
for inspiring me and making my PhD a wonderful experience.     
I want to thank my friends and colleagues in the Kent Fungal Group and the School of 
Biosciences who have helped me in so many ways and made it a privilege to be part of this 
laboratory. I would also like to say a huge thank you to Hannah Chapman, who has supported 
me through ups and downs, listened to a ridiculous amount of practice presentations and 
always offered invaluable advice.    
Finally, I want to thank the Kent Cancer Trust along with the University of Kent 50th 
















A total laryngectomy is a surgical procedure for the treatment of advanced laryngeal cancer. 
The vocal cords are removed during the procedure, leaving patients with an inability to form 
speech. The gold standard of speech rehabilitation involves the use of small silicone valves 
called voice prostheses (VPs) which are inserted into the throat. C. albicans is a major 
coloniser of VPs, often being found in polymicrobial biofilms, causing loss of device function 
as well as creating a reservoir for infections. As a result, VPs have to be regularly changed at 
great patient stress and clinical cost. In this study, we present precision antifungal-focussed 
treatment guidelines which significantly increase VP in situ lifespan from a mean of 71.9 to 
192.0 days, a 2.7-fold increase, in a 20 patient cohort. In addition, we find that the high CO2 
environment of the throat (due to the CO2 content of exhaled breath) increases the biofilm-
forming capacity of C. albicans. All stages of biofilm growth (attachment, maturation and 
dispersal) are enhanced in 5% CO2 and this is accompanied by increased antifungal tolerance; 
providing a possible explanation for the success of C. albicans in the VP niche. Finally, we 
explore potential treatment options for high CO2 biofilms, identifying the glycolytic inhibitor 
2-deoxyglucose as a promising candidate. Overall, our study characterises a clinically relevant 
CO2-mediated increase in C. albicans biofilm formation which could influence future biofilm 
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Modern medicine has seen an increase in the development and use of indwelling medical 
devices such as voice prostheses (VPs), catheters, dentures, tracheostomy tubes and many 
others. The use of such devices, on either a temporary or permanent basis, has prolonged and 
improved the quality of life for numerous patients. However, a common complication 
surrounding the use of indwelling devices is their susceptibility to colonisation by 
microorganisms, often leading to device failure as well as providing a reservoir of potential 
pathogens. Indeed, it has been estimated that 60-70% of nosocomial infections are associated 
with medical devices [1]. Colonisation of an indwelling medical device normally requires 
device removal sometimes accompanied with antimicrobial therapy, making medical device 
management and infection prevention very expensive. A variety of microorganisms, both 
bacterial and fungal, have been observed to colonise medical devices. For instance, 
Staphylococcus aureus and Staphylococcus epidermidis commonly colonise central venous 
catheters [2], while Escherichia coli is a prevalent coloniser of urinary catheters [3]. Candida 
species, particularly Candida albicans, are widespread fungal colonisers of many medical 
devices including voice prostheses, central venous catheters, dentures, tracheostomy tubes, 
and urinary catheters [4]. 
        
1.1 Candida albicans 
C. albicans is a member of the Saccharomycetaceae family of ascomycete fungi and is 
distantly related to the prototypical yeast species Saccharomyces cerevisiae [5]. C. albicans is 
a commensal organism located on the mucosal surfaces of the oral cavity, gastrointestinal 
tract and genitourinary tract of most healthy individuals [6][7]. Despite being a commensal 
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organism, it is also an opportunistic pathogen [6][8]; in fact, it is the most widespread of all 
the human fungal pathogens [9]. Infection with C. albicans is particularly a problem among 
immunocompromised individuals or persons with implanted medical devices such as 
catheters or voice prostheses [10][11]. 
 
1.1.1 Genetics of C. albicans  
C. albicans has a diploid genome of approximately 32Mb which is divided between eight pairs 
of chromosomes [12]. Within this diploid genome there are several genes which have 
homologues in S. cerevisiae, however, there are also numerous other genes with no S. 
cerevisiae homologues [6]. These genes with no obvious S. cerevisiae homolog are thought to 
be promising candidate genes essential for human interactions. This is because the majority 
of S. cerevisiae strains are not able to adhere to, or invade, human tissues. The products of 
these genes, especially those of genes which also do not have human homologues, could 
represent favourable targets for antifungal therapies [6]. 
 
An unusual characteristic of the C. albicans genome is the fact that the CUG codon encodes 
serine instead of leucine [13]. Species which have this abnormality within their genetic code 
are grouped into the CUG clade. Alongside C. albicans in this clade are other pathogenic 
Candida species such as Candida parapsilosis and Candida tropicalis [14]. 
 
It has been reported that clinical isolates of C. albicans exhibit a variable karyotype [15]. This 
phenomenon was first described by Magee and Magee in 1987 [12]. Changes in karyotype 
have been proposed as a mechanism to survive in conditions of stress, for instance, strains of 
C. albicans growing on L-sorbose often lose one of their chromosome 5s. Upon return to a 
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glucose-containing medium, the remaining chromosome 5 is replicated, restoring the number 
of chromosomes to normal [16]. Likewise, strains which are resistant to fluconazole (a triazole 
antifungal often used to treat C. albicans infections) tend to have higher occurrence of loss of 
chromosome 4 or gain of chromosome 3 [17]. Janbon, G. et al. suggest that the genome of C. 
albicans contains a reservoir of genes whose expression is governed by chromosome number 
[16]. These genes could regulate crucial functions, such as alternative carbon source 
utilisation, which become necessary under certain stress conditions. 
 
1.1.2 Life cycle of C. albicans  
Candida albicans was traditionally considered to be asexual, only existing as an obligate 
diploid [18]. However, it has now been discovered that mating occurs between diploid mating 
type-like (MTL) a and α strains in this organism, producing an a/α tetraploid product [18]. 
While this is similar to the mating program in Saccharomyces cerevisiae (two haploid mating 
types; a and α which combine to generate an a/α diploid product) [19] it differs in several key 
respects.     
 
Mating in C. albicans is reliant on a reversible phenotypic switch between two states termed 
‘white’ and ‘opaque’. Only the ‘opaque’ state is capable of mating efficiently; ‘opaque’ cells 
have been demonstrated to mate approximately 106 fold more readily than ‘white’ cells [20]. 
‘White’ cells are fairly round and form white, dome-shaped colonies on solid agar, they also 
express a specific set of genes. In contrast, ‘opaque’ cells tend to be larger and more oblong, 
forming darker colonies which grow flatter against solid agar. ‘Opaque’ cells also express a 




This unusual mating program involving a reversible phenotypic switch hitherto seems to be 
unique to C. albicans as well as the very closely related fungal species Candida dubliniensis 
[22]. It appears that ‘white’ cells are better suited for growth and survival within a mammalian 
host; ‘opaque’ cells are unstable at temperatures above 35oC and primarily colonise skin [23]. 
Therefore, it is likely this unusual mating program has evolved to allow Candida albicans to 
survive the variety of environments within a mammalian host while still being able to produce 
mating-competent cells [20].    
 
Only C. albicans cells which are homozygous at the MTL locus (a/a or α/α) are capable of 
reversibly switching between ‘white’ and ‘opaque’ states, and are thus capable of efficient 
mating [18]. This is because two homeodomain proteins called Mtla1 and Mtlα2, encoded by 
the MTLa and MTLα alleles respectively (Figure 1.1), work together to inhibit white-opaque 
switching [20]. These proteins are both present in MTL heterozygous cells (a/α) and thus 
white-opaque switching cannot occur, only one of these two proteins is present in MTL 
homozygous cells, meaning white-opaque switching is not suppressed and mating (between 
a/a cells and α/α cells) can take place. Since the MTL locus controls both white-opaque 
switching and the mating type of C. albicans cells, it ensures switching only occurs in mating-
competent cells, i.e. does not occur in MTL heterozygous cells since these cells are not capable 
of mating anyway [24]. It is important to note that only certain C. albicans strains, such as 
strain WO-1, exhibit efficient white-opaque switching; the common laboratory strain CAl4 
does not switch (it is fixed in the ‘white’ state) because it is MTL heterozygous [20]. It has 
however been demonstrated that CAl4 a and α strains, generated from directed mutagenesis 
of the MTLα1 and MTLα2 or MTLa1 genes respectively, are capable of white-opaque 












In the life cycle of Saccharomyces cerevisiae, the a/α diploid product of mating returns to a 
haploid state through meiosis [19]. However, there does not appear to be a meiosis step in 
the life cycles of Candida species, despite the presence of a number of genes in the genome 
which are homologous to genes involved in meiosis in S. cerevisiae [24]. Instead, the 
tetraploid Candida albicans offspring employs a parasexual mechanism to return to a normal 
diploid state [24]. This involves the random and cooperative loss of chromosomes, resulting 
in genetically varied progeny with a range of phenotypes [18].  
 
Furthermore, Forche, A. et al. discovered that, although meiosis does not occur in Candida 
albicans, recombination between homologous chromosomes does. The recombination relies 
upon Spo11, a highly conserved protein which is responsible for the formation of double-
strand DNA breaks during conventional meiosis in eukaryotes. This genetic recombination 
carried out by Spo11 during the parasexual cycle of Candida albicans is likely to have evolved 
to increase genetic diversity without the need for meiosis [18].   
 
Figure 1.1: The Mating-type like (MTL) locus of Candida albicans. The MTLa allele is made up of 
8746 base pairs and encodes four different proteins, the Mtla1 protein (gene abbreviated to a1 
in the figure) is an important homeodomain protein associated with white-opaque switching. The 
MTLα allele is made up of 8861 base pairs and encodes five different proteins, the homeodomain 
protein Mtlα2 and another transcriptional regulatory protein Mtlα1 (gene abbreviated to α2 and 
α1 respectively in the figure) are also crucial in white-opaque switching. Key: PAP – poly(A) 
polymerase, PIK – phosphatidyl inositol kinase, OBP – protein with similar sequences to oxysterol 
binding proteins. Figure adapted from Figure 1 in Miller, M. et al. [20]. 
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A key trait of C. albicans is its ability to grow as a biofilm upon both biotic and abiotic surfaces 
(see Section 1.3); this is crucial to the success of C. albicans in colonising medical devices such 
as voice prostheses. MTL homozygous ‘opaque’ cells only form very thin and fragile biofilms 
[25], whereas MTL homozygous ‘white’ cells form robust biofilms with similar architecture to 
MTL heterozygous biofilms [26]. Despite the similar architecture, MTL homozygous ‘white’ 
biofilms display unique pathogenic characteristics. a/α biofilms are impermeable to 
molecules ranging from 300Da to 140kDa, impenetrable to polymorphonuclear leukocytes, 
and tolerant to antifungals. However, the opposite is true for a/a or α/α biofilms [26]. 
Clinically this implies biofilms composed of mating-competent cells could be easier to treat 
and may not persist in the host as long as a/α biofilms. Consistent with this, natural C. albicans 
a/α strains exhibit increased virulence and competitive fitness in a mouse model for systemic 
infection compared to their spontaneous MTL homozygous offspring [27].  
 
Interestingly, biofilm formation is regulated by different signalling pathways in MTL 
homozygous and heterozygous cells. a/α biofilms are regulated by the Ras1-Cyr1-PKA 
pathway (see Section 1.2.1) whereas a/a and α/α biofilms are regulated by the MAP kinase 
pathway (see Section 1.2.2) [26]. The MAP kinase pathway also regulates the pheromone 
response during mating and it has been shown that α-pheromone induces ‘white’ a/a cells to 
attach to plastic and silicone surfaces and promotes biofilm maturation [25]. Moreover, the 
addition of 10% of ‘opaque’ cells (in a 50:50 ratio of a/a and α/α) to majority MTL homozygous 
‘white’ cells increases biofilm development by up to 59% [25]. It has been hypothesised that 
biofilms mostly composed of ‘white’ cells facilitate the mating between minority ‘opaque’ 
cells embedded in the matrix by protecting pheromone gradients that direct chemotropism 
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during the mating process. This could be the reason ‘white’ cells respond to mating 
pheromones even though they themselves cannot efficiently mate [25].  
 
1.1.3 Pathogenicity of C. albicans 
As previously stated, C. albicans is the most widespread, and hence the most important, of all 
the human fungal pathogens [9]. Although it is normally a harmless member of normal human 
microflora (it is present on the skin and mucosal surfaces of 30-70% of healthy individuals) 
[28], it can opportunistically cause infection. Candida albicans infections are primarily a 
problem among immunocompromised persons such as HIV/AIDS patients or in hospital 
patients who have indwelling medical devices such as catheters [6]. The  eradication of other 
competing commensals following antibiotic treatment can also cause people to become 
susceptible to Candida infections [6]. Furthermore, it is well documented that Candida 
species, particularly C. albicans, form biofilms on voice prostheses in total laryngectomy 
patients [10].   
 
The infections caused by C. albicans range from superficial infection of mucosal surfaces 
(commonly referred to as candidiasis) to a full systemic infection called candidaemia which 
can advance to disseminated candidiasis whereupon fungal growths can occur within internal 
organs such the kidney, heart and brain [6]. The most well-known candidiasis infection is 
pseudomembranous candidiasis, more commonly referred to as thrush. The symptoms 
include white spots which, upon removal, reveal a region of inflammation in the underlying 
membrane. These infections frequently affect mucosal membranes of the vagina, 
oropharynx, oesophagus and intestine [5]. A particularly prevalent form of 
pseudomembranous candidiasis is vulvovaginal candidiasis (VVC) which by some estimations 
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may affect as many as 75% of women at some point during their life time [5]. Another well 
described pseudomembranous candidiasis is oral-pharyngeal candidiasis (OPC). This form of 
candidiasis is especially a problem in immunocompromised individuals; it is extremely 
common amongst AIDS patients, so much so that the onset of OPC is regarded as a marker of 
AIDS development in HIV patients [29]. 
 
Superficial mucosal surface infections can be readily treated with a range of antifungals. For 
example, VVC is usually successfully treated with azole antifungals like fluconazole and 
albaconazole [5]. However, candidaemia is extremely dangerous and can be fatal; even after 
treatment with first line antifungals such as fluconazole, it is still linked to a high mortality 
rate [30]. As with many C. albicans infections, weakened immune defences are a significant 
risk factor for developing candidaemia. In healthy individuals, neutrophils provide suitable 
defence against C. albicans in the blood. As such, neutropenia, either as a result of particular 
blood cancers or treatment with immunosuppressants, significantly increases the risk of 
developing candidaemia. Furthermore, damage to the mucosa of the gastrointestinal tract, 
for example due to surgery, is also a risk factor as it enables the spread of C. albicans living in 
the gastrointestinal tract [31]. The symptoms of candidaemia range from fever and chills 
which do not abate following antibiotic treatment to severe sepsis or septic shock similar to 
that of bacterial septicaemia [5]. However, sometimes there is a lack of precise symptoms 
which is a major reason for the high mortality since diagnosis may occur too late for antifungal 
therapies [32]. It has been reported that even a delay of as little as 12-24 hours can double 
mortality rate [33]. Due to this, it has become common practice to prophylactically administer 
antifungals after any event which is likely to increase the risk of candidaemia, such as after 




Although the majority of cases of candidiasis and candidaemia are caused by C. albicans, there 
are other species within the Candida genus which are also pathogenic in humans. These 
include Candida glabrata, Candida tropicalis, Candida dubliniensis and Candida parapsilosis.  
Candida species have increasingly become associated with nosocomial infections [8]; in fact, 
Candida albicans is recognised as the fourth most common cause of all hospital-acquired 
infections in the USA [6]. 
 
1.1.4 Iron homeostasis in C. albicans 
C. albicans is able to colonise a wide range of niches within the host, both as a commensal 
and a pathogen, all with highly variable micronutrient availabilities. Iron is an essential 
micronutrient for virtually all life on Earth; it is required in the form of haem and iron-sulphur 
clusters for the activity of several cellular proteins, such as enzymes involved in amino acid 
biosynthesis, complexes of the mitochondrial electron transport chain, and enzymes involved 
with lipid biosynthesis [34]. Despite being so essential, high-iron levels result in cellular 
toxicity due to the production of reactive oxygen species via the Fenton reaction [35].   
 
Bioavailable iron is found at extremely low concentrations in the blood (approximately 10-
15nM Fe3+) [36] but is highly abundant in the gastrointestinal tract [37]. Mammalian hosts 
actively sequester iron through its binding to several proteins (see below), thus limiting its 
bioavailability to potential pathogens. This process is termed ‘nutritional immunity’ and forms 
an important part of host defences against pathogenic microorganisms [38]. Consequently, 
an ability to acquire sufficient amounts of iron from the host sequestration molecules is a 
prerequisite for a microorganism to become pathogenic. This is even more complex for 
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microorganisms which can be both commensal and virulent since they have to survive in both 
high- and low-iron environments. The opportunistic pathogen C. albicans has therefore 
evolved mechanisms to obtain sufficient iron in iron-scarce environments (as an invasive 
pathogen in the blood or tissues), while protecting against iron-toxicity in surroundings where 
iron is plentiful (as a commensal in the gastrointestinal tract) [39].   
 
1.1.4.1 C. albicans iron acquisition mechanisms  
C. albicans possesses an array of iron-uptake machinery; including direct acquisition from host 
proteins/molecules, a reductive iron-uptake system similar to that in S. cerevisiae of free or 
chelated Fe3+, and a siderophore import system. 
 
Upon entry into the free iron-poor environment of the blood, C. albicans is able to acquire 
iron directly from haemoglobin molecules where the majority of the bloodstream iron is 
found. C. albicans has been observed to lyse erythrocytes, releasing the haemoglobin [40]. 
After which a C. albicans cell surface receptor, Rbt5, binds to the haemoglobin [41] and 
internalises it via endocytosis as Rbt5-haemoglobin complexes [42]. The haem oxygenase 
Hmx1 is required to release the haemoglobin-bound ferrous iron within the cell [43] (Figure 
1.2).  
 
The small amount of extracellular non-haemoglobin bound iron in the blood is bound by an 
iron-chelating glycoprotein called transferrin, and this serves as the major iron delivery 
system for the host [44]. C. albicans has exhibited utilisation of host transferrin as a source of 
iron in vitro [45]. Certain pathogenic bacteria, such as those from the Neisseriaceae and 
Pasteurellacea families, possess a specific transferrin receptor (composed of the proteins 
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TbpA and TbpB) [46]. It is unclear whether C. albicans has a similar mechanism for transferrin 
usage, although the fact direct contact with transferrin is required suggests it probably does. 
The ferric iron (Fe3+) obtained from the transferrin enters the C. albicans cells via a reductive 
iron-uptake system highly conserved with that of S. cerevisiae [45]. Ferric reductases, Cfl1 and 
Cfl95, in the plasma membrane reduce the Fe3+ to Fe2+ [47]. This Fe2+ is then oxidised back to 
Fe3+ by a multicopper ferroxidase, e.g. Fet31, which is complexed to an iron permease called 
Ftr1 that transports the Fe3+ into the cell [48]. The activity and proper assembly of the 
multicopper ferroxidase enzymes with the iron permeases relies on Cu2+ which is supplied by 
















Figure 1.2: The three pathways of iron-acquisition in C. albicans.  The reductive uptake pathway is 
responsible for the uptake of soluble Fe3+ in the environment as well as that obtained from ferritin 
and transferrin. Siderophore uptake involves the uptake of small Fe3+ chelators called siderophores. 
Haemoglobin uptake enables C. albicans to utilise Fe2+ from host haemoglobin molecules. Figure 
taken from Figure 1 in Chen, C. et al. [56]. 
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Within host tissues the majority of iron is bound to the protein ferritin. C. albicans is able to 
obtain iron from directly ferritin in vitro, either from exogenously provided ferritin or from 
epithelial cells in culture, in a mechanism involving the cell-surface adhesin Als3 [50]. Als3 is 
a hyphal-specific protein which accumulates ferritin on the surface of hyphal C. albicans cells. 
Yeast-form cells are unable to bind ferritin, meaning the yeast-to-hyphal switch is crucial for 
the use of ferritin-derived iron [50]. After ferritin aggregation, C. albicans was observed to 
acidify culture media to dissociate Fe3+ from the ferritin, likely by destabilising its tertiary 
structure [50]. The dissociated Fe3+ enters the fungal cell using the same reductive iron-
uptake system detailed above [50] (Figure 1.2). As discussed in Section 1.4.2, Als3 also plays 
major roles in C. albicans cell adhesion and biofilm formation, suggesting this single protein 
is responsible for multiple virulence attributes and provides a link between virulence and iron 
acquisition. Indeed, an als3∆/∆ null mutant displayed severely attenuated virulence in a RHE 
oral candidiasis model [51], however, had wild-type virulence levels in a murine bloodstream 
infection model [52].  
 
The final method of iron acquisition by C. albicans involves siderophore uptake (Figure 1.2). 
Siderophores are small high-affinity Fe3+ chelators which several pathogenic bacteria and 
fungi synthesise to scavenge iron from their environment [53]. C. albicans is quite unusual in 
that it possesses a siderophore importer, Sit1 [54], but its genome does not encode the known 
fungal siderophore biosynthetic enzymes [55]. Thus, C. albicans is able to utilise exogenous 
siderophores [54], such as those synthesised by other microorganisms, but does not appear 
to produce its own. Siderophore activity seems to be more important for C. albicans iron 
acquisition within host tissues as a sit1∆/∆ null mutant has reduced virulence in a RHE 
infection model but not in a murine bloodstream infection model [54]. 
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1.1.4.2 Regulation of iron homeostasis in C. albicans   
 In order to obtain sufficient iron in iron-limiting environments while at the same time 
protecting from iron-toxicity in iron-replete surroundings, C. albicans must be able to quickly 
and robustly switch from aggressive iron-uptake to significantly reducing or halting it 
altogether and vice versa. Unsurprisingly, this switch is under very tight control both at a 
transcriptional and post-translational level.  
 
A transcriptional regulatory network composed of the transcription factors Sfu1 and Sef1, 
along with the CCAAT-binding HAP complex precisely regulates iron homeostatic genes in 
response to surrounding iron levels [56][57]. In low-iron environments, such as that of the 
bloodstream, the expression of SEF1 is increased, the Sef1 transcription factor in turn 
upregulates components of all three of the major C. albicans iron-uptake pathways 
(haemoglobin uptake, reductive iron uptake, and siderophore uptake) [56]. The increase in 
SEF1 expression relies upon indirect control by the HAP complex via the transcriptional 
repressor SFU1 which represses SEF1 and iron-uptake genes. Upon iron-deprivation, the 
expression of the HAP complex component gene HAP43 (CAP2) is elevated [57]. The genes for 
the other HAP complex components, HAP2 and HAP3 (HAP32), are also upregulated, and the 
expression of HAP5 maintained, in a Hap43-dependent manner. The four components; 
Hap43, Hap2, Hap3 and Hap5 come together to form the HAP complex which is responsible 
for the repression of SFU1 and iron-utilisation genes [57]. In this way, the transcriptional 
repressor HAP complex is able to indirectly activate iron-uptake pathways. Sef1 also directly 
activates HAP43 in a positive-feedback loop [56]. Under iron-replete conditions, the HAP 
complex is not active [57], meaning Sfu1 is able to repress SEF1 and hence reduce the 
expression of iron-uptake genes [56]. 
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In addition to the transcriptional control, Sef1 is also subject to post-translational control in a 
circuit with Sfu1 (functioning in a transcriptional-independent role) and the cyclin-dependent 
kinase Ssn3 [58] (Figure 1.3). In iron-replete environments, Sfu1, in addition to acting as a 
transcriptional repressor as detailed above, forms a complex with Sef1 in the cytoplasm. This 
prevents Sef1 entering the nucleus and leads to its degradation, thus allowing Sef1 activity to 
be rapidly halted when C. albicans cells have sufficient iron in order to avoid iron-related 
toxicity [58]. Conversely, in iron-deplete environments Sef1 forms a different complex with 
Ssn3, resulting in its phosphorylation, nuclear localisation and transcriptional activity [58] 












Figure 1.3: Post-translational control of Sef1 by Sfu1 and Ssn3. In iron-replete media, Sef1 is 
sequestered in the cytoplasm by Sfu1 where it is degraded. In iron-deplete media, Sef1 is 
phosphorylated by Ssn3, promoting its stabilisation and translocation into the nucleus where it 
can active iron-uptake genes. Figure adapted from Figure 4 in Chen, C. et al. [58]. 
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Overall, Sef1 protects against iron-limitation while Sfu1 protects against iron-toxicity, and due 
to these opposing roles they have differing roles in virulence. For instance, Sef1 is required 
for virulence and survival in the bloodstream; a sef1∆/∆ mutant exhibited a significant 
virulence defect in a murine intravenous infection model but a sfu1∆/∆ mutant did not [56]. 
Likewise, in a competitive fitness mouse infection model for persistence in host tissues, the 
sef1∆/∆ mutant was significantly outcompeted by the wild-type. However, the sfu1∆/∆ 
mutant displayed a significant competitive advantage against the wild-type, presumably due 
to an increased ability to take up extracellular iron [56]. Both Sef1 and Sfu1 appear to 
contribute to commensalism since in a murine gastrointestinal infection model (which mimics 
commensalism) both null mutants displayed significant competitive defects compared to 
wild-type. The sfu1∆/∆ mutant showed the most pronounced effect, possibly indicating that 
Sfu1 is the most important for commensalism [56]. Consistent with this, Pande, K. et al. 
discovered that passage of C. albicans through the murine gastrointestinal tract elicited a 
phenotypic switch to a novel commensal cell type which the authors called GUT 
(Gastrointestinally-IndUced Transition) [59]. These GUT cells have enhanced fitness within the 
murine gastrointestinal tract and exhibited increased transcript levels of SFU1 with decreased 
transcript levels of SEF1 and iron-uptake genes, consistent with the relative abundance of iron 
in the GI tract [59].         
 
These murine model experiments demonstrate the clear link between iron homeostasis and 
C. albicans virulence. This link extends beyond Sef1-mediated iron uptake in low-iron host 
niches; Als3 for instance has key direct roles in virulence in addition to its function in iron-
acquisition. It has even been argued that C. albicans uses the iron-status of its surroundings 
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to identify where it is in the mammalian host and thus whether it should express virulence or 
commensal factors [39].  
 
1.2 Candida albicans Morphogenesis and Signalling Pathways  
An important aspect of C. albicans biology, in terms of pathogenesis, is its ability undergo 
morphogenesis from a yeast, to pseudohyphal or hyphal forms in response to environmental 
cues (Figure 1.4). The virulence of C. albicans is closely linked with the capacity to switch 
between these forms; hyphal C. albicans cells are frequently located at sites of tissue invasion, 
and moreover, cells which are unable to readily form hyphae exhibit reduced virulence [6]. In 
particular, other Candida species which do not commonly produce true hyphae are not often 
isolated from human tissues, implying a decreased virulence. However, as strains that are 
incapable of growing in the yeast form also have less virulence it has been proposed that both 
the yeast and hyphal forms play important roles during infection [60][61]. For instance, hyphal 
cells express specific cell wall proteins, such as Hwp1 [62], which enable attachment to human 
tissues and subsequent tissue invasion. Other hyphal cell wall proteins, for example Hyr1 [63], 
also contribute to the avoidance of neutrophil- and macrophage-mediated phagocytosis. On 
the other hand, yeast cells seem to be crucial for dissemination into the bloodstream and the 





1.2.1 The Ras1-Cyr1-PKA pathway 
There are several signalling pathways which induce the C. albicans morphogenic switch by 
transducing environmental signals from the exterior to the interior of the cell (Figure 1.5), 
including the Ras1-Cyr1-protein kinase A and the mitogen-activated protein kinase (MAPK) 
pathways [6]. Ras signalling is crucial to the integration of environmental cues with 
morphogenesis and C. albicans possesses two Ras genes - RAS1 and RAS2, which encode the 
small GTPase Ras1 and a highly divergent Ras-like protein termed Ras2 [65]. The importance 
of Ras1 signalling to the virulence of C. albicans is demonstrated by the fact that mutants 
Figure 1.4: The three different morphological forms of Candida albicans. Yeast cells have a rounded 
shape and can bud and separate from each other. Pseudohyphal cells are more elongated and 
remained attached to each other at a constricted site called the septation site. It is believed that the 
branching growth pattern of pseudohyphal cells enables acquisition of nutrients that are away from 
the parental colony. Hyphal cells are very long and polarised with no noticeable constrictions between 
cells. The elongating structure from the round yeast cell when it is induced into true hyphal growth is 
called a germ tube. The blue lines in the diagram represent the nucleus in each cell morphology and 
the green bands represent the septin rings which form at the boundary between the mother and 
daughter cells. Figure adapted from Box 1 in Berman, J. et al. [6].  
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which lack Ras1 are defective in their ability to undergo hyphal transition and exhibit reduced 
virulence in mouse infection models [66]. Ras signalling is now known to mediate the 
induction of hyphal growth in response to a variety of environmental cues including growth 
at 37oC (via alleviation of Hsp90-mediated repression of the Ras1-Cyr1-PKA pathway) 



















Figure 1.5: Summary of the signalling pathways and stimuli which regulate the yeast-to-hyphae 
morphogenic switch in Candida albicans. Several different pathways are responsible for inducing the 
yeast-to-hyphae switch: MAP kinase pathway (green), Cyr1-PKA pathway (blue), pH response pathway 
(red), and matrix response pathway (orange). There are also two pathways which negatively regulate the 
switch: Tup1-Nrg1-Rpg1 pathway (purple) and Rbf1 pathway (grey). The environmental conditions which 




Upon activation, Ras1 directly interacts with and activates Cyr1 (the C. albicans adenylate 
cyclase), causing an increase in the production of the second messenger cAMP [66]. cAMP 
causes the derepression of two isoforms of protein kinase A (PKA) by triggering the 
dissociation of the PKA regulatory subunit (Bcy1) from the catalytic subunits (Tpk1 or Tpk2). 
The activation of PKA stimulates several processes within the cell including the yeast-to-
hyphae switch [28]. PKA is believed to phosphorylate the transcription factor Efg1 on 
threonine-206, thereby activating it and resulting in the expression of HSGs [72]. The Tpk1 
and Tpk2 isoforms have some redundant functions in C. albicans, however, they have also 
been demonstrated to have specific roles. For instance, Tpk1 is necessary for the formation 
of hyphae on solid media but not in liquid media, while the opposite is true for Tpk2. Tpk2 is 
also required for agar invasion but Tpk1 is not [73]. Moreover, Tpk2 seems to play more of a 
role in biofilm formation as a tpk2Δ/Δ mutant exhibited attenuated adhesion to a polystyrene 
surface and hence formed less dense biofilms [74]. A recent phosphoproteomic study using 
tpk1Δ/Δ, tpk2Δ/Δ, and a tpk1Δ/Δtpk2Δ/Δ double mutant identified 31 predicted Tpk1-specific 
phosphorylation sites and 27 predicted Tpk2-specific sites. Cell wall, membrane and 
signalling-related proteins were enriched in the Tpk1-specific targets, whereas filamentation 
and transporter-related proteins were enriched in the Tpk2-specific targets. This study also 
found 68 predicted Tpk-redundant phosphorylation sites [75]. 
 
A number of environmental signals promote the yeast-to-hyphae switch via the Ras1-Cyr1-
PKA pathway. Some of these signals, including CO2 interface directly with the Cyr1 adenylate 
cyclase to activate it [69]. CO2 is able to do this because, unlike most signalling molecules, it 
is able to enter the cell by simple diffusion and is maintained in the cell as HCO3- via conversion 
by a carbonic anhydrase encoded by NCE103 [69]. It has recently been discovered that the 
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expression of NCE103 is controlled in response to CO2 availability by the bZIP transcription 
factor Rca1; Rca1 is regulated in a CO2-dependent manner by the Sch9 kinase via a cascade 
mediated by lipid/Pkh1/2 signalling [76]. A lysine residue at position 1373 is critical for CO2 
activation of Cyr1. This lysine residue is located in the C-terminal catalytic domain and makes 
up a receptor site which detects increased HCO3- levels [77], leading to increased cAMP 
production and activation of  PKA filamentation [69]. The response of C. albicans to CO2 is of 
interest because within a mammalian host, the levels of CO2 are approximately 150x that of 
normal air (~5% compared to 0.03%). It could be the case that high levels of CO2, such as those 
found within the upper respiratory tract (where voice prostheses are located), may promote 
C. albicans colonisation. However, it is interesting to note that other pathogenic Candida 
species, including C. dubliniensis, C. glabrata, C. parapsilosis and C. krusei, do not undergo the 
yeast-to-hyphae transition in response to elevated CO2 [78]. Although this does not rule out 
the fact that the adenylate cyclase of the latter species is activated by carbon 
dioxide/bicarbonate; the physiological significance of CO2 sensing with regards to Candida 
infection remains to be determined.  
 
Furthermore, it appears that CO2 is used as a communication molecule in C. albicans 
biomasses. In addition to the host-derived CO2, microorganisms themselves produce and 
secrete metabolic CO2 into their immediate microenvironment. It was observed by Hall, R. et 
al. that in C. albicans biomasses, metabolic CO2 initially provides HCO3- as a metabolic 
intermediate, thereby supporting growth, but eventually accumulates to sufficient levels to 
induce filamentous growth via activation of Cyr1 [77]. Given the well-known connection 
between C. albicans morphogenesis and virulence, along with the fact that C. albicans cells 
are often found in mixed biofilms on medical devices such as voice prosthesis, it would seem 
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likely that this new found role of metabolically derived CO2 contributes to pathogenicity by 
increasing host tissue invasion via morphogenic switching (Figure 1.6) as well as supporting 











Muramyl dipeptide (MDP), the minimal biologically active subunit of bacterial peptidoglycan, 
also induces C. albicans filamentation by acting directly upon Cyr1 [79]. A further signal which 
can cause morphogenesis through direct interaction with Cyr1 are amino acids. Amino acids, 
when in the presence of glucose, activate Cyr1 via upstream signalling through the G-protein 
coupled receptor Gpr1 and its Gα protein Gpa2 [80]. Upon its activation by Gpr1, Gpa2 is 
believed to bind to a Gα domain on the Cyr1 adenylate cyclase thereby activating it [80]. This 
binding of Gpa2 to a fungal adenylate cyclase Gα domain has been demonstrated in fission 
yeast [81] but it is yet to be proved experimentally in C. albicans.   
 
Figure 1.6: Model for how metabolic CO2 signalling may contribute to the pathogenicity of Candida 
albicans. Cells proliferate on the epithelial surface, the fungal growth results in pockets of elevated 
CO2 at the bottom of the biomass. This elevated CO2 induces cells to undergo the yeast-to-hyphae 
switch, promoting hyphal growth and thus increasing the surface adherence of the cells. At the same 
time, protruding hyphae detect a range of host environmental signals including serum, pH, and more 
CO2, further enhancing filamentation and subsequent tissue invasion. Figure adapted from Figure 7 
in Hall, R. et al. [77].  
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In contrast, acidic pH causes a reduction in signalling through the Ras1-Cyr1-PKA pathway via 
a Ras1-independent downregulation of Cyr1 activity [82]. C. albicans cells grown at pH 4 in 
hyphae-inducing conditions do not form hyphae, instead remaining as yeast or pseudohyphal 
cells and this is not reliant upon Ras1. It has also been observed that low extracellular pH 
results in fast and sustained decreases in intracellular pH which potentially contributes to 
reduced cAMP signalling through the reduction of intracellular bicarbonate levels [82].    
 
The yeast-to-hyphae switch in response to exposure to serum relies on Ras1 signalling 
upstream of Cyr1 [71]. The component of serum principally responsible for the induction of 
hyphal growth is D-glucose which is able to activate both the Ras1-Cyr1-PKA pathway and the 
MAP-kinase pathway [71][83]. The precise mechanism of Ras1 activation by D-glucose in C. 
albicans remains to be elucidated but in S. cerevisiae it depends on both an intracellular 
phosphorylated form of D-glucose and a G-protein coupled receptor Gpr1 with its Gα protein 
Gpa2 [84]. Gpr1-type receptors have been characterised in C. albicans [80] and so a similar 
mechanism for Ras1 activation may exist in this pathogen. However, deletion of either CaGpr1 
or CaGpa2 had no effect on D-glucose-mediated cAMP signalling, but deletion of CaCdc25 
(the C. albicans Ras1 GEF) or CaRas1 eliminated this signalling [80]. These findings indicate 
Ras1 activation via Cdc25 is the primary mechanism by which D-glucose induces 
morphogenesis. The response of C. albicans to D-glucose is of physiological relevance because 
links between candida infection and hyperglycaemia [85] as well as insulin-dependent 
diabetes mellitus [86] have been reported. Moreover, C. albicans cells have increased 
tolerance to oxidative and cationic stresses upon exposure to levels of glucose that may be 




The CaRas2 protein contains several variations in conserved motifs typically thought to be 
critical for Ras-related activities and is thus considered an unusual Ras protein. Sequence 
alignment using BLAST has shown that the C. albicans Ras2 protein only has 25%-30% identity 
with all other fungal Ras proteins in the database except a Ras-like protein only found in 
Candida dubliniensis (80% identity) [88]. When RAS2 is deleted in a ras1∆/∆ background, 
intracellular cAMP levels are restored to approximately 30% of wild type levels (ras1∆/∆ 
mutant has a 20x reduction in cAMP). Ras1 and Ras2 may therefore exhibit antagonistic roles 
in C. albicans [88]. This is intriguing since the deletion of RAS2 in a ras1∆/∆ background results 
in a significantly increased defect in hyphal morphogenesis. Nevertheless as ras2∆/∆ mutants 
themselves exhibit normal hyphal development [88] the role of Ras2 in morphogenesis and 
pathogenesis in C. albicans has yet to be elucidated.  
 
1.2.2 The MAP kinase pathway 
Ras1 has also been shown to regulate hyphal transition in response to other environmental 
cues, such as nitrogen starvation [89], via MAP kinase signalling. As with the Cyr1/PKA 
pathway, the regulatory MAP kinase cascade is also activated by Ras1 [66] and consist of the 
kinases Cst20, Hst7 and Cek1 [90][91][92][93][94]. Ras1/MAPK signalling culminates in the 
phosphorylation and activation of the transcription factor Cph1, which in turn promotes the 
expression of hyphal-specific genes (HSGs) [80] such as Als3 (adhesin) [95], Hwp1 (invasin) 
[62], Hyr1 (host immune response modulator) [63], and Hgc1 (hyphal-specific cyclin) [96]  
(Figure 1.5). It has been shown that inactivation of the Ras1-Cyr1-PKA pathway inhibits 
filamentous growth in the majority of usual hyphae-inducing conditions, however, 
inactivation of the MAP kinase pathway only prevents filamentous growth in only a specific 
subset of conditions [91].  
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1.2.3 Alternative pathways driving the yeast-to-hyphae switch 
Although Ras1-Cyr1-PKA and MAP kinase signalling are the major pathways responsible for 
promoting the yeast-to-hyphae switch, there are also several other pathways which drive C. 
albicans morphogenesis under certain environmental conditions. For instance, the Rim101 
pathway induces the transition of yeast-to-hyphae in response to extracellular pH levels. At 
an alkaline pH, a number of proteins, including Rim8, stimulate the proteolytic cleavage of 
the carboxyl terminus of the zinc-finger transcription factor Rim101. This truncated version 
of Rim101 activates the expression of alkaline-specific genes and represses acid-induced 
genes. It also results in the activation of HSGs, stimulating the yeast-to-hyphae switch (Figure 
1.5). Surprisingly, the presence of the Rim101 pathway is not required for growth at either 
alkaline or acidic pH in vitro. However, it has been demonstrated that it is essential for a 
number of host-pathogen interactions and thus can be considered extremely important in 
vivo for the pathogenicity of C. albicans [97]. Furthermore, C. albicans cells embedded in a 
matrix are stimulated to switch to hyphal growth via a pathway involving the transcription 
factor Czf1 (Figure 1.5). It has been speculated that the ability of C. albicans to switch to 
hyphal growth in response to embedded conditions may be important in promoting invasion 
of the fungal cells into host tissues [98].         
   
Genotoxic stress resulting in perturbations in the normal cell cycle can cause also a yeast-to-
hyphae switch in C. albicans. For instance, mutations which prevent DNA damage repair or 
DNA replication pathways are capable to prompting filamentous growth. These situations will 
activate the DNA damage/replication checkpoints, in turn activating the Rad53 checkpoint 
kinase which plays a key role in promoting hyphal growth [99]. Moreover, it has been 
observed that reactive oxygen species, such as those produced from hydrogen peroxide 
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released by phagocytic cells also stimulates hyphal growth through Rad53 signalling [100].   
 
1.2.4 Negative regulation of the yeast-to-hyphae switch 
In addition to the signalling pathways which drive the yeast-to-hyphae switch, there are also 
negative regulators that are controlled by Ras signalling (Figure 1.5). Hyphal-specific genes 
are repressed by the global-repressor Tup1 [101] via the specific DNA-binding proteins Nrg1 
[102][103] and Rfg1 [104]; the deletions of each of these three proteins results in C. albicans 
cells which are constitutively hyphal even under non-hyphal inducing conditions 
[101][102][103][104]. Approximately half of the genes found to be upregulated during hyphal 
development in response to 37oC and serum are repressed by Tup1 and Nrg1 or Rfg1, 
suggesting that repression removal is a crucial step in the yeast-to-hyphae switch [105]. 
Consistently, it has been found that hyphal-inducing conditions such as serum exposure and 
growth at 37oC cause a reduction in the expression levels of NRG1, leading to the conclusion 
that one way in which repression of hyphal-specific genes is overcome during the yeast-to-
hyphae switch is via down-regulation of the repressors [103]. Ras1-Cyr1-PKA pathway 
activation results in the prompt but short-term removal of Nrg1 from the promoters of 
hyphal-specific genes. The maintenance of this repression elimination, and hence hyphal 
development, is achieved through the subsequent recruitment of the Hda1 histone 
deacetylase which deacetylates a subunit of NuA4 histone acetyltransferase, causing it to also 
be removed from the promoter. This results in the coiling of the portion of the promoter 
containing the Nrg1 binding site, preventing the re-binding of Nrg1. It is important to note the 





1.3 Candida albicans Biofilms 
Biofilms are structured communities of microorganisms which are attached to either a living 
or non-living surface. The cells are often encased within a matrix of self-made extracellular 
polymeric substance (EPS); this EPS is composed of DNA [107][108], lipids [107], proteins 
[107][109] and polysaccharides [107]. Medically, biofilms are of particular importance 
because it is thought that a significant percentage of human microbial infections include 
biofilm formation [110][111][112]. Indeed, estimates from the National Institutes of Health 
suggest pathogenic biofilms (bacterial and fungal) are responsible for up to 80% of all 
microbial infections in the US [113].   
 
Moreover, cells which reside within biofilms have distinctive phenotypes compared to 
planktonic cells, for example, they exhibit increased tolerance to antibiotic and antifungal 
drugs. It has been estimated that bacteria, for example Pseudomonas aeruginosa (P. 
aeruginosa), residing within a biofilm are 10-1000x more tolerant to antibiotics than their 
planktonic counterparts [114]. While C. albicans biofilm cells are more tolerant to antifungals 
including fluconazole, nystatin and amphotericin B [115]. The reasons for this increased 
tolerance are complex but include the presence of an extracellular matrix reducing the ability 
of antimicrobial agents to reach the cells [116][117], metabolic differences (such as 
modulation of glycolysis, ergosterol biosynthesis and mitochondrial respiration) [118] 
inherent to biofilms and upregulation of efflux pumps [119]. C. albicans biofilms are usually 
composed of a mixture of morphological forms; typically yeast, pseudohyphal and true hyphal 





1.3.1 Stages of Candida albicans biofilm formation  
The formation of a biofilm is the result of a very precise and complex series of events that are 
divided into distinct stages; attachment, initiation, maturation and dispersion (Figure 1.7). 
 
Attachment: The first step in biofilm formation, and hence the colonisation of a surface, is 
the initial attachment of cells to that surface [120]. At the beginning of this stage, the majority 
of C. albicans cells are yeast form [115]. Both nonspecific factors, such as cell surface 
hydrophobicity and electrostatic forces, and specific factors, such as adhesins on the yeast 
cell surface binding to precise ligands on the substratum to be colonised, are responsible for 
the preliminary attachment of C. albicans cells [120]. The adhesins, such as members of the 
agglutinin-like sequence (Als) family (Als1-7 and Als9), are glycosylphosphatidylinositol (GPI) 
anchored cell wall proteins. The Als adhesins possess a folded N-terminal domain required for 
protein-ligand interaction, a 600-1000 residue serine/threonine-rich tandem domain, and a 
C-terminal peptide which covalently bonds GPI [121]. The N-terminal domain contains a 
peptide binding cavity (PBC) which can accommodate the final 6 peptides in the C-terminals 
of a variety of proteins, with a salt bridge being formed between the C-terminal carboxylic 
acid group and a positively charged invariant lysine at the end of the PBC [122]. In this way 
the adhesins are capable of binding numerous structurally unrelated ligands. Mechanisms 
underlying C. albicans attachment to abiotic surfaces are not fully understood but are likely 
to involve the PBC binding to adsorbed proteins, as well as possibly involving hydrophobic 
interactions since an als1∆/∆als3∆/∆ double mutant exhibited significantly reduced 
interaction with a hydrophobic AFM tip [123]. After attachment, the C. albicans cells form a 




Initiation: Approximately 3-6 hours after the initial attachment, pseudohyphal and hyphal 
cells start forming from the proliferating yeast-form cells [8]. After around 11 hours, colonies 
of C. albicans cells begin to appear as thick tracks over the surface being colonised [115]. This 
step in biofilm development is characterised by the appearance of extracellular material 
covering the C. albicans colonies. Communities of C. albicans continue to grow and secrete a 
matrix of self-made EPS composed of DNA (5%) [107][108], lipids (15%) [107], proteins (55%) 
[107][109] and polysaccharides (25%) [107].  
 
Maturation:  The maturation phase of biofilm growth lasts between 24-48 hours [120]. 
Colonies of C. albicans continue to grow and secrete EPS, increasing the amount of 
extracellular material encasing the biofilm [115]. This extracellular matrix serves as a physical 
barrier to the surrounding environment and also contributes to the structural integrity of the 
biofilm, protecting it from mechanical disruption. Mature biofilms possess a complex 3D 
structure which is thought to signify the optimum spatial arrangement to allow nutrient 
influx, waste disposal, and the founding of microniches within the biofilm. For instance, 
microcolonies within a mature biofilm are separated by water channels which enable the 
circulation of nutrients throughout the biofilm. Typically, a mature C. albicans biofilm 
comprises a thin layer of yeast cells which attaches a thicker layer of yeast, pseudohyphal and 
hyphal cells to the substratum [124].  
 
Dispersion: The final stage of biofilm development is the dispersal stage during which yeast-
form cells bud off from hyphal cells within a mature biofilm and disperse in order to establish 
additional biofilms elsewhere [115][125]. In actuality, C. albicans biofilms disperse yeast-form 
cells during all stages of growth with greater dispersion occurring once the biofilm has 
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reached maturity [126]. Interestingly, the yeast-form cells emerging from mature biofilms 
have distinct characteristics compared to typical planktonic yeast cells. The dispersed cells 
display enhanced adherence, increased propensity to filament, and increased biofilm forming 
capability. Overall, this contributes to increased pathogenicity in a mouse model of blood 
disseminated candidiasis [126]. The dispersed biofilm cells are fully-equipped with key 

















Figure 1.7: Stages of Candida albicans biofilm formation. Biofilm formation in C. albicans follows 
four clearly defined stages: cells attach to a surface in the yeast-form, they begin to proliferate and 
produce extracellular matrix while undergoing the yeast-to-hyphal switch, this continues for 24-48 
hours to produce the mature biofilm, before finally dispersing yeast-form cells to establish new 
biofilms elsewhere. Figure adapted from Figure 1 in Lohse, M. et al. [125].  
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1.3.2 Regulation of Candida albicans biofilm formation 
C. albicans biofilm formation is an exceedingly complex process involving very tightly 
regulated, interwoven signalling pathways centrally controlled by a set of nine transcription 
factors; Bcr1, Brg1, Efg1, Tec1, Ndt80, Rob1, Flo8, Rfx2 and Gal4 [127][128]. These nine 
essential regulators are subject to autoregulation (Figure 1.8) and coordinate the expression 


















Figure 1.8: The nine core transcription factors which form a highly interconnected network to 
control Candida albicans biofilm formation. All of these transcription factors, apart from Gal4, are 
subject to autoregulation. Direct binding interactions where the transcription factors regulate each 
other are specified by double-headed arrows, and binding interactions where one transcription 
factor regulates the other are specified by single-headed arrows. This highlights the complexity of 
the regulation of C. albicans biofilm formation. Figure taken from Figure 2 in Lohse, M. et al. [125].  
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Interestingly, the nine ‘core’ transcription factors have been shown to function during 
different developmental stages within C. albicans biofilms [128][129]. Governing key 
processes such as initial attachment, matrix deposition and dispersal. Thus, positive 
regulators downstream of the ‘core’ also show stage specificity in their function, for example 
adhesins such as the Als family are predominantly upregulated in early stage biofilms [130] 
















The transcription regulator Bcr1 has important roles in the attachment of C. albicans cells to 
a surface to initiate biofilm formation, as well as the cell-cell attachments which maintain 
architectural integrity during maturation. The bcr1∆/∆ mutant is unable to form biofilms and 
Figure 1.9: The stages of C. albicans biofilm formation and the transcription factor network which 
controls it. The master regulators have been demonstrated to primarily function within different stages 
of C. albicans biofilm growth. Other positive regulators also function at different time points, with the 
majority of the adhesins functioning in the earlier stages. Figure taken from Figure 1 in Chong, P. et al. 




also cannot switch to hyphal growth under certain conditions. However, when present within 
mixed biofilms formed using wild-type cells, bcr1∆/∆ mutant cells produce lots of hyphae 
[131]. These hyphal cells are unable to adhere to surfaces and initiate biofilm formation, thus 
the Bcr1 transcription factor is required to impart some function on hyphal cells vital to 
biofilm development. In fact, Bcr1 upregulates at least 11 genes encoding cell wall proteins, 
including the adhesins Als1, Als3, and Hwp1 which have been shown to have critical roles in 
biofilm formation [127][132][133][134]. This is not the whole story however, since more than 
thirty transcription factors (including Bcr1) have been shown to be necessary for adherence 
[135].  Moreover, Fox, E. P. et al. demonstrated that different sets of adhesins are upregulated 
in early and late biofilms, adding further complexity to this field [128]. Additional work needs 
to be conducted to fully understand the intricacies of biofilm adherence.     
 
Extracellular matrix (ECM) deposition is a hallmark of biofilm growth but knowledge is 
currently limited on the regulation of this process, as well as the exact purpose of all the 
components. Mass spectrometry has identified over 500 proteins in the matrix, the majority 
of which are enzymes. Intriguingly, several of these enzymes do not possess traditional export 
sequences and so it’s questionable if they are actively secreted, instead likely coming from 
lysed cells within the biofilm [107]. It has been proposed that these extracellular enzymes 
may digest cellular components to provide nutrients to C. albicans cells in the maturing 
biofilm. They may also have roles in promoting the dispersal phase of biofilm growth while 
also protecting biofilm cells from host immune cells. However, these hypotheses are yet to 
be experimentally validated [107][125]. Extracellular DNA (eDNA) is another key component 
of the biofilm ECM. In bacterial biofilms, eDNA contributes to several aspects of biofilm 
formation ranging from adhesion to structural stability and antimicrobial tolerance [136]. P. 
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aeruginosa biofilms disperse upon treatment with DNase [137].  It is likely that eDNA plays 
similar roles in C. albicans biofilms, indeed, Martins, M. et al. demonstrated that eDNA is 
present at all stages of C. albicans biofilm growth and DNase treatment reduces overall 
biofilm biomass in latter phases of development [108].     
 
Two transcription factors called Zap1 and Rlm1 have been identified as having roles in the 
regulation of ECM deposition. Zap1 is a negative regulator of two glucoamylases, Gca1 and 
Gca2, which are involved in β-1,3-glucan biosynthesis, a major component of the biofilm 
matrix that has been linked to biofilm-associated drug tolerance [116][117]. Consequently, a 
zap1∆/∆ mutant has been shown to have increased matrix production [138]. Furthermore, a 
group of alcohol dehydrogenases regulated by Zap1 including Adh5, Csh1 and Ifd6, have been 
reported to have functions in matrix deposition. It has been proposed that these alcohol 
dehydrogenases create aryl and acyl alcohols which function as quorum-sensing molecules 
which control several biofilm maturation events [138]. Rlm1 functions in a pathway with the 
glucan synthase Fks1 to regulate the production of cell wall and ECM β-1,3-glucan during C. 
albicans biofilm growth, and a rlm1∆/∆ mutant has decreased matrix production resulting in 
reduced antifungal tolerance [139].       
    
It has recently been published that extracellular vesicles (EVs) produced within C. albicans 
biofilms have a crucial role in ECM deposition and thus antimicrobial tolerance. Mutants 
lacking key components of the endosomal sorting complexes required for transport (ESCRT) 
pathway have reduced biofilm EV production along with reduced matrix glucan and mannan 
levels. The authors proposed that EVs have a direct role in matrix biogenesis, since the 
addition of wild-type vesicles to mutant biofilms resulted in the restoration of matrix 
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polysaccharide levels and antimicrobial tolerance. This suggests that the EVs are delivering 
functionally-relevant cargo which is actively contributing to ECM production [140].       
 
Another key aspect of C. albicans biofilm growth is the formation of hyphal cells. Hyphal cells 
are required for biofilm formation because the expression of several cell surface adhesins, 
such as Hwp1 and Eap1, is highly upregulated during hyphal growth. These adhesins are 
required for attachment (both cell-cell and cell-surface) during biofilm maturation, and as a 
result it means Ras signalling is strongly linked to the development of biofilms [141]. It was 
discovered by Ramage, G. et al. that the hyphal-defective mutant efg1∆/∆ (as well as efg1∆/∆ 
cph1∆/∆) is unable to form biofilms [142]. Rather than the true basal layer which wild-type C. 
albicans cells form, these mutants only produce very few surface-attached cells. Despite this, 
strangely, the surface-attached mutant cells have no susceptibility to fluconazole and limited 
susceptibility to amphotericin B [142]. These are important observations because it appears 
as though simple surface-adhesion is sufficient to induce the antifungal tolerance 
characteristic of cells in biofilms; this tolerance does not require biofilm maturation [115].  
 
Dispersion is the final stage in C. albicans biofilm formation and, as with all other aspects of 
biofilm growth, is a highly regulated process. The transcription factor Nrg1 (see Section 1.3.4), 
whose degradation is inhibited by the C. albicans quorum-sensing molecule farnesol [143], 
has been shown to promote biofilm cell dispersion [144]. Conversely, the transcription factor 
Ume6 negatively regulates dispersion with overexpression of the UME6 gene reducing biofilm 
cell distribution [126]. A histone deacetylase complex composed of four core members (Set3, 
Hos2, Snt1, and Sif2) has also been revealed to be required for dispersion, possibly through 
being recruited to particular genes by Nrg1 [145]. Environmental factors such as nutrient 
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availability have been suggested to affect dispersion, and some experimental evidence points 
to biofilm dispersal increasing in rich media compared to nutrient-poor media [146]. The 
precise molecular mechanisms behind these dispersal responses to the environment are yet 
to be elucidated.     
 
1.3.3 Antimicrobial tolerance within C. albicans biofilms 
A principal, and perhaps the most medically relevant, phenotype of biofilms is that they 
exhibit increased antimicrobial tolerance compared to planktonic cells. Some fungal biofilms 
can be up to 20000-fold more tolerant to antifungals by some estimations [147]. The 
repertoire of antifungals for the treatment of fungal infections is significantly lower than that 
of antibiotics for bacterial infections. The development of novel antifungals is hindered by the 
eukaryotic nature of fungal cells and hence the large similarities to host mammalian cells. 
Thus, clinicians are limited in the range of treatment options available, particularly if the 
fungal pathogen displays tolerance or resistance. Potential host toxicity of these antifungals 
is also a major issue and long-term usage antifungals such as fluconazole is associated with 
adverse effects in the host [148]. Currently, there are 5 classes of antifungals; azoles, 
polyenes, echinocandins, allylamines, and pyrimidine analogs [149]. C. albicans employs a 
variety of mechanisms to increase its tolerance to these antifungals; some of these 
mechanisms are shared between planktonic and biofilm cells but others are specific to the 
biofilm scenario.   
 
Azoles: Azoles such as fluconazole and miconazole are primarily fungistatic and function by 
inhibiting the lanosterol 14α-demethylase enzyme in the ergosterol biosynthetic pathway 
[150][151]. Ergosterol is unique to fungi; it is the main constituent of the fungal cell 
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membrane and functions to regulate membrane fluidity, asymmetry, and hence its integrity 
[152].  
 
One mechanism C. albicans biofilms use to increase tolerance to fluconazole is by increasing 
the expression of the ERG genes which encode the components of the ergosterol biosynthetic 
pathway. This causes changes in azole target levels, often resulting in a failure of the 
antifungal to efficiently eradicate the pathogen [153]. A study by Borecká-Melkusová, S. et al. 
showed that the ERG9 and ERG11 (encodes lanosterol 14α-demethylase) genes were 
upregulated in C. albicans biofilms following treatment with fluconazole. The ERG3 gene was 
also upregulated during biofilm growth independently fluconazole treatment [154]. 
Additionally, Nailis et al. reported significant increases in ERG1, ERG3, ERG11 and ERG25 gene 
expression in mature C. albicans biofilms after fluconazole treatment [155]. Contrary to this, 
a whole transcriptome analysis found no significantly altered gene expression in mature C. 
albicans biofilms after fluconazole treatment [156]. However, this could be explained by 
another mechanism which C. albicans biofilms use to increase tolerance – β-1,3-glucan in the 
ECM binds to azoles [157] (as well as other antifungals such as amphotericin B [156]). When 
in a biofilm, the cell wall of C. albicans undergoes architectural changes, increasing its β-1,3-
glucan content. In addition, β-1,3-glucan is also secreted and forms a major component of  
the biofilm ECM [157]. It could be that once a biofilm is sufficiently mature, the cell walls and 
ECM prevents certain drugs even reaching the cells.  
 
A further mechanism of azole tolerance is the upregulation of drug efflux pumps within 
biofilm-associated cells [158]. Two groups of efflux pumps have been associated with azole 
resistance in C. albicans; the Cdr1 and Cdr2 pumps (ATP-binding cassette (ABC) transporters 
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encoded by the CDR1 and CDR2 genes) and the Mdr pumps (major facilitator (MF) superfamily 
encoded by the MDR genes) [159]. An additional member of the MF superfamily encoded by 
FLU1 has also been implicated in fluconazole resistance [160]. In vitro studies have shown 
expression of CDR1, CDR2, MDR1 and FLU1 is increased in C. albicans biofilm cells compared 
to planktonic cells [158][161]. This has also been confirmed in vivo [130]. However, it has been 
argued these drug efflux pumps probably only play a major role in antifungal tolerance in the 
early stages of biofilm formation. Drug efflux pump gene expression increases in as little as 
15 minutes of initial attachment to a surface [158] but decreases as C. albicans biofilms 
mature [161]. This is intriguing since tolerance usually increases as biofilms age. Furthermore, 
it has been shown that knockout mutants of CDR1, CDR2, and MDR1 are sensitive to azoles 
planktonically and in early stage biofilms but maintain tolerance within late stage biofilms, 
indicating these drug efflux pumps are not necessary for the azole tolerance of mature 
biofilms [161][162].    
        
Polyenes: Polyenes such as amphotericin B and nystatin function by binding to ergosterol in 
the fungal cell membrane. Upon binding, transmembrane pores are formed which induce the 
leakage of electrolytes and cytoplasmic contents, resulting in cell death [153].  
 
Similar to the azoles, C. albicans biofilms can resist polyene treatment by alterations in gene 
expression. Significant increases in SKN1, KRE1 and ERG1 expression have been observed in 
mature biofilms upon addition of amphotericin B [155]. This is consistent with a report of a 
small population of highly amphotericin B tolerant biofilm-associated yeast-form cells which 
had significant upregulation of ERG25, SKN1, and KRE1 [163]. SKN1 and KRE1 encode proteins 
involved in β-1,6-glucan biosynthesis (another component of fungal cell walls and ECM) and 
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restructuring of the glucan portion of cell walls has been associated with transient 
amphotericin B tolerance [164]. The authors proposed that a synergistic effect of the 
alteration of cell wall β-1,6-glucan content along with ergosterol changes is responsible for 
the increased tolerance, and these mechanisms were activated by the biofilm environment 
[163]. In addition, amphotericin B is bound by β-1,3-glucan and so can be sequestered in the 
biofilm ECM similar to azoles [156]. Consistent with this, C. albicans biofilms grown under flow 
have greater matrix deposition than statically grown biofilms and are significantly more 
tolerant to amphotericin B [165].        
     
Echinocandins: Echinocandins such as caspofungin function by inhibiting the β-1,3-glucan 
synthase enzyme Fks1 [166], preventing the incorporation of β-1,3-glucan in the cell walls of 
C. albicans cells as well as in the ECM of biofilms. In comparison to the other antifungal classes 
discussed here, echinocandins possess a reasonably good efficacy against Candida biofilms in 
vitro [167][168] and in vivo [169]. Notably, since the Fks1 enzyme isn’t found within 
mammalian cells, echinocandins display low levels of host toxicity. However, their use is fairly 
limited, predominantly being used for invasive candidiasis, as they are expensive and have a 
high molecular weight meaning they have to be administered intravenously [149]. 
 
Allylamines: Like the azoles, allylamines target ergosterol biosynthesis. They do this by 
inhibiting the squalene oxidase enzyme in the ergosterol biosynthetic pathway [153].  
  
Pyrimidine analogs: Pyrimidine analogs such as 5-flucytosine function by disrupting fungal 
DNA and RNA synthesis [170]. It becomes an active antifungal upon being converted into 5-
fluorouracil by cytosine deaminase, a fungal-specific enzyme [171]. 5-fluorouracil cannot be 
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used as an antifungal itself since it is highly toxic to mammalian cells and poorly taken up by 
fungal cells [170]. 
 
In addition to the tolerance mechanisms specific to each drug class, there are a variety general 
biofilm mechanisms which increase tolerance to several of the antifungals. Firstly, simply the 
fact that biofilms have a high cell density enables a certain level of antimicrobial tolerance; 
resuspended biofilm cells retain tolerance but are more susceptible when diluted [162]. This 
mechanism is not specific to biofilms as high planktonic cell densities (1 x 108 cells/ml) also 
exhibit increased tolerance to azoles and amphotericin B compared to lower densities (1 x 103 
cells/ml) [162].  
 
Additionally, the presence of persister cells within C. albicans biofilms contributes to their 
tolerance against a variety of antifungals. Persister cells are thought to be metabolically 
dormant phenotypic variants, as oppose to mutants, which can resist antimicrobial 
concentrations much higher than the usual MICs [172]. LaFleur et al. observed a biphasic 
killing pattern of C. albicans biofilms when treated with amphotericin B and/or the antiseptic 
chlorhexidine, suggesting the presence of a subpopulation of highly tolerant cells [172]. 
Importantly, the biofilm defective mutant efg1∆/cph1∆ gives rise to persisters, showing the 
formation and tolerance of persister cells is not reliant on the development of a mature 
biofilm, instead simply occurring as a result of attaching to a surface. Furthermore, drug efflux 
does not account for persister cell survival since a mutant lacking the drug efflux pumps Cdr1, 
Cdr2, Mdr1 and Flu1 exhibits the same biofilm killing profile with the same amphotericin B 
and chlorhexidine MICs as wild type [172]. It is also important to note that persister cell 
production appears to be strain specific in C. albicans as GDH2346 forms persisters but 
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SC5314 does not [173], indicating persister cells are one of many reasons for C. albicans 
biofilm tolerance.  
 
The presence of an extracellular matrix is a crucial feature of biofilms which contributes to 
tolerance to several antifungals; including azoles, polyenes, echinocandins and pyrimidine 
analogs [117]. C. albicans biofilms with a more extensive matrix, such as those grown under 
flow conditions, exhibit higher tolerances than those with less matrix material [165]. As 
previously mentioned, β-1,3-glucan in the ECM is able to bind to fluconazole [157] and 
amphotericin B [156], potentially reducing their penetration into biofilms. Furthermore, the 
cell walls of biofilm-associated cells are up to 2x thicker and contain more β-1,3-glucan than 
those of planktonic cells [157], resulting in them being able to bind 4-5x more fluconazole per 
cell wall [117]. Biofilms of a β-1,3-glucan synthase heterozygous knockout mutant 
(FKS1/fks1∆), which have a 30% reduction in β-1,3-glucan content, exhibited higher 
susceptibility to the pyrimidine analog 5-flucytosine and the echinocandin andulafungin than 
wild-type [117]. Further evidence for the important role of the ECM in biofilm tolerance 
comes from the fact that mutants lacking the glucan transferase genes BGL2 and PHR1, and 
the exoglucanase gene XOG1, have increased sensitivity to fluconazole specifically when in a 
biofilm. These enzymes are predicted to be in the ECM and are critical for the delivery and 
accumulation of β-1,3-glucan in the matrix.        
 
From the above discussion it is clear that antimicrobial tolerance within C. albicans biofilms is 
complex and cannot be attributed to a single mechanism. While all the mechanisms described 
here have been shown to contribute to biofilm tolerance in several growth scenarios, they 
are probably not all utilised in every situation. The precise mechanisms of tolerance are likely 
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to be dependent on the experimental set-up used to grow the biofilms. For example, biofilms 
which are grown under flow conditions have a significantly different structure [174][175] and 
exhibit altered antifungal tolerance patterns from static biofilms [165][175]. Moreover, there 
appears to be contradiction between some studies; Nailis et al. found several ERG genes 
upregulated in mature biofilms after fluconazole treatment [155], whereas Vediyappan et al. 
concluded there were no significantly differentially expressed genes upon fluconazole 
treatment [156]. However, this could be due to the different experimental model systems 
used to grow the biofilms in the first place. This means that biofilms formed under different 
conditions in vivo are likely to have different tolerances as well as different mechanisms used 
to achieve these.   
 
1.3.4 Current treatment strategies for C. albicans biofilms 
Due to the high level of antimicrobial tolerance exhibited by C. albicans biofilms and the 
plethora of mechanisms used to achieve this, current treatment strategies are limited. There 
are presently no biofilm-specific therapeutics available, however, there has been some 
success using the currently available antifungals often in combinations with other 
compounds.   
 
Echinocandins such as caspofungin and micafungin have displayed efficacy against in vitro C. 
albicans and C. parapsilosis biofilms [167]. This is likely due to their mode of action; inhibiting 
the synthesis of the major cell wall and ECM component β-1,3-glucan which has been 
implicated in biofilm-related antifungal tolerance. Liposomal formulations of the polyene 
amphotericin B have also been demonstrated to rapidly (95% biofilm killing in 12h) kill C. 
albicans biofilms in vitro in a dose-dependent manner [176]. This study also found 
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caspofungin to be effective against C. albicans biofilms [176]. Furthermore, liposomal 
amphotericin B has been observed to be effective at treating a catheter-associated biofilms 
in an in vivo rabbit model [177].     
 
Combination therapy of traditional antifungals with other compounds seems to be an 
appealing option for C. albicans biofilm treatment. The hope being that treatment 
concentrations of antifungals, many of which have associated side-effects and host toxicity, 
can be reduced and still be effective. For instance, the combination of fluconazole and the 
antibiotic doxycycline significantly reduced the sessile minimum inhibitory concentration 
(SMIC) of fluconazole from 64-512µg/ml to 1-16µg/ml against biofilm-associated C. albicans 
cells. This combination was even effective against planktonic cells of strains known to be 
fluconazole-resistant [178].  
 
Combinations of antifungals with painkillers such as aspirin have also had some success 
against C. albicans biofilms. Aspirin has shown efficacy against Candida biofilms on its own, 
although only at concentrations above those typically used for therapeutic effects in humans 
which limits its clinical use [179]. However, combination of amphotericin B and aspirin, at 
clinically relevant concentrations, reduced amphotericin B MIC values against C. albicans and 
C. parapsilosis biofilms in vitro [180]. In addition, administration of caspofungin after pre-
treatment with the painkiller diclofenac significantly reduced C. albicans biofilm growth on an 
in vivo rat catheter model compared to treatment with each drug alone [181]. This may be 
due to a diclofenac-mediated increase in membrane permeability, diclofenac treatment has 
also been shown to reduce the expression level of genes downstream of the Ras1-Cyr1-PKA 
pathway including EFG1 and hyphal-specific genes ALS1, ALS3, HWP1 and ECE1 which have 
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important roles in biofilm formation (Figure 1.9) [182]. The authors of the in vivo rat catheter 
study propose that coating medical devices with diclofenac, together with using traditional 
antifungals, could be a potential treatment strategy to eradicate C. albicans biofilms [181].   
 
Treatment of C. albicans biofilms with miconazole has been shown to induce the intracellular 
production of superoxide radicals. SOD5 and SOD6 genes, encoding the superoxide dismutase 
enzymes Sod5 and Sod6 which rapidly convert toxic superoxide into molecular oxygen, were 
upregulated following miconazole treatment. The addition of the Sod inhibitor N,N’-
diethyldithiocarbamate (DDC) increased the fungicidal activity of miconazole against C. 
albicans biofilms [183].    
 
Finally, some recent studies have focussed on the use of more unusual compounds in the 
treatment of C. albicans biofilms. Yan, Y. et al. identified the Chinese herbal medicine 
component shikonin as being able to inhibit the formation and break up mature C. albicans 
biofilms [184]. Shikonin treatment also reduced fungal burden in a murine VVC model. Similar 
to diclofenac treatment, shikonin treatment resulted in the downregulation of hyphal- and 
biofilm-related genes such as EFG1, ALS1, ALS3, HWP1 and ECE1 as well as upregulation of 
negative hyphal regulators TUP1 and NRG1 [184]. An additional study showed polyphenol 
extracts from green tea elicited a dose-dependent inhibition of C. albicans biofilm formation 
[185].    
 
1.3.5 Models used to study biofilms 
There are numerous methods/models used to grow biofilms both in vitro and in vivo. One of 
the most frequently used in vitro model systems are microtiter plate-based models in which 
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biofilms are either grown on the bottom and walls of the wells on a plate (often a 96-well 
plate), or on a removable surface placed within the wells (often a silicone disc/square in a 
12/24-well plate) [186] (Figure 1.10). Microtiter plate-based models are closed systems i.e. 
there is no addition/subtraction of material to/from the wells throughout the course of the 
experiment. As a result, the microenvironment within the wells will alter during the 
experiment (nutrients will diminish, waste products will accumulate, etc.). These model 
systems are widely used due to their low cost, efficiency because a large number of tests can 
be performed simultaneously, and the fact that these systems are excellent for screening 















Figure: 1.10: The in vitro biofilm model used within this study. Biofilms were grown on 1cm2 silicone 
squares which mimic the surface of the voice prosthesis. They were placed in modified 24-well plate lids 
so that they protrude into RPMI media containing C. albicans cells when placed on a 24-well plate. This 
enables easy washing and quantification of growth without disruption of the biofilm by transferring to 
new plates containing PBS or XTT reagent (see Materials and Methods).    
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Another method for growing biofilms in vitro is the flow displacement biofilm model system. 
In this system, growth medium is continually added, and waste-products removed, from the 
experimental system. There are two general groups of flow displacement systems: the 
‘continuous flow stirred tank reactor’ (CFSTR) and the ‘plug flow reactor’ (PFR) [186]. A CFSTR 
system is operated at a steady state i.e. growth medium is added at the same rate as waste 
is removed, thus nutrient/waste concentrations stay the same. When dilution rate is higher 
than the growth rate (doubling time) of a microorganism, planktonic cells are washed away 
only leaving behind cells attached to a surface that will grow into a biofilm. A PFR system 
consists of the growth medium being added at one end and flowing through the reactor as a 
‘plug’ to the other, mixing only occurs by diffusion in a radial direction. Unlike a CFSTR system, 
a PFR system is not stirred, meaning conditions change gradually through the reactor. In a 
CFSTR system, conditions are constant throughout [186].    
 
A further method for in vitro biofilm growth is a cell-culture-based system. These model 
systems often use human cell lines in order to replicate in vivo conditions in vitro. For instance, 
models of oral and vaginal candidiasis have been produced, these use reconstituted human 
epithelia (RHE) as the surface upon which C. albicans forms a biofilm. These models do have 
limitations however because commensal microflora and cell-mediated immune responses are 
not present [186]. As previously discussed, C. albicans not only causes superficial candidiasis 
infections, but can also cause serious systemic infections. With this in mind, another type of 
in vitro biofilm model has been developed which investigates the ability of the different 
morphogenic forms of C. albicans to adhere to endothelium under flow conditions similar to 
those found in blood vessels [188]. Glass slides are covered with immortalised human 
microvascular endothelial cells (HMEC-1 cell line) and placed in a parallel plate flow chamber, 
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a suspension of C. albicans cells then flows through the chamber. With this model it was 
discovered that C. albicans cells in the yeast form adhere more readily to endothelial cells 
than filamentous forms do. This contrasts to the findings of other assays which used static 
conditions [186]. 
 
Microfluidic devices are yet another model used to study biofilm growth. They are extremely 
useful pieces of equipment because it is possible to use them to generate biofilms under 
conditions which are physiologically relevant, such as physiological flow rates and low fluid-
to-cell ratios. The channels within microfluidic devices are typically very small (50-500µm 
wide, 30-250µm deep, 5-40mm long) and this small size allows microscopic analysis of any 
biofilms grown at a single-cell resolution. Environmental conditions can also be precisely 
regulated in microfluidic devices [189].     
    
Although a lot can be learned from in vitro biofilm growth models, it is also necessary to study 
biofilm growth in vivo. These in vivo biofilm models are typically carried out in either 
Caenorhabditis elegans worms or, if a vertebrate model is required, in murine animals. 
Investigations using C. elegans as a model system have typically focused on bacterial biofilm 
formation and have allowed the identification of both bacterial and host genes which are 
required for bacterial adhesion and Biofilm growth. In vivo studies of C. albicans biofilms are 
usually conducted in murine animal models, primarily to examine biofilm formation as a result 
of implanted medical devices such as catheters [186]. These animal models have been used 
to investigate the in vivo susceptibility and molecular response of C. albicans biofilms to 
several antifungal compounds (such as fluconazole and caspofungin) [190], to increase 
understanding of the molecular basis of C. albicans biofilm formation, and to study the role 
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of specific adhesins (such as Eap1) in biofilm formation [191]. Animal models also provide an 
insight into the changes in gene expression in biofilms in vivo over time [130].    
 
1.4 Laryngeal Cancer, Laryngectomies and Voice Prostheses 
Head and neck cancer is the sixth most common cancer worldwide and the eighth most 
common cancer in the UK with 650,000 new cases (12,000 in the UK) and 350,000 deaths 
(4,000 in the UK) attributed to it each year worldwide [192][193]. Laryngeal malignancy is the 
most frequent head and neck cancer, making up 26.2% of newly diagnosed male cases and 
13.1% of female cases in the UK [193]. Approximately 12,000 people are diagnosed with 
laryngeal cancer each year in the United States [194].   
 
Laryngeal malignancy is treated with radiotherapy if it is diagnosed at an early stage, however, 
at later stages treatment involves surgery often in conjunction with radiotherapy [194]. 
Unfortunately, the majority of head and neck cancers are diagnosed at an advanced stage; 
62% of new diagnoses in Northern Ireland are at Stage III or IV (Stage IV alone accounts for 
45%) [193]. This means many cases of laryngeal cancer have to be treated with a surgical 
procedure known as a laryngectomy after which the patient relies on the use of an indwelling 
medical device called a voice prosthesis to form speech. It has been estimated that there are 
currently 50,000–60,000 laryngectomees living in the United States [194]. 
 
As with all indwelling medical devices, the surface of a voice prosthesis provides an 
environment for the growth of microorganisms sequestered away from the host’s immune 
system. This ultimately leads to the failure of the device and can also be a source of potentially 
harmful infections [195][196]. Thus, voice prostheses need to be regularly changed, 
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contributing to much inconvenience and stress to the patient as well as financial cost to 
medical institutions. Management and prevention of microorganism growth on voice 
prostheses is crucial to increasing the lifespan of these devices, and an understanding of 
biological pathways which microorganisms utilise during colonisation is critical to this. 
 
1.4.1 Laryngectomies and Voice Prostheses 
A laryngectomy involves the partial or total removal of the larynx, along with surrounding 
lymph nodes, and results in the alteration of the upper airway anatomy (Figure 1.11) [197]. 
This surgery is often used to treat laryngeal or hypopharyngeal cancers, with the precise 
surgery approach dependent on the stage of the cancer; earlier stage cancers can be treated 
with a partial laryngectomy to remove only the affected part of the larynx, whereas patients 











 Figure 1.11: Upper airway anatomy before and after total laryngectomy. A total laryngectomy removes 
the larynx, including the vocal cords, and separates the trachea from the oesophagus and the mouth. After 




Following the surgery, the patient will no longer be able to breathe through their mouth or 
nose, instead breathing through a hole at the base of the neck called a stoma [197]. 
Furthermore, as the vocal cords are located within the larynx (Figure 1.11), most total 
laryngectomy patients are no longer able to form speech on their own. There are three major 
methods which 85-90% of laryngectomees employ to achieve speech; oesophageal speech, 
artificial larynx speech and tracheoesophageal speech [194]. Oesophageal speech involves 
creating vibrations to mimic speech using air emitted from the oesophagus. This method of 
speaking can be advantageous because it does not rely on additional devices, however, it does 
take time to learn and proves difficult to achieve. Artificial larynx speech involves using an 
external electrical device (called an artificial larynx) which produces vibrations when held on 
the cheek or under the chin. These vibrations are then modulated by the patient’s mouth to 
generate speech. This method tends to be used in the short-term following a laryngectomy 
operation before the patient learns one of the other techniques [194].          
 
The gold standard for speech rehabilitation is tracheoesophageal speech which requires the 
use of a small silicone valve known as a voice prosthesis [198] (Figure 1.12). The voice 
prosthesis (VP) is inserted into a hole called the tracheoesophageal puncture (TEP) made by 
the surgeon behind the stoma between the trachea and the oesophagus. It is made up of a 
one-way valve surrounded by a flange to prevent the TEP from closing and functions to direct 
air from the trachea into the oesophagus while inhibiting foods and liquids flowing through 
to the lungs. Air is forced through the voice prosthesis by covering the stoma with a finger, 
and this redirected air causes the top of the oesophagus to vibrate which can be modulated 
















1.4.2 Microbial colonisation of voice prostheses 
Although VPs produce the best results in terms of voice quality, they also pose a major 
problem. The silicone of the prostheses, as with many synthetic materials of indwelling 
medical devices, is readily colonised by microorganisms. The foods, liquids and saliva [199] 
which begin to coat the silicone surface of the VP, along with the high humidity and 
approximate 37oC temperature in the oesophagus, provide the perfect environment for 
microbe attachment and growth as a biofilm [10]. These microbes range from bacteria to 
fungi, with both often being found together in a mixed community. Streptococcal species such 
as Streptococcus mitis and Streptococcus sobrinus, Staphylococcal species such as 
Staphylococcus aureus [200], and Pseudomonas aeruginosa [201] are the major bacterial 
microorganisms frequently isolated from voice prostheses. Candida species, particularly 
Candida albicans, Candida glabrata, and Candida tropicalis, are the primary fungal 
Figure 1.12: Two types of voice prostheses commonly used for speech 
rehabilitation following total laryngectomy. (A) The Provox Vega voice 





microorganisms which grow on VPs in a biofilm and ultimately cause the devices to fail [202]. 
The exact microbial composition on a particular voice prostheses is influenced by several 
factors including patient diet, lifestyle and the voice prostheses management regime to which 
they subscribe [10]. This is highlighted by a study conducted in India by Sayed et al. which 
found a different microbial landscape compared to similar European studies [201].  
 
Device failure is predominantly attributed to ‘leakage’ caused by microorganism biomass 
preventing the valve fully closing, hindering the VP function and hence resulting in the 
replacement of the device [192][195]. Moreover, the microbial colonisation also acts as a 
reservoir from which potential pathogens can cause infection such as pneumonia if the voice 
prosthesis remains in the body for too long [196]. The mean VP lifespan is highly variable 
across different studies and has been reported as being between 120 and 200 days 
[201][203], after which it needs to be replaced in an invasive procedure.  
 
C. albicans is the most prevalent fungal coloniser of a VP surface and as such a significant 
number of device failures are associated with the presence of C. albicans [202][204][205]. 
Since fungal cells have a larger biomass than bacterial cells, it has been hypothesised that the 
fungal cells directly contribute to voice prosthesis failure due to valve ‘leakage’ more than 
bacterial cells. Although the importance of the role the bacterial cells play should not be 
underestimated. Consequently, this study focuses on the C. albicans colonisation of voice 






1.4.3 Current strategies for the prevention of microbial colonisation of voice prostheses 
Due to the inherent tolerance of biofilms to perturbations and treatments (see Section 1.3.3), 
there have been limited treatment strategies for prolonging VP in situ lifespan which has 
resulted in some intuitive approaches. These treatment approaches to prevent microbial 
colonisation of VPs broadly fall within two categories: modifications to the silicone surface 
itself or prophylactic treatments (for example with antifungals) and dietary recommendations 
[10].  
 
Voice prosthesis silicone surface modifications: Several studies have focussed on the coating 
of silicone VPs with a thin-layer of metal. A gold or titanium coating (<100nm) did not affect 
the physical properties of the VP or cause any difference in speech quality [206]. However, 
further evidence is required to determine if this approach leads to decrease in biofilm 
formation. Promising results have been observed by coating Groningen button VPs with a 
palladium/tin salt mixture which significantly attenuated biofilm formation compared to 
uncoated VPs [207]. The Blom-Singer Advantage is a commercially available VP which contains 
7% silver oxide in the valve. In a 33 patient cohort with particularly early failing VPs, the Blom-
Singer Advantage exhibited a significantly increased mean lifespan in situ compared to other 
indwelling VPs such as the Provox 2 (36 days to 110 days) [208]. 
 
Hydrophobicity has been shown to influence biofilm formation on VPs in vivo [209]. 
Therefore, studies have been carried out to determine if the addition of hydrophobic 
fluorocarbons, such as fluoro-alkylsiloxanes, to the silicone surface can reduce microbial 
colonisation. Coating a silicone surface with long chain fluoro-alkylsiloxanes reduced 
microbial adherence and also increased the rate of detachment of microbes which did 
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manage to attach [210]. The benefit of fluorocarbon coating is very reliant on the 
fluorocarbon chain length as short chain (1 fluorocarbon unit) perfluoro-alkylsiloxane actually 
increased microbial colonisation in vivo whereas long chain (8 fluorocarbon units) perfluoro-
alkylsiloxane reduced it [211].     
 
Finally, covalently adding quaternary ammonium salts to the silicone surface has been 
proposed to prevent microbial VP colonisation. Antibacterial activity of silicone coated with 
quaternary ammonium salts against both Gram-positive and Gram-negative species has been 
demonstrated in vitro and in vivo [212]. Quaternary ammonium salts also reduced the 
number of viable yeast and bacteria in an artificial throat mixed biofilm VP model [213].     
   
Prophylactic treatments and dietary recommendations: The effects of bacteria with 
probiotic attributes, such as Lactobacilli and some Streptococcal species, on biofilm formation 
have been investigated. Exposure of biofilms grown in an artificial throat model to 
suspensions of the probiotic Lactococcus lactis 53 and Streptococcus thermophilus B strains 
reduced CFU of both bacteria and yeasts on Groningen and Provox 2 VPs compared to 
untreated controls [214]. Biosurfactants released by S. thermophilus B inhibit the adhesion of 
Candida species to silicone rubber [215]. Certain dietary modifications to increase a patient’s 
probiotic intake have also been proposed to have beneficial effects of the in situ lifespans of 
VPs. For instance, the consumption of buttermilk has been widely regarded as prolonging the 
function of VPs; in an artificial throat model which mimicked buttermilk ingestion, biofilm 




The use of antifungal agents to ‘decontaminate’ the oropharynx has been considered to 
enhance the lifespan of VPs. Historically, the use Amphotericin B lozenges [217] and buccal 
bioadhesive slow-release Miconazole nitrate tablets [218] to reduce oropharyngeal fungal 
burden have resulted in increases in voice prosthesis lifespans. However, the Amphotericin B 
lozenges and Miconazole tablets have since been discontinued by the pharmaceutical 
company [10]. Overall, there is little evidence that oral administration of antifungals prolongs 
VP lifespan and there is also a concern that prophylactic antifungal use may contribute to the 
emergence of resistant strains.     
 
Finally, there have been some promising results investigating the use of synthetic salivary 
peptides, which exhibit bactericidal and fungicidal activity and are active against antifungal 
resistant Candida strains [219], to increase VP lifespan. Synthetic peptides dhvar4 and dhvar5, 
which are analogs of human histatin-5, were studied in an artificial throat VP model to 
determine their effect on VP biofilm integrity. Dhvar4 had no significant effect on mixed 
biofilms growing on Groningen button VPs, on the other hand, dhvar5 significantly reduced 
both bacteria and yeast numbers [220]. Intriguingly, airflow resistance through the VP valve, 
a hallmark of biofilm growth on these devices, remained high during dhvar5 treatment. 
Treatment with the mucolytic N-acetylcysteine removed most of the extracellular matrix 
(ECM) and decreased airflow resistance. This prompted the authors to conclude that VP 
lifespans are not only dictated by cell growth itself but also by the extent of biofilm ECM 
deposition [220]. These results raise important questions about which biofilm attribute (cell 




Overall, there have been some promising results in various studies investigating different 
strategies to prevent polymicrobial biofilm formation and thus increase VP lifespan. However, 
there has been limited success in translating these studies into effective clinical treatments 
and as such average VP lifespan has not increased significantly in the last 10 years [221].    
 
1.5 Aims of this Study 
The colonisation of voice prostheses by microorganisms such as Candida albicans and their 
subsequent removal is a significant burden to total laryngectomy patients. Despite numerous 
attempts, voice prosthesis lifespans have not significantly increased over the last 10 years and 
according to some studies may even be lower than originally thought [221]. Candida albicans 
is the primary fungal microbe consistently found on failed voice prostheses [202] and 
significantly contributes to their failure. Here, we further investigate the microbial landscape 
on failed voice prostheses while exploring treatment strategies, principally prophylactic 
antifungal application directly on VP surfaces, to increase VP in situ lifespan. We focus on the 
effect of physiologically relevant concentrations of CO2 (5%) [222] on biofilm formation in C. 
albicans to gain insights into its success in the VP scenario which could prove useful in the 
development of novel antifungal treatments in the future. We also hope that our findings will 
be more widely applicable to C. albicans infections in high CO2 niches within the host, many 
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2.1 Author Contributions 
All authors are members of a multidisciplinary team (MDT) at Canterbury Hospital, 
Canterbury, Kent. 
 
I (Daniel R. Pentland) wrote this paper in its entirety. Microorganism identification from early 
failing voice prostheses and initial antimicrobial sensitivity testing was carried out by Dr. Mark 
Baker at the William Harvey Hospital, Ashford, Kent. I was responsible for the full analysis of 
this microbiology data and the conclusions drawn. I also carried out all the experiments 
detailed within this paper.  
 
Throughout my PhD, as a member of the MDT at Canterbury Hospital, I met with other 
members every 3 months where I discussed, advised and was involved in both the formulation 
and the implementation of the novel VP antifungal treatment guidelines detailed in the paper. 
Together with Sarah Stevens and Leila Williams, I collated anonymised VP lifespan data for 
before and after antifungal treatment guidelines implementation. I was then responsible for 
the statistical analyses of this data presented in the paper.   
 
Finally, I have disseminated this research through presentations at both public lectures and 
professional conferences: 
1. July 2016 – British Yeast Group (University of Swansea, UK) 





2. January 2017 – Kent Cancer Trust Annual Public Lecture (University of Kent, UK) 
Oral presentation – ‘A Multi-Disciplinary (MDT) Approach to Combat Biofilm 
Formation on Voice Prostheses’   
3. May 2017 – Molecular Mechanisms of Host-Pathogen Interactions and Virulence in 
Human Fungal Pathogens (Nice, France) 
Poster – ‘Investigating the Colonisation of Voice Prostheses by Candida albicans’ 
4. September 2017 – British Yeast Group (University of Kent, UK) 
Poster – ‘Investigating the Colonisation of Voice Prostheses by Candida albicans’ 
5. March 2018 – Advanced Laryngectomy: Rehabilitation and Surgical Voice 
Restoration Course (Imperial College London, UK) 
Oral presentation – ‘Candida: The Facts. What it is, What it Does, and How to Control 
it’ 
6. June 2018 – British Yeast Group (University of Leicester, UK) 
Oral presentation – ‘Investigating the Effects of High CO2 on Candida albicans Biofilm 












Surgical voice restoration, which involves the use of a small silicone voice prosthesis (VP), is 
the gold standard for speech rehabilitation following total laryngectomy, a common 
treatment for advanced laryngeal cancer. Reported VP lifespans within patients are highly 
variable and the devices have to be changed on a regular basis, resulting in frequent clinician 
visits and increased medical costs. Multi-species biofilms comprised of both bacterial and 
fungal microorganisms easily colonise VPs, leading to loss of device function as well as 
creating a reservoir for infections. Through studying the biofilm composition on 159 early 
failing VPs from 48 total laryngectomy patients, we have confirmed that Candida species, 
particularly Candida albicans, are the predominant fungal species colonising early failing VPs. 
We also find that Staphylococcus aureus is the most common bacterial coloniser within our 
patient cohort. In addition, we present a 20 patient study of a novel antifungal focussed 
treatment strategy which significantly increases VP in situ lifespan from a mean of 71.9 to 
192.0 days, a 2.7-fold increase. Our treatment guidelines represent a significant advance in 
both our understanding of voice prosthesis failure and a new effective method to increase 





Head and neck cancer is the sixth most common cancer worldwide and the eighth most 
common cancer in the UK with 650,000 new cases (12,000 in the UK) and 350,000 deaths 
(4,000 in the UK) attributed to it each year worldwide [192][193]. Laryngeal malignancy is the 
most frequent head and neck cancer, making up 26.2% of newly diagnosed male cases and 
13.1% of female cases in the UK [193]. Approximately 12,000 people are diagnosed with 
laryngeal cancer each year in the United States [194].   
 
Laryngeal malignancy is treated with radiotherapy if it is diagnosed at an early stage, however, 
at later stages treatment involves surgery often in conjunction with radiotherapy [194]. The 
majority of head and neck cancers are diagnosed at an advanced stage; for example 62% of 
new diagnoses in Northern Ireland are reported to be at Stage III or IV (Stage IV alone accounts 
for 45%) [193]. Late diagnosis means that many cases of laryngeal cancer have to undergo a 
partial or total laryngectomy. It has been estimated that there are currently 50,000–60,000 
people who have had a laryngectomy living in the United States [194]. 
 
Following a total laryngectomy, the patient will no longer be able to breathe through their 
mouth or nose, instead breathing through a hole at the base of the neck called a 
tracheostoma (stoma) [197]. Furthermore, as the vocal cords are located within the larynx, 
most total laryngectomy patients are no longer able to form speech on their own. There are 
three major methods which 85-90% of laryngectomees employ to achieve speech; 
oesophageal speech, artificial larynx speech (use of a handheld device called an electrolarynx) 
and tracheoesophageal speech [194]. The gold standard for speech rehabilitation is 
tracheoesophageal speech which requires the use of a small silicone valve known as a voice 
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prosthesis (VP) [198]. The voice prosthesis is inserted into a tracheoesophageal puncture 
(TEP): a surgically-created puncture which is made behind the stoma between the trachea 
and the oesophagus. A VP is made up of a one-way valve within a central barrel with an 
anterior (tracheal) flange and a posterior (oesophageal) flange which serve to retain it within 
the tracheoesophageal wall. The VP functions to direct air from the trachea into the 
oesophagus during speech while inhibiting passage of food and liquid to the lungs. Air is 
forced through the voice prosthesis by covering the stoma, and this redirected air is 
modulated by the mouth to create speech [194].  
 
Voice prostheses are susceptible to colonisation by microbial biofilms [223]. Such 
contamination may be enhanced by the environment of the oesophagus e.g. foods, liquids 
(including saliva), humidity and constant temperature [10][199], and device failure has been 
attributed to such microbial growth as it can prevent valve closure [224][225] and thereby 
allow leakage of oesophageal contents into the airway. A loss of valve functionality can also 
lead to reduced airflow for speech and requires replacement of the device [192][195]. 
Moreover, the microbial colonisation may act as a reservoir of potential pathogens which may 
lead to life-threatening infections such as pneumonia [196]. The mean VP lifespan is highly 
variable across different studies and has historically been reported as being between 120 and 
200 days [201][203]. However, a recent large-scale study which analysed the lifespan of 3648 
VPs reported an average of 86 days [221].       
 
A number of strategies have been proposed to increase VP lifespan, such as the use of 
magnets to support the closing of the valve [226] and the incorporation of compounds, for 
example silver oxide, within the VP material to prevent microbe colonisation [227]. VPs 
 63 
 
containing magnets such as the Provox ActiValve have been shown to have longer in situ 
lifespans than other models [221][228]. However, the overall levels of success with these 
approaches has been variable and importantly the average VP device lifespan has not 
significantly increased over the last 10 years [221].  
 
Co-colonisation of VPs by bacterial and fungal species is commonly reported. Streptococcal 
species (e.g. Streptococcus mitis and Streptococcus sobrinus), Staphylococcal species (e.g. 
Staphylococcus aureus) [200], and Pseudomonas aeruginosa [201] are among the major 
bacterial microorganisms frequently isolated from voice prostheses. Candida species, 
particularly Candida albicans, Candida glabrata, and Candida tropicalis, are the primary 
fungal microorganisms isolated from VPs [202]. Microorganisms, such as C. albicans, colonise 
VPs by growing as biofilms. Biofilms are structured communities of microorganisms which are 
attached to either a living or non-living surface. The cells are often encased within an 
extracellular matrix composed of DNA [107][108], lipids [107], proteins [107][109] and 
polysaccharides [107]. Medically, biofilms are of particular importance because it is thought 
that a significant percentage of human microbial infections include biofilm formation 
[110][111][112]. Furthermore, cells within biofilms can be up to 1000x more tolerant to 
antimicrobial treatment than their planktonic counterparts [114][115].    
 
The exact microbial composition on any particular voice prostheses is influenced by several 
factors including patient diet, lifestyle and the voice prosthesis management regime to which 
they subscribe [10]. This is highlighted by a study conducted in India [201] which found a 
different microbial landscape with much higher numbers of P. aeruginosa,  to that described 
in similar European studies [204]. C. albicans is the most prevalent fungal coloniser of a voice 
 64 
 
prosthesis surface and thus a significant number of device failures correlate with the presence 
of C. albicans [202][204]. It is a commensal yeast that is found on the mucosal surfaces of the 
oral cavity, gastrointestinal tract and genitourinary tract of most healthy individuals [6][7]. C. 
albicans is a dimorphic fungus and biofilm formation of this organism involves a switch from 
growing in the typical budding yeast form to a filamentous hyphal form. This switch in 
morphology is also closely related to the shift from growing as a commensal organism to 
becoming pathogenic, since the hyphal form can invade human tissue [6]. Hyphal C. albicans 
cells express specific cell wall proteins, such as Als1 and Hwp1, which enable attachment to 
surfaces (and between cells) during biofilm maturation [132][133]. The yeast-to-hyphae 
switch is driven by a variety of environmental stimuli, including growth at 37oC [67][68], 
exposure to high levels of CO2 [69], and serum exposure [71].  
 
Despite being a commensal organism, it is also an opportunistic pathogen [6][8]; in fact, it is 
the most widespread of all the human fungal pathogens [9]. The infections caused by C. 
albicans range from superficial infection of mucosal surfaces (commonly referred to as 
candidiasis) to a full systemic infection called candidaemia which can advance to disseminated 
candidiasis whereupon fungal growths can occur within internal organs such the kidney, heart 
and brain [6]. The other fungal species which commonly colonise voice prostheses, such as C. 
glabrata, C. tropicalis and C. parapsilosis, also cause infections [229][230][231][232] and have 
been increasingly associated with nosocomial infections [8].  
 
Here we characterise the microflora found on early failing voice prosthesis from 48 patients 
within Kent (South East UK) over a 5-year period (2011-2016). We observe that multi-species 
biofilms form in most cases with C. albicans and S. aureus being the most prevalent. We 
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demonstrate that the high CO2 environment experienced in the airway promotes C. albicans 
biofilm formation on VPs, providing an explanation for its prevalence. We devised a strategy 
to tackle yeast contamination that involved the directed application of antifungals verified to 
be most effective in drug sensitivity assays of clinical isolates. We report results from a 20 
patient study that verifies antifungal treatment as an effective approach to VP lifespan 
extension. Over 8 years, this study documented voice prosthesis in situ lifespan, both before 
and after implementation of the antifungal treatment guidelines. Statistical analyses 
confirmed that the treatment guidelines significantly increased voice prosthesis lifespan 
within the patient cohort. Our guidelines represent a significant advance in both our 




2.4 Materials and Methods 
2.4.1 Patient cohort and voice prostheses 
Biofilms from a total of 159 voice prostheses from 48 patients were analysed for 
microorganism composition. All prostheses were removed from patients attending one of the 
three main acute hospital sites within East Kent, UK: William Harvey Hospital, Ashford; 
Canterbury Hospital, Canterbury; Queen Elizabeth the Queen Mother Hospital, Margate. 38 
of these patients had multiple voice prosthesis failures and were followed as part of the 
Candida management guideline impact study, which documented the voice prosthesis 
lifespans before and after implementation of the treatment guidelines.  
 
2.4.2 Microorganism isolation and identification 
To determine which microorganisms were present, a failed voice prosthesis was removed 
from the patient and sealed in a sterile pot. Upon receipt at the microbiology laboratory, the 
voice prosthesis was added to 2ml saline solution along with glass beads and vortexed at 
2500rpm for 30 seconds. The resulting suspension was plated on chromogenic agar to 
preliminarily distinguish species. 50μl of the suspension was also plated on Sabouraud 
Dextrose Agar (SDA) plates (Oxoid, CM0041) containing 100μg/ml chloramphenicol (Oxoid, 
SR0078) to promote the growth of fungal species while inhibiting bacterial growth. 
Chromogenic agar and SDA plates were incubated for 48 hours at 37oC. Bacterial colonies 
were then picked from the chromogenic plates and fungal colonies were picked from the SDA 
plates, species were identified using matrix assisted laser desorption ionisation time-of-flight 





2.4.3 MALDI-ToF mass spectrometry identification of microorganisms 
MALDI-ToF mass spectrometry was used to identify species isolated from failed voice 
prostheses within this study. Fungal and bacterial colonies were picked and applied to a steel 
MALDI target plate before being overlaid with an α-cyano-4-hydroxycinnamic acid (4-HCCA) 
matrix (Sigma-Aldrich, 70990) [233]. MALDI-ToF mass spectrometry was performed using a 
Bruker MALDI Biotyper (Bruker) as per the manufacturer’s instructions. The resulting mass 
spectra were compared to a reference database for identification using the MBT Compass 
and MBT Explorer Software along with the MBT Compass Library which comprises 
approximately 2750 species from 471 microorganism genera.  
 
2.4.4 Antifungal sensitivity testing 
Antifungal sensitivity testing was performed using the FungitestTM commercial testing kit 
(BioRad, 60780) as per the manufacturer’s instructions. Briefly, isolated colonies were 
selected from culture plates (see Microorganism isolation and identification) and suspended 
in 3ml sterile distilled water. This suspension was then used to inoculate 3ml of RPMI-1640 
media to a density of 103 CFU/ml and 100µl of this resulting suspension was placed in each 
well of the FungitestTM plate. The FungitestTM plates were incubated for 48 hours at 37oC, at 
which point the fungal growth was measured via a colorimetric readout (blue = no growth, 
pink = growth). Isolates were assigned sensitive, intermediate or resistant based upon the 
European Committee on Antimicrobial Sensitivity Testing (EUCAST) breakpoint 






2.4.5 Antibacterial sensitivity testing 
Antibacterial sensitivity testing was carried out to determine the minimum inhibitory 
concentrations (MICs) of clinically commonly used antibiotics. The sensitivity testing was 
performed using a standard broth microdilution procedure in accordance with the 
International Standard ISO 20776-1 method (detailed at: 
https://www.iso.org/obp/ui/#iso:std:iso:20776:-1:ed-2:v1:en) as recommended by EUCAST 
[235]. Isolates were assigned sensitive, intermediate or resistant based upon the EUCAST 
breakpoint recommendations for each antibiotic and/or species [236].  
 
2.4.6 Scanning electron microscopy (SEM) of voices prosthesis surfaces 
Segments were taken from the valve and flange of a Provox Vega voice prosthesis and 
mounted onto 12.5mm aluminium SEM specimen stubs (Agar Scientific, AGG301) with 
superglue. The surfaces were imaged at ambient temperature with a Hitachi S-3400N 
scanning electron microscope, using the variable pressure scanning electron microscopy (VP-
SEM) mode with a chamber pressure of 30Pa and accelerating voltage of 10kV. The 
backscattered electron (BSE) detector in conjunction with the energy dispersive X-ray 
spectroscopy (EDS) detector was used throughout with a working distance of 10mm. The 
acquisition software was Oxford Instruments INCA and images were exported directly from 
this.  
 
2.4.7 Atomic force microscopy (AFM) of voice prosthesis surfaces 
Segments were taken from the valve and flange of a Provox Vega voice prosthesis and 
mounted onto 15mm AFM specimen discs (Agar Scientific, F7003) with superglue. These 
surfaces were imaged at ambient temperature using a Bruker Multimode 8 scanning probe 
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microscope with a Nanoscope V controller, using the ScanAsyst peak-force tapping mode with 
a 50μm x 50μm scan area and a 700nm scan height. SCANASYST-AIR (Bruker) silicon nitride 
cantilevers (tip height of 2.5-8.0μm, nominal tip radius of 2nm) with a nominal spring constant 
of 0.4N/m and a resonance frequency of 70kHz were used throughout. The image acquisition 
software was Nanoscope 8.15 R3sr5 and the processing software was Nanoscope Analysis. 
 
2.4.8 Candida strains and growth media  
Candida strains (Table S3) were routinely grown at 30oC in yeast peptone dextrose (YPD) 
media (2% peptone (BD Bacto), 2% D-glucose (Fisher Scientific), 1% yeast extract (BD Bacto)). 
For the biofilm growth assays, Candida biofilms were grown at 37oC in RPMI-1640 media 
(Sigma-Aldrich, R8755) supplemented with 80µg/ml uridine (Sigma-Aldrich, U3750). Candida 
strains were maintained in YPD + 20% glycerol at -80oC for long-term storage and revived at 
30oC on YPD + 2% Technical Agar (Oxoid) plates. 
 
2.4.9 In vitro biofilm growth assays 
C. albicans biofilms were grown on a PDMS silicone elastomer (Provincial Rubber, S1). The 
silicone was cut into 1cm2 squares and placed in clips in a modified 24-well plate lid (Academic 
Centre for Dentistry Amsterdam, AAA-model – Figure S1) so they could be suspended in 
media within a sterile 24-well plate (Greiner Bio-one, CELLSTAR, 662160). Silicone squares 
were incubated in 1ml 50% Donor Bovine Serum (DBS) (Gibco, 16030074) for 30 min at 30oC, 
then washed twice with 1ml Phosphate-Buffered Saline (PBS – 137mM NaCl, 2.7mM KCl, 
10mM Na2HPO4, 1.8mM KH2PO4, pH 7.4) to remove excess DBS. Candida strains were 
inoculated into a test tube containing 5ml YPD media and placed in a 30oC orbital shaking 
incubator with constant shaking at 180rpm for 18h. OD600 measurements were taken and a 
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volume of overnight culture corresponding to OD600 = 1.0 (3 x 107 CFU/ml) was removed. 
These cells were pelleted by centrifugation at 4000rpm for 5 min at which point the 
supernatant was discarded. The resultant pellet was re-suspended in 5ml PBS to wash and 
centrifuged again at 4000rpm for 5 min. The PBS supernatant was discarded and the pellet 
re-suspended in fresh PBS (at an OD600 of 1.0). The OD600 1.0 standard cell suspension was 
added to wells (1ml per well) in a pre-sterilised 24-well plate and the lid with the silicone 
squares attached was placed on top so the silicone squares protruded into the cell 
suspension. These plates were then incubated at 37oC (in either 0.03% CO2 or 5% CO2) without 
shaking for 90 min to allow cell attachment to the silicone. After the attachment phase, the 
silicone squares were washed twice with 1ml PBS to remove any unattached cells and 
transferred to 1ml RPMI-1640 media (Sigma-Aldrich, R8755). They were then incubated at 
37oC (in either 0.03% CO2 or 5% CO2) without shaking for up to 48 h to allow biofilm 
maturation. Growth of biofilms on the surface of a sterile VP was conducted using the same 
protocol. 
 
2.4.10 Biofilm quantification via XTT assay     
Biofilm growth was quantified using an XTT assay [237]. Biofilms were washed twice with 1ml 
PBS to remove any planktonic cells before proceeding to quantification. After washing, the 
biofilms were transferred to a new pre-sterilised 24-well plate (Greiner Bio-one, CELLSTAR, 
662160) containing 30µg/ml XTT labelling reagent (Roche, 11465015001) and incubated at 
37oC for 4h. After incubation, the biofilms were removed from the 24-well plate and the 
absorbance of the remaining XTT labelling reagent was measured at 492nm using a BMG 




2.4.11 Antifungal treatment of biofilms 
Biofilms were seeded on silicone elastomer sections as described above and grown in RPMI-
1640 for 24h at 37oC. The biofilms were then transferred to fresh RPMI-1640 media containing 
an antifungal, either; Fluconazole, Miconazole or Nystatin to represent those used in the 
clinical guidelines (Figure S4). Fluconazole (Santa Cruz Biotechnology, sc-205698) was made 
as a 50mg/ml stock solution in ethanol and diluted in RPMI-1640 final concentrations of 
32µg/ml and 128µg/ml. Miconazole (Santa Cruz Biotechnology, sc-205753) was made as a 
50mg/ml stock solution in DMSO and also diluted in RPMI-1640 to final concentrations of 
32µg/ml and 128µg/ml. Nystatin (Santa Cruz Biotechnology, sc-212431) was made as a 
5mg/ml stock solution in DMSO and diluted in RPMI-1640 to final concentrations of 2µg/ml 
and 8µg/ml. Drug vehicle controls (0.25% ethanol for Fluconazole, 0.25% DMSO for 
Miconazole and 0.15% DMSO for Nystatin) were used to ensure the solvents were not 
affecting biofilm growth. The biofilms matured in the RPMI-1640 media containing the select 
antifungal for a further 24h at 37oC in both 0.03% and 5% CO2 before proceeding to 
quantification via the XTT assay. Experiments were performed in biological and technical 
triplicate.  
 
2.4.12 Mixed species biofilm competition assays 
Biofilms were set up as described previously, except that for mixed biofilms C. albicans and C. 
parapsilosis clinical isolate overnight cultures were each counted and adjusted to 1.5x107 
CFU/ml to give a 3x107 CFU/ml overall inoculum (equivalent to OD600 of 1.0) for the 90 min 
attachment phase. After attachment, the silicone squares were washed twice with 1ml PBS 
to remove any unattached cells and transferred to 1ml RPMI-1640 media (Sigma-Aldrich, 
R8755). They were then incubated at 37oC in both 0.03% CO2 or 5% CO2 without shaking for 
 72 
 
48h to allow biofilm maturation before proceeding to quantification via the XTT assay. 
Experiment was performed in biological and technical triplicate. 
 
2.4.13 Biofilm composition analysis via chromogenic agar 
Silicone squares with biofilms on them were dropped into 2ml PBS and vortexed for 10 
seconds at 2500rpm to release the biofilm cells from the surface. The resulting biofilm cell 
suspension was plated on Candida Ident. Agar (Fluka Analytical, 94382) in triplicate (200µl per 
plate). The chromogenic agar plates were incubated at 30oC for 48h, at which point 
photographs of the plates were taken. C. albicans colonies appeared green and C. parapsilosis 
colonies stayed white on the Candida Ident Agar plates. 
 
2.4.14 Analysis of voice prosthesis lifespans 
Voice prosthesis lifespans of patients living in East Kent, UK were investigated over the course 
of 8 years (2010-2018). In total, 38 patients had their voice prosthesis lifespan documented. 
However, 18 patients were removed from further analysis due to a lack of adherence to the 
guidelines, moving out of the hospital catchment area resulting in incomplete data entries, 
incomparable data (e.g. changes in voice prosthesis type or width), or simply not enough voice 
prostheses failures/changes for statistical analysis within the time period. The voice 
prosthesis lifespans of the remaining 20 patients, before and after the implementation of our 
treatment guidelines, were analysed using the Online Application for Survival Analysis 2 
(OASIS 2) platform [238]. In total, 143 voice prostheses before and 176 after implementation 
of the guidelines were included in this study. Kaplan-Meier survival curves were plotted and 
log-rank tests performed to statistically compare device lifespans before and after the 
treatment guidelines. Wilcoxon Signed-Rank tests were also carried out to determine if the 
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guidelines effect was significant when taking into account the inherent differences in device 
lifespan from patient to patient. For all analyses, the significance level (α) was 0.05. 
  
2.4.15 Treatment guideline approval 
Treatment guidelines for the treatment of voice prostheses with antifungal drugs were 
approved by the East Kent Hospital University Foundation Trust (EKHUFT) Voice Prosthesis 
Infection Management Multi-disciplinary team (MDT), EKHUFT Antimicrobial Stewardship 
Group, EKHUFT Drugs and Therapeutics Committee, EKHUFT ENT Audit Group, and EKHUFT 
Adult Speech and Language Therapy Service, East Kent Prescribing Group. 
 
2.4.16 Study approval 
The collection and identification of microorganisms on early failing voice prosthesis study was 
approved by the University of Kent Research Ethics and Governance Committee.  
 
The voice prosthesis lifespan study was approved by the EKHUFT Research and Innovation 
Department in accordance with the Department of Health’s Research Governance Framework 
for Health and Social Care and EKHUFT Research and Innovation policy. The EKHUFT Research 
and Development reference number for this project is 2018/GAP/20. This study was also 







We conducted a study to determine the most common fungal and bacterial species found 
upon failed voice prostheses. Our study cohort comprised 48 patients (41 males and 7 
females) within the National Health Service catchment area of East Kent, UK, who had a total 
of 159 early failed voice prostheses sent for microbial analysis between them over the five-
year period of the study. The mean age of the patient cohort at the start of the study was 
69.5 years (age range = 35 – 90 years). The microbial composition of biofilms on the failed 
voice prosthetic surfaces was analysed by initial culturing on chromogenic agar followed by 
matrix assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-ToF). 
Bacterial and fungal species were usually found together on early failing VPs suggesting a 
prevalence for mixed species biofilm formation as previously described [204].  
 
2.5.1 Analysis of bacterial species found on early failing voice prostheses 
S. aureus was the most frequently isolated bacterial species (Figure 1B), being found on 
multiple early failing VP (Figure 2.1B and 2.1C). This finding is in line with previous studies that 
also identified S. aureus as the prevalent bacterial organism found within VP biofilms  
[200][239]. However, S. aureus was one of several Staphylococcal species identified, the 
others being identified at lower frequencies included Staphylococcus epidermidis and 
Staphylococcus schleiferi (Figure 2.1B and 2.1C). We also identified the S. aureus strain 
methicillin-resistant S. aureus (MRSA) on 5 VPs and counted these separately from the rest of 
the S. aureus isolates (Figure 2.1B and 2.1C). These 5 VPs all came from the same patient, 
suggesting there are likely patient-specific reasons for this colonisation. P. aeruginosa was the 
second most frequent bacterial species found on early failing VPs (Figure 2.1B and 2.1C). 
Previous studies have also identified P. aeruginosa as a prevalent bacterial species found 
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within VP biofilms [201]. Several Streptococcus species were also identified, but at a low 
frequency, including Streptococcus milleri, Streptococcus mitis, and Streptococcus 
intermedius (Supplementary Table S2.1).  
 
It is worth noting that the same bacterial species were frequently isolated from sequential 
VPs removed from the same patient implicating a common pattern of biofilm establishment. 
In total, 30 of 38 patients (78.9%) had the same bacterial species present on at least 2 voice 

































Figure 2.1: The range and distribution of bacterial species found on voice prostheses within this study. 
(A) An example of a failed voice prosthesis removed from a patient. Note the ring of colonisation on the 
prosthesis hood around the valve mechanism. (B) Bar graph representation of absolute numbers of times 
each bacterial species was isolated from 159 early failing VPs. (C) Pie chart representation of percentage 
of total bacteria isolated from 159 early failing VPs. 
Provox Vega VP 
before insertion 
Provox Vega VP 
after early failure 
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2.5.2 Analysis of fungal species found on early failing voice prostheses 
Yeast species were commonly isolated from early failing VPs. Within the 159 voice prostheses, 
107 (67.3%) were colonised by a single yeast species, 37 (23.3%) were colonised by multiple 
yeast species, and just 15 (9.4%) showed no yeast species presence. Interestingly, the three 
VPs without yeast colonisation came from the same patient, and represented 100% of their 
failed voice prostheses. In total, 178 yeast isolates were identified and 168 (94.4%) of these 
were Candida species, the remaining 10 fungal isolates were made up of Saccharomyces 
cerevisiae (8) and Pichia manshurica (2). S. cerevisiae and P. manshurica isolates were 
normally found alongside Candida species (62.5% and 100% respectively). The most 
frequently isolated yeast species was C. albicans (Figure 2.2). This is in line with previous 
studies which identified C. albicans as the yeast species most commonly found on VPs 
[202][204][240]. The non-albicans Candida isolates constituted 44.4% of all fungal isolates, 
with Candida glabrata being the most common of these (Supplementary Table S2.2). 
 
As had been observed for bacteria, the same fungal species were frequently isolated from 
multiple early failing VPs from the same patient. In total, 38 of the 48 patients had more than 
one voice prosthesis failure during the course of the study and 29 (76.3%) of these had the 
same fungal species on at least 2 VPs (25 of these also had the same bacterial species on at 
least 2 voice prostheses). The most commonly reoccurring fungal species was C. albicans, 































Figure 2.2: The range and distribution of fungal species found on voice prostheses within this study. 
(A) Bar graph representation of absolute numbers of times each yeast species was isolated from 159 







2.5.3 Co-isolation frequencies of different species from early failing voice prostheses 
Fungal and bacterial species were often found together on VPs, 134 (84.3%) of the early failing 
VPs had at least one species of each present. The two most numerous species in this study, S. 
aureus and C. albicans, were the most commonly co-isolated, being found together on 60 VPs 
(Table 2.1). This may simply be due to the fact they were the two most prevalent species on 
voice prostheses in this study. However, it has previously been demonstrated that these two 
organisms have a synergistic advantage within the biofilm scenario [241][242]. Thus, it is likely 
these two microorganisms also have a synergistic relationship on VPs. Furthermore, other 
Candida species were frequently isolated alongside S. aureus (Table 2.1), again possibly 
indicating a relationship between fungal and bacterial species. Other bacterial species such 
as P. aeruginosa and S. marcescens were co-isolated with C. albicans the majority of the time; 
57.1% and 83.3% respectively (Table 2.1). It was very rare for only fungal species to be 
present; only 10 (6.3%) VPs harboured solely fungal species and all of these were either the 
first or second voice prosthesis failure of their respective patients. After a second failure, 
there was never solely fungal species present. The significance of this, if any, is yet to be 
determined.  
 
The two most commonly co-isolated fungal species were C. albicans and C. glabrata which 
were isolated together on 17 VPs; on 73.9% of VPs where C. glabrata was present, C. albicans 
was also co-isolated (Table 2.1). C. krusei was co-isolated with C. albicans 63.6% of the time. 
Interestingly, C. parapsilosis was seldom co-isolated with other Candida species; of the 14 VPs 
which harboured C. parapsilosis, only 1 also had other Candida species (C. albicans and C. 





























































































































































































2.5.4 Factors promoting microbial colonisation of voice prostheses  
Examination of early failing VPs often suggested an uneven distribution of microbial growth 
across the device surface (Figure 2.1A). We investigated surface topography using atomic 
force and scanning electron microscopy as roughness has been shown to be an important 
driver of colonisation [243][244]. The prosthesis hood and oesophageal flange of the device 
exhibited a significantly rougher topography than the valve which appeared smooth using 
these high resolution techniques (Figures 2.3B and 2.3C). The roughness of the oesophageal 
flange was particularly evident in the AFM 3D plot of its surface (Figure 2.3D). In line with 
previous studies, this may suggest that the flange, specifically the valve-flange interface, 
provides a more likely site for initial attachment [224]. This proposition is also consistent with 
our observations that failed voice prostheses often exhibit heavy colonisation on the 
prosthesis hood and oesophageal flange (Figure 2.1A), particularly at the rougher inner edge 






































Figure 2.3: Atomic force and scanning electron microscopy surface topography of the valve and 
oesophageal flange of the Provox Vega voice prosthesis. (A) The Provox Vega voice prosthesis. (B) SEM 
images of the (i) valve and (ii) inner-side of the prosthesis hood were taken at x120 magnification. The 
scale bars represent 700μm. (C) AFM images of the (i) valve and (ii) oesophageal flange were taken of 
50μm x 50μm surface areas with a scan height of 700nm. (D) AFM 3D plot of a 50μm x 50μm area of the 










Environmental factors may also contribute to microbial contamination and early failure of 
voice prostheses. High CO2 levels promote the C. albicans yeast-to-hyphae switch via the 
Ras1-Cyr1-PKA pathway [69]. This morphogenic switch is associated with C. albicans virulence 
[6] as well as being required for biofilm formation [142]. Due to the high CO2 levels (∼5%) 
experienced in the airway as a result of exhaled breath [245], we contemplated whether CO2 
could be exerting an effect on C. albicans biofilm formation in the VP scenario. Indeed, when 
seeded onto a voice prosthetic surface, C. albicans has increased biofilm growth in 5% CO2 
after 24h than in atmospheric air (Figure 2.4). This offers an explanation as to why C. albicans 
is such a prevalent coloniser of early failing VPs, as the valve mechanism and parts of the 















Figure 2.4: C. albicans biofilm forming on the flange of a voice prosthesis in vitro in both 
atmospheric air and elevated CO2 conditions. C. albicans biofilm formation was assessed on a Provox 
Vega VP at 37oC under atmospheric air and elevated CO2 conditions that mimic exhaled breath. 
Images were collected after 24h at x8 and x100 magnification. The experiment was repeated three 
times and representative images are presented. 
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2.5.5 C. parapsilosis does not have a competitive advantage over C. albicans in biofilm 
establishment  
We observed that Candida parapsilosis was rarely co-isolated with another Candida species. 
Of the 14 VPs which harboured C. parapsilosis, only 1 also had another Candida species 
present. This is a stark contrast to other Candida species, such as C. glabrata which was found 
on 23 VPs, 19 of which also had additional Candida species (Table 2.1). This led us to 
investigate whether C. parapsilosis exhibited a competitive advantage over C. albicans with 
regards to biofilm growth. A C. parapsilosis clinical isolate found as the sole yeast species on 
a failed VP was selected for this investigation. Biofilms were seeded using equal cell numbers 
of the C. albicans and C. parapsilosis clinical isolates either alone or in combination and 
incubated for 48h to mature. Overall biofilm growth was analysed by measuring the metabolic 
activity of the biofilms using the XTT colorimetric assay which gives a colour readout that 
correlates well with cell number [237] (Figure 2.5). The proportions of C. albicans and C. 
parapsilosis cells were then analysed by removing biofilms from the silicone surface and 
plating the resulting cell suspension on chromogenic agar (Supplementary Figure S2.2). 
Strikingly, while the C. albicans G-3065 clinical isolate was able to form a robust biofilm on 
the silicone surface, the C. parapsilosis G10402 clinical isolate was not (Figure 2.5). Moreover, 
when these two clinical isolates were seeded together, the resultant biofilm was composed 
primarily of C. albicans cells (Supplementary Figure S2.2). In addition, while C. albicans 
biofilms were significantly increased (p < 0.01) when grown in the presence of increased CO2 
this was not observed for C. parapsilosis. These data suggest that the identification of C. 
parapsilosis in isolation on failed VPs may not arise from a competitive advantage over C. 





















2.5.6 Antimicrobial sensitivity of clinical isolates 
Antibacterial sensitivities (sensitive, intermediate or resistant) were assigned based upon 
EUCAST breakpoint recommendations for each antibiotic in each particular species [236]. The 
sensitivities of the five most common bacterial species found on early failing VP to an example 
antibiotic from the five major antibiotic classes [246] are reported (Table 2.2). Only 10 (8.5%) 
of the most common bacterial isolates tested for sensitivity against the β-lactam antibiotic 
Amoxicillin were judged to be sensitive, and these were all S. aureus isolates. All of the P. 
Figure 2.5: In vitro biofilm assay using C. albicans and C. parapsilosis early failing VP clinical isolates. 
Biofilms were seeded and grown for 48h to mature before quantification using the XTT assay. The C. 
albicans G-3065 clinical isolate makes bigger biofilms than the C. parapsilosis G10402 clinical isolate, and 
this biofilm formation is influenced by CO2 concentration. The graph represents three independent 
experiments each containing triplicates, error bars denote Standard Deviation. Paired two-tail t-tests were 
carried out: *p<0.05, **p<0.01, ***p<0.001, n.s. = not significant.  
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aeruginosa, S. marcescens, MRSA, and K. pneumoniae isolates tested for Amoxicillin 
sensitivity were resistant. 76 (74.5%) were deemed to be sensitive to the macrolide 
Erythromycin, with a significant number of S. aureus isolates being found to be resistant. The 
majority of the common bacterial isolates were sensitive to the fluoroquinolone Ciprofloxacin 
with 111 (93.3%) being judged as sensitive, however, all of the MRSA isolates tested were 
resistant to Ciprofloxacin. Likewise, a high number of isolates were sensitive to the 
tetracycline Tetracycline (104 – 87.4%), but this antibiotic did not exhibit good activity against 
the P. aeruginosa and S. marcescens isolates with 5 (83.3%) of both species being resistant. 
Finally, 115 (96.6%) of the common bacterial isolates tested were sensitive to the 
aminoglycoside Gentamicin, this was in fact the most effective antibiotic tested in this study 







































 Table 2.2: Antibiotic sensitivity of the five most common bacterial species isolated from early 
failing VPs. The number of sensitive, intermediate and resistant isolates based upon EUCAST 
breakpoint recommendations [47] are given for the five most commonly isolated bacterial species.  
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Antifungal sensitivity testing was performed using the FungitestTM commercial testing kit (see 
Materials and Methods). Sensitivities (sensitive, intermediate or resistant) were assigned 
based upon EUCAST breakpoint recommendations for each antifungal in each particular 
species [234]. The majority of the fungal isolates from the voice prostheses were sensitive to 
Fluconazole, Miconazole and Nystatin (Table 2.3); three commonly used antifungals in the 
clinical setting. Of the 168 Candida isolates, 155 were tested for Fluconazole sensitivity and 
139 of these were found to be sensitive (89.7%). Moreover, 123 of the Candida isolates were 
tested for Miconazole sensitivity and 107 were sensitive (87.0%). Finally, 129 of the Candida 
isolates were tested for Nystatin sensitivity and 126 of these were found to be sensitive 
(97.7%). Nystatin therefore appeared to be the most effective antifungal with regards to 








































Table 2.3: Antifungal sensitivity of the five most common Candida species isolated from early failing 
VPs. The number of sensitive, intermediate and resistant isolates based upon EUCAST breakpoint 




2.5.7 Antifungal sensitivity of C. albicans clinical isolates within biofilms 
It has been established that biofilm-associated cells are commonly more tolerant to 
antimicrobials than their planktonic counterparts [115]. As laboratory based sensitivities are 
based upon planktonic growth we investigated whether C. albicans isolates obtained from 
early failing VPs demonstrated antifungal tolerance when grown as a biofilm on a silicone 
surface. Biofilms were seeded and grown for 24h before the addition of antifungals, after 
which they were grown for an additional 24h to observe the effect of drug application. 
Antifungal concentrations were selected based upon previously reported MIC values for these 
antifungals against C. albicans biofilms [115]. Due to the previously observed effect of high 
CO2 concentration increasing C. albicans biofilm growth (Figures 2.4 and 2.5), we also sought 
to investigate whether CO2 level had any influence on the activity of the antifungals.  
 
Overall, the clinical isolates displayed higher tolerances to Fluconazole and Miconazole 
compared to Nystatin (Table 2.4). Moreover, this azole tolerance was significantly increased 
in biofilms grown in high CO2 environments (Supplementary Figures S2.3 and S2.4). For 
instance, G-8424 biofilms grown in 0.03% CO2 had an average decrease in XTT activity of 59% 
relative to the untreated control upon treatment with 32µg/ml Fluconazole (p < 0.001), 
whereas there was no significant decrease in relative XTT activity in the 5% CO2 G-8424 
biofilms (Table 2.4 and Supplementary Figure S2.3). This is also true for the 128µg/ml 
Miconazole treatments in all three isolates (Table 2.4 and Supplementary Figure S2.4). 
Furthermore, despite the fact that 0.03% and 5% CO2 G-1625 biofilms both displayed 
significant decreases in relative XTT activity upon Fluconazole treatment, the relative XTT 
activity is still significantly higher (p < 0.05) in the biofilms grown in 5% CO2 (Supplementary 
Figure S2.3). Nystatin sensitivities were generally independent of CO2 concentration (Figure 
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2.6). The G-3065 and G-8424 clinical isolate biofilms were more tolerant to Fluconazole and 
Miconazole than the G-1625 isolate, however, all isolate biofilms exhibited good sensitivity to 
Nystatin (Table 2.4). Based on these data, we conclude that Nystatin is the most potent 
against C. albicans biofilms on silicone surfaces and also offers the greatest protection against 
the CO2 biofilm activation. However, Fluconazole and Miconazole are still both efficacious 



















Table 2.4: Antifungal sensitivity of biofilms of three C. albicans clinical isolates from early failing VPs. 
Action of antifungals was measured via the percentage XTT assay activity relative to untreated in both 























2.5.8 Development and clinical testing of antifungal treatment guidelines (ATG) to extend 
VP lifespan  
Although VP biofilms are likely to be formed from several species we hypothesised that an 
antifungal approach to reduce colonisation would be effective in extending device lifespan. 
The rationale behind this was based primarily upon the likelihood that yeast contamination 
Figure 2.6: Nystatin sensitivities of C. albicans clinical isolate biofilms. Biofilms were seeded and grown for 
24 hours before addition of Nystatin, they were then grown for a further 24 hours before quantification 
using the XTT assay. The relative XTT activity is presented with the 0.03% and 5% CO2 biofilms normalised 
to the 0.03% and 5% CO2 untreated controls respectively. This prevents the general higher growth of 5% CO2 
biofilms impacting the analysis. Graphs represent three independent experiments each containing 
triplicates, error bars denote Standard Deviation. Two-way ANOVAs followed by a Tukey test for multiple 
comparisons were carried out: *p<0.05, **p<0.01, ***p<0.001. Stars directly above the bars indicate a 
significant difference to untreated in the same CO2 environment, for clarity only comparisons which were 




would contribute significant biomass that is more likely to impair valve function. In addition, 
we have observed that the elevated CO2 environment in which a VP sits promotes biofilm 
growth of the most commonly isolated yeast, C. albicans. As other commonly isolated 
bacteria, such as S. aureus and P. aeruginosa have been reported to use Candida hyphae as a 
scaffold to attach to during biofilm formation [247], it may be the case that antifungal 
treatment also attenuates the bacterial colonisation.  
 
The antifungal drugs selected for treatment were chosen based upon safety and the fungal 
sensitivity data (Tables 2.3 and 2.4), with Nystatin being demonstrated to be the most 
effective as it had the lowest levels of resistance (Table 2.3) along with being reported as 
having few side effects and no drug interactions [248]. Previous studies have also identified 
that most non-albicans Candida species have higher azole MICs [249][250], whereas all 
Candida species have low in vitro nystatin MICs [251]. Moreover, C. albicans sensitivity to 
Nystatin when in a biofilm appears to be unaffected by CO2 level (Figure 2.6).   
 
Our antifungal voice prosthesis management pathway involves determining the identity and 
antimicrobial sensitivities of microorganisms present on a failed VP. Based on the antifungal 
sensitivities of the colonising fungal species, a course of antifungals (most commonly 
Nystatin) is suggested and prescribed for topical application directly to the VP (brushed 
through it with a voice prosthesis cleaning brush). Fluconazole may be prescribed for oral use 
if tissue granulation is present around the TEP. Subsequent VP lifespans should be carefully 
monitored to determine if treatment is having a positive effect on device lifespan and 
accompanying microbiology analysis conducted to assess the emergence of antifungal 
resistance. If Nystatin does not improve device lifespan sufficiently then Miconazole gel 
 94 
 
applied directly to the voice prosthesis is the next treatment option after Nystatin, depending 
on the results of sensitivity testing.  Any patients that do not observe a VP lifespan increase 
are referred to the managing multi-disciplinary team (MDT) for discussion and 
recommendations on further treatment options. The treatment guidelines are briefly 
summarised in Figure 2.8C, described in detail in Supplementary Figure S2.5 and found with 
an additional information document at http://southkentcoast.referralsupport.co.uk/wp-
content/uploads/2019/04/Clinical-guidelines-for-the-management-of-early-voice-
prostheses-failure-associated-with-Candida-infection-EKPG-Oct-2016.pdf.    
 
To test the effectiveness of our antifungal approach to managing early voice prosthesis failure 
associated with Candida colonisation, VP data from 38 patients was assessed. VP lifespan data 
from the patient cohort before and after their placement on the ATG was assessed. Over the 
course of the study, 18 patients were removed from further analysis because of either; known 
lack of adherence to the ATG, moving out of the hospital catchment area resulting in 
incomplete data entries, a change in voice prosthesis type or width or insufficient VP 
replacement data. This left 20 patients with complete VP lifespan data entries before and 
after guideline implementation on which to conduct statistical analyses.  
 
Throughout the 8 year course of the study, the lifespan of 319 voice prostheses (143 before 
and 176 after guidelines) across the 20 patient cohort were analysed. These 319 voice 
prostheses represented all the VP changes for the 20 patients when the removed VP was 
replaced by the same model of the same width. This ensured there were no external factors 
such as VP surface/surface area influencing the results. We also included all changes and not 



























Figure 2.7: Kaplan-Meier survival curves showing the voice prosthesis in situ lifespans before and after 
implementation of our antifungal treatment pathway. (A) Device lifespans were documented before and 
after implementation of the ATG. Kaplan-Meier survival curves were plotted using the OASIS2 online 
platform [49] and a log-rank test was used to compare the survival curves: p<0.001. Red line is at 180 days 
lifespan which we targeted as the ideal lifespan to achieve. (B) After lifespan analysis across all devices 
was performed, the lifespans were categorised into groups depending on which VP model a patient was 
using. Kaplan-Meier survival curves were again plotted using the OASIS2 online platform [49] and log-rank 
tests were used to compare them: Blom-Singer Classic, Before vs. After; p<0.001. Provox Vega, Before vs. 
After; p<0.001. 
Blom-Singer Classic Before Guidelines 
Blom-Singer Classic After Guidelines 
Provox Vega Before Guidelines 









Overall, implementation of the ATG resulted in a significant (p < 0.001) increase in VP lifespan 
within our patient cohort (Figure 2.7A). Importantly, this lifespan increase was not dependent 
on VP manufacturer/model as both the Blom-Singer Classic and the Provox Vega (the two 
most common VPs in this study) had similar lifespan increases (Figure 2.7B). It is also 
important to highlight that the lifespans of these two VP models were not significantly 
different to one another either before or after the treatment guidelines implementation 
(Figure 2.7B). The mean voice prostheses lifespan before guideline implementation was 71.9 
days (range = 4-401 days) and this increased to 192.0 days (range = 2-661 days) after 
implementation of the antifungal management pathway, representing an average 270% 
increase in lifespan (Figure 2.8B).  
 
Although there was variation in average post guideline VP lifespan increase between patients, 
the majority of the patients in our cohort experienced an overall increase in device lifespan 
(Figure 2.8A). Two patients did not exhibit an increase in VP lifespan, instead having a slight 
decrease of -2.4 days and -45.5 days respectively (Figure 2.8A). However, these two patients 
had long-lived voice prostheses on average (97.1 days and 193.3 days respectively) in 
comparison with the rest of the cohort prior to the introduction of the new antifungal clinical 
guidelines. This is particularly evident for patient 16 whose voice prostheses were already 
lasting longer than the post treatment guidelines mean lifespan across all patients. Thus, the 






























Figure 2.8: The antifungal treatment guidelines along with its effects on voice prosthesis lifespan within 
each patient. (A) Dumbbell chart representation of the mean VP lifespan difference after guideline 
implementation for each of the 20 patients. (B) Box plot representation of VP in situ lifespans before and 
after guideline implementation, Wilcoxon Signed-Rank test: ***p<0.001. (C) Summary of the treatment 
pathway. As of January 2019, this management pathway has been distributed to 34 different speech and 





Although we did not identify any cases of resistance to antifungal application, our MDT have 
applied a 6 months (180 days) limit before VP change. This length of time was chosen primarily 
to reduce the possibility of development of antifungal resistance amongst the colonising 
Candida species and also to ensure that the VP remains structurally sound. Before ATG use 
only 8 VPs (5.6%) reached this target across all 20 patients, while post-ATG 63 VPs (35.8%) 
lasted at least 180 days (Figure 2.7A). It is worth noting that after the treatment guidelines 
were implemented, several VPs were being routinely changed because they had been in situ 





2.6 Discussion  
2.6.1 C. albicans is the most prevalent fungi isolated from early failing VPs 
The colonisation of VP by microorganisms, specifically Candida species, resulting in their 
degradation and failure has long been documented [217]. However, whether the presence of 
Candida led directly to early failure and whether antifungal treatment would provide an 
effective option for prevention of early failure has not previously been tested. Our analysis of 
the colonising organisms found on failed VPs is in line with previous investigations in that a 
number of bacterial and Candida species are present.  
 
We found that Candida albicans is the most prevalent fungal microorganism found on failed 
voice prostheses. Buijssen, K. et al. found that C. albicans was the most common fungal 
species, being present in 77% of biofilms from failed voice prostheses, C. tropicalis was second 
with 52% and C. glabrata third with 46% [204]. Likewise, in a 2002 study conducted by 
Bauters, T. et al. C. albicans was also the most common, being identifed in 41.4% of voice 
prosthesis biofilms, followed by C. glabrata (33.1%) and C. krusei (15.9%) [202]. In our study, 
C. albicans was found on 56.0% of voice prostheses while C. glabrata (14.5%) and C. tropicalis 
(10.7%) were the second and third most commonly found fungal species respectively. C. 
glabrata and C. tropicalis were found here with much lower frequency than observed by 
Bujissen, K. et al. [204]. This could reflect a difference in the identification methods used, 
different patient demographics or lifestyles. Different lifestyles and dietary habits have 
previously been suggested to have an impact on the microbial colonisation of voice 
prostheses. For instance, a study conducted in India by Sayed, S. et al. found a different 
microbial picture on voice prostheses compared to European studies that may be attributed 
to the very different patient lifestyles and geographical location [201]. C. glabrata was 
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isolated from only 9.1% failed VPs in the Indian study [201]; a much lower frequency than in 
the European studies discussed above [202][204], although not too dissimilar to our study 
(14.5% VPs with C. glabrata). In addition, Sayed, S. et al. identified P. aeruginosa on 63.6% 
failed VPs [201] whereas Bujissen, K. et al. did not find this species at all [204] and we 
identified P. aeruginosa on only 4.4% VPs. Moreover, Chaturvedi, P. et al. found that in the 
Indian scenario, C. tropicalis was the most prevalent fungal species colonising voice 
prostheses [205]. The high consumption of dairy products such as yoghurt and buttermilk in 
India has been proposed to influence biofilm growth on voice prostheses. The presence of 
Streptococcus thermophilus and Lactobacillus in yoghurt may reduce biofilm formation 
[215][252], while the high lactoferrin content in buttermilk (also found in saliva) has 
antibacterial and antifungal properties against organisms such as C. albicans and 
Streptococcus mutans [253][254][255].  
 
Our study found S. aureus as the most prevalent bacterial species on failed voice prostheses, 
present on 64.2% of voice prostheses, often in combination with one or more Candida 
species. This was expected since S. aureus is a member of the normal oral and perioral 
microbiota [256]. Moreover, it is the third most commonly isolated organism with C. albicans 
in poly-microbial infections (a significant proportion of which are nosocomial infections) 
[257]. Synergistic relationships between S. aureus and C. albicans have previously been 
documented. S. aureus is poor at forming biofilms on its own, however, it has been suggested 
that the hyphal C. albicans cells provide a scaffold on which the S. aureus cells can attach 
within a poly-microbial biofilm [247]. This may well be the scenario in the mixed biofilms on 
the failed VPs and offers an explanation as to why these two microorganisms are frequently 
on the same device. The attachment of S. aureus to C. albicans could also be a mechanism 
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which the bacteria uses to invade human tissues and disseminate infection, being carried on 
the hyphae as they penetrate the epithelial layers [258]. Within a mixed biofilm, S. aureus 
cells also become coated in C. albicans matrix material, enhancing its antibiotic tolerance 
[241]. Furthermore, S. aureus and C. albicans mixed biofilms can withstand higher shear 
stresses than pure C. albicans biofilms [242]. Given the high frequency that these two 
microorganisms are found together, along with the synergy they have been previously shown 
to exhibit, their inter-species relationship in the voice prosthesis setting should not be 
underestimated. The potential impact of this relationship is highlighted by the fact co-
infection results in increased mortality in mouse models than either microorganism alone 
[259][260].  
 
In addition to the large numbers of S. aureus isolates, several other bacterial species were 
identified on voice prostheses in this study, including P. aeruginosa (4.4% of VPs) and S. 
marcescens (3.8% of VPs). The study performed by Sayed, S. et al. in India concluded P. 
aeruginosa was the most common bacterial species on voice prostheses [201]. It is likely, as 
the authors of the Indian study also proposed, that the differences in ratios of microorganisms 
identified in studies of this nature are due to the different geographical areas and the varied 
patient lifestyles within them (see above). 
  
We investigated whether C. parapsilosis possesses any competitive advantage over C. 
albicans, demonstrating that C. albicans is able to outcompete C. parapsilosis and form the 
majority of mixed mature biofilms in vitro. This was surprising based on our epidemiological 
observations; there must be other factors contributing to the success of C. parapsilosis in vivo, 
such as patient diet, flora, and lifestyle, which we were unable to mimic in our in vitro assay. 
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C. parapsilosis is adept at forming biofilms [261], however, its biofilms tend to be composed 
primarily of yeast-form cells and have a thinner, less structured overall organisation 
compared to C. albicans biofilms [237]. Moreover, unlike other Candida species, the biofilm-
forming ability of C. parapsilosis is strain specific [261] so it could be that the G10402 clinical 
isolate we used is a poor producer of biofilms when it is the sole organism. The explanation 
behind the apparent competitive fitness against other fungal species on voice prostheses in 
vivo remains a mystery. Although, it should be highlighted that the microorganism 
identification methods used in this study were qualitative not quantitative. Thus, despite the 
presence of C. parapsilosis on 14 of the voice prostheses, it may not have formed a significant 
proportion of these biofilms.    
 
2.6.2 Antifungal sensitivity testing of biofilm-associated cells 
Within clinical settings, drug sensitivity tests on isolates are routinely carried out on 
planktonic cells (as we have done in this study). However, our azole and Nystatin biofilm 
sensitivity results highlight a potential need to also conduct antimicrobial sensitivity tests on 
biofilm cells. It is well-known that biofilm-associated cells have increased tolerance to 
antimicrobial agents [153], and it has been estimated by the National Institutes of Health that 
pathogenic biofilms (bacterial and fungal) are responsible for up to 80% of all microbial 
infections in the US [113]. Therefore, testing antimicrobial sensitivity of isolates while they 
are growing as biofilms may be more representative of the scenario within patients and 
certainly more representative of medical device colonisation such as that of VPs. We observed 
an increase in tolerance to the azoles Fluconazole and Miconazole in C. albicans biofilms 
grown in high CO2 environments. Again, demonstrating discrepancy between traditional 
sensitivity testing methods and the clinical scenario. This tolerance increase could be due to 
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several reasons including the increased expression of drug efflux pumps as well as a possible 
increase in matrix deposition displayed by biofilms grown in high CO2, both of which have 
been associated with biofilm antimicrobial tolerance [157][159][161]. 
 
2.6.3 Precision antifungal treatment guidelines significantly increase voice prostheses 
lifespans 
We have demonstrated that the lifespan of voice prostheses can be significantly increased by 
focusing on the prevention/management of the Candida colonisation, without directly 
treating the bacterial colonisation. We decided upon this approach based on several reasons. 
Firstly, due to the larger size of yeast cells compared to bacterial cells, we theorised that yeast 
contamination would contribute significant biomass that may impair valve function. 
Combined with our observation that the elevated CO2 environment may promote Candida 
biofilm formation, we thought the Candida colonisation could be the principal cause of voice 
prosthesis failure. Secondly, C. albicans is particularly adept at degrading silicone rubber 
[204]. Finally, there is a substantial level of agreement across several different studies that 
Candida species, particularly C. albicans, are the predominant fungal species found on voice 
prostheses [202][204][205]. The picture is not as consistent in regards to bacterial species 
with some studies finding Pseudomonas aeruginosa as the most common bacteria [201], 
some finding Lactobacilli as the most common [262], and others finding Staphylococcus 
aureus as the predominant species (this study). Therefore, we proposed a treatment focusing 
on the Candida colonisation would likely be more wide-ranging than an equivalent bacterial 




To our knowledge, this is the first long-term study of the effect of a voice prosthesis 
management regime that advises topical application of antifungals directly on the device 
surface. Historically, the use of Amphotericin B lozenges [217] and buccal bioadhesive slow-
release Miconazole nitrate tablets [218] to reduce oropharyngeal fungal burden have resulted 
in increases in voice prosthesis lifespans. However, these studies did not investigate the use 
of antifungals directly on the VP surface. Furthermore, the Amphotericin B lozenges and the 
buccal bioadhesive Miconazole tablets have since been discontinued by the pharmaceutical 
company [10]. More recently, much of the focus on enhancing voice prosthesis lifespans in 
situ has been on the designs of the voice prostheses themselves. Provox released the 
ActiValve model for patients which have experienced particularly early failing voice 
prostheses [226], and this model does have a significantly increased lifespan compared to 
traditional voice prostheses [228].  
 
Prior to implementation of our voice prostheses antifungal treatment guidelines, the average 
in situ lifespan of voice prostheses within our patient cohort was 71.9 days. This is similar to 
a recent large-scale study of voice prosthesis lifespans in the U.S. by Lewin et al. which found 
an average lifespan of 86 days [221]. While being slightly less than a study by Kress et al. which 
found an average lifespan of 108 days [228]. The average device lifespan within our patient 
cohort increased to 192.0 days after clinicians started following the management guidelines 
– a 2.7-fold increase. The actual lifespan of voice prostheses post guidelines implementation 
may be higher than the 192.0 days reported here, as we recommended the clinicians change 
some voice prostheses prophylactically after 6 months (180 days) in situ. This ensures there 
is no emerging antifungal resistance as well as no structural deterioration of the device due 
to mechanical stress and the constant application of antifungals.  
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In conclusion, C. albicans is the most prevalent fungal species found on failed voice 
prostheses. We have demonstrated that directed application of topical antifungals onto the 
voice prosthesis surface to combat fungal colonisation results in significantly extended voice 
prosthesis lifespans. As of January 2019, our voice prosthesis treatment guidelines have been 
distributed to 34 centres (32 in the UK and 2 internationally). We hope to collaborate with 










































Supplementary Table S2.1: Distribution of bacterial species on 159 voice prostheses. Number is 
















Supplementary Table S2.2: Distribution of fungal species on 159 voice prostheses. Number is the 
absolute number of voice prostheses upon which the particular species was found. 
































Supplementary Figure S2.1: The in vitro biofilm model used within this study. Biofilms were grown on 
1cm2 silicone squares which mimic the surface of the voice prosthesis. They were placed in modified 24-
well plate lids so that they protrude into RPMI-1640 media containing C. albicans cells when placed on 
a 24-well plate. This enables easy washing and quantification of growth without disruption of the biofilm 
by transferring to new plates containing PBS or XTT reagent (see Materials and Methods).    
Supplementary Figure S2.2: Chromogenic 
agar of C. albicans (G-3065) and C. 
parapsilosis (G10402) clinical isolate 
biofilms. Although they did not mature into 
a full biofilm, C. parapsilosis cells did attach 
to the silicone surface. The majority of the C. 
albicans and C. parapsilosis mixed biofilms 
are made up of C. albicans cells. Green 
colonies: C. albicans, white colonies: C. 






Supplementary Figure S2.3: Fluconazole sensitivities of C. albicans clinical isolate biofilms. Biofilms were 
seeded and grown for 24 hours before addition of Fluconazole, they were then grown for a further 24 hours 
before quantification using the XTT assay. The relative XTT activity is presented with the 0.03% and 5% CO2 
biofilms normalised to the 0.03% and 5% CO2 untreated controls respectively. This prevents the general 
higher growth of 5% CO2 biofilms impacting the analysis. Graphs represent three independent experiments 
each containing triplicates, error bars denote Standard Deviation. Two-way ANOVAs followed by a Tukey 
test for multiple comparisons were carried out: *p<0.05, **p<0.01, ***p<0.001. Stars directly above the 
































Supplementary Figure S2.4: Miconazole sensitivities of C. albicans clinical isolate biofilms. Biofilms were 
seeded and grown for 24 hours before addition of Miconazole, they were then grown for a further 24 hours 
before quantification using the XTT assay. The relative XTT activity is presented with the 0.03% and 5% CO2 
biofilms normalised to the 0.03% and 5% CO2 untreated controls respectively. This prevents the general 
higher growth of 5% CO2 biofilms impacting the analysis. Graphs represent three independent experiments 
each containing triplicates, error bars denote Standard Deviation. Two-way ANOVAs followed by a Tukey 
test for multiple comparisons were carried out: *p<0.05, **p<0.01, ***p<0.001. Stars directly above the 




















 Supplementary Figure S2.5: Detailed voice prosthesis management guidelines. As of January 2019, this 
management pathway has been distributed to 34 different speech and language therapy centres (32 in the 
UK, 2 internationally) upon request.   
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C. albicans is the predominant fungal pathogen worldwide with its ability to form biofilms 
crucial to its success as well as enabling it to be a prevalent coloniser of medical devices. C. 
albicans is a dimorphic yeast, existing in both budding yeast and filamentous hyphal forms, 
and the capacity to switch between these forms is extremely important to its biofilm 
producing proficiency. CO2 concentrations in mammalian hosts are more than 150x that in 
the atmosphere (5% vs. 0.03%) and it has been well established that 5% CO2 stimulates the 
yeast-to-hyphal morphogenic switch via the Ras1-Cyr1-PKA pathway. However, until now the 
effect of high CO2 on C. albicans biofilm growth was unknown. Here, we show that 5% CO2 
enhances each stage of the C. albicans biofilm forming process; from attachment through 
maturation to dispersion, and this is accompanied by an increased tolerance to azoles and 
iron sequestration. We find that elevated CO2 leads to an increase in expression of glucose 
transporters and that treatment with the glycolytic inhibitor 2-deoxyglucose (2-DG) is equally 
effective in both 0.03% and 5% CO2 environments. This suggests that 2-DG maybe repurposed 
as an anti-biofilm compound for use under conditions of elevated CO2. We also observe that 
C. albicans biofilm growth is reliant upon the adenylate cyclase Cyr1 but elevation of CO2 can 
override the requirement for Ras1. Transcriptome analysis reveals key biofilm formation 
pathways governed by the central biofilm regulators Efg1, Brg1, Bcr1 and Ndt80 are 
upregulated in C. albicans biofilms grown in 5% CO2 compared to those in atmospheric 
(0.03%) CO2. We thus characterise a 5% CO2-mediated increase in C. albicans biofilm 
formation which could have important clinical implications for the prevention/treatment of 





C. albicans is a commensal yeast located on the mucosal surfaces of the oral cavity, 
gastrointestinal tract and genitourinary tract of most healthy individuals [6][7]. Despite being 
a commensal organism, it is also an opportunistic pathogen [6][8]; in fact, it is the most 
widespread of all the human fungal pathogens [9] and is the fourth most common cause of 
hospital-acquired infections in the USA [6]. Infection with C. albicans is a particular problem 
among immunocompromised individuals or persons with implanted medical devices such as 
catheters or voice prostheses [10][11]. C. albicans can readily colonise medical devices and 
grow on their surfaces, isolated from the host immune system, as biofilms [4].  
 
Biofilms are structured communities of microorganisms attached to a surface. The cells are 
often encased within an extracellular matrix (ECM) which is commonly comprised of DNA 
[107][108], lipids [107], proteins [107][109] and polysaccharides [107]. C. albicans is able to 
form biofilms on both abiotic and biotic surfaces and biofilm-associated cells are considerably 
more tolerant to traditional antifungals when compared to planktonic cells [147]. The reasons 
for this increased tolerance are complex but include; the presence of an ECM which can act 
as a barrier to prevent antimicrobial agents to reaching the cells [116][117], the presence of 
metabolically dormant persister cells inherent to biofilms [172], and the upregulation of drug 
efflux pumps [119]. A significant percentage of human microbial infections arise from, or are, 
mediated via the formation of a biofilm [110][111][112], and this, combined the limited 
treatment options available, means the ability of C. albicans to grow as a biofilm is of 
particular medical interest.   
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C. albicans is a dimorphic fungus, meaning it has the ability to undergo a morphogenetic 
switch from a yeast, to pseudohyphal or hyphal forms in response to environmental cues. The 
virulence of C. albicans is closely linked with the capacity to switch between these forms; 
hyphal C. albicans cells are frequently located at sites of tissue invasion, and cells which are 
unable to readily form hyphae exhibit reduced virulence [6]. This yeast-to-hyphal switch is 
critical in the biofilm formation process as hyphal cells express a number of specific cell 
surface adhesins which enable cell-cell attachment as well as cell-surface attachment during 
biofilm maturation [134]. These adhesins, such as the agglutinin-like sequence (Als) protein 
family which consists of 8 members (Als1-7 and Als9), possess a folded N-terminal domain 
required for protein-ligand interaction, a 600-1000 residue serine/threonine-rich tandem 
domain, and a C-terminal peptide which covalently bonds to glycosylphosphatidylinositol 
(GPI) to anchor the adhesin in the fungal cell wall [121]. The Als proteins also contain an 
amyloid forming region (AFR) in the N-terminal domain [263] which interacts with AFRs of 
other Als proteins. This results in the formation of large molecular weight clusters of Als 
proteins on the fungal cell wall called nanodomains which can bind multivalent ligands with 
high avidity [264]. These nanodomains form in response to forces applied to the adhesin 
molecules, such as that created under laminar flow, which cause the AFR to unfold and 
facilitate Als molecule aggregation [265][266]. Nanodomains strengthen adhesion and 
support the structure of mature biofilms [267].  
 
C. albicans biofilm formation is a complex process involving tightly regulated, interwoven 
signalling pathways centrally controlled by a set of nine transcription factors; Bcr1, Brg1, Efg1, 
Flo8, Gal4, Ndt80, Rob1, Rfx2 and Tec1. These nine essential regulators function at different 
stages throughout C. albicans biofilm formation [129] and coordinate the expression of over 
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a 1000 target genes upregulated during biofilm formation [127]. C. albicans biofilm formation 
can divided into distinct stages that are governed by programmes of gene expression; 
attachment, initiation, maturation and dispersion. The attachment stage involves the initial 
attachment of C. albicans cells, primarily in the yeast-form [115], to a surface [120]. Both 
nonspecific factors, such as cell surface hydrophobicity and electrostatic forces, and specific 
factors, such as adhesins on the yeast cell surface binding to precise ligands on the substratum 
to be colonised, are responsible for the preliminary attachment [120]. Approximately 3-6 
hours after the initial attachment, pseudohyphal and hyphal cells start forming from the 
proliferating yeast-form cells [8]. This initiation step is characterised by the appearance of 
extracellular material. The maturation phase of biofilm growth lasts between 24-48 hours 
[120]. Colonies of C. albicans continue to grow and secrete ECM, increasing the amount of 
material encasing the biofilm [115]. The final stage of biofilm development is the dispersal 
stage during which yeast-form cells bud off from hyphal cells within a mature biofilm and 
disperse in order to establish additional biofilms elsewhere [115][125]. The yeast-form cells 
emerging from mature biofilms have distinct characteristics compared to typical planktonic 
yeast cells; with enhanced adherence, an increased propensity to filament, and increased 
biofilm forming capability [126]. 
 
Elevated CO2 levels, as found in a number physiologically relevant scenarios such as in exhaled 
breath or hypercapnia, have been shown to promote the yeast-to-hyphal switch in C. albicans. 
CO2 is converted to bicarbonate ions HCO3- by the enzyme carbonic anhydrase which in turn 
activate the adenylate cyclase Cyr1, resulting in increased cAMP levels and the PKA 
dependent activation of hyphal specific genes [69]. The yeast-to-hyphal switch is critical to 
the biofilm maturation process of C. albicans [142], as well as being important to its virulence 
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[6]. Therefore, it has been hypothesised that high CO2 could drive C. albicans biofilm 
formation and increase its propensity to cause infection. The effect of CO2 is particularly 
important within the context of biofilm development on voice prostheses (VPs) since these 
devices are situated in the throat of patients where they are consistently exposed to high CO2 
(5%) levels during exhalation. If CO2 does play a role in C. albicans biofilm maturation it could 
offer a possible explanation as to why C. albicans is found in such high frequencies on failed 
voice prostheses. In addition as it has been estimated that as many as 80% of all microbial 
infections directly or indirectly involve pathogenic biofilms [113] and that CO2 content within 
the blood is also elevated (46mmHg and 40mmHg for venous and arterial blood respectively 
versus 0.3mmHg found in atmospheric air) [222][268]. Thus, the work presented here could 
be more widely applicable to bloodstream infections and biofilm formation within the body.  
        
Here we demonstrate that high CO2 concentration (5%) increases C. albicans biofilm 
formation on silicone surfaces. Transcriptome analysis reveals that several core biofilm 
regulatory pathways, including those governed by Efg1, Bcr1, Brg1, and Ndt80, are 
upregulated in C. albicans biofilms grown in 5% CO2. We also demonstrate that a high CO2 
environment results in increased tolerance of biofilms to azole antifungals, as well as 
enhanced dispersal of cells from mature biofilms. Moreover, a transcription factor knockout 
(TFKO) library screen demonstrated transcription factors involved in the acquisition of iron, 
such as the HAP transcription factors Hap43, Hap2, Hap3 and Hap5, to be important for C. 
albicans biofilm formation on a silicone surface in atmospheric CO2 conditions. However, high 
CO2 was able to overcome the requirement for HAP transcription factor activity and enable 
C. albicans biofilms to forage for essential metabolites to support growth. Overall, we propose 
that C. albicans has adapted to utilise the high CO2 environment found in the host to promote 
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its ability to colonise and to compete for nutrition. Our analysis reveals new approaches that 
can be taken to prevent C. albicans biofilm formation in high CO2 environments that pave the 




3.4 Materials and Methods 
3.4.1 Candida strains and growth media  
Candida strains (Supplementary Table S3.1) were routinely grown at 30oC in yeast peptone 
dextrose (YPD) media (2% peptone (BD Bacto), 2% D-glucose (Fisher Scientific), 1% yeast 
extract (BD Bacto)). For biofilm growth assays, Candida biofilms were grown at 37oC in RPMI-
1640 media (Sigma-Aldrich, R8755) supplemented with 80µg/ml uridine (Sigma-Aldrich, 
U3750) if required.  
 
3.4.2 In vitro biofilm growth assays 
C. albicans biofilms were grown on a PDMS silicone elastomer (Provincial Rubber, S1). The 
silicone was cut into 1cm2 squares and placed in clips in a modified 24-well plate lid (Academic 
Centre for Dentistry Amsterdam, AAA-model) so they could be suspended in media within a 
24-well plate. Silicone squares were incubated in 1ml 50% Donor Bovine Serum (DBS) (Gibco, 
16030074) for 30 minutes at 30oC, then washed twice with 1ml Phosphate-Buffered Saline 
(PBS – 137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.8mM KH2PO4, pH 7.4) to remove excess 
DBS. Candida strains were inoculated into a test tube containing 5ml YPD media and placed 
in a 30oC orbital shaking incubator with constant shaking at 180rpm for 18h. OD600 
measurements were taken and a volume of overnight culture corresponding to OD600 = 1.0 (3 
x 107 CFU/ml) was removed. These cells were pelleted by centrifugation at 4000rpm for 5 min 
at which point the supernatant was discarded. The resultant pellet was resuspended in 5ml 
PBS to wash and centrifuged again at 4000rpm for 5 min. The PBS supernatant was discarded 
and the pellet re-suspended in fresh PBS (at an OD600 of 1.0). The OD600 1.0 standard cell 
suspension was added to wells (1ml per well) in a pre-sterilised 24-well plate (Greiner Bio-
one, CELLSTAR, 662160) and the lid with the silicone squares attached was placed on top so 
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the silicone squares protrude into the cell suspension. These plates were then incubated at 
37oC (in either 0.03% CO2 or 5% CO2) without shaking for 90 min to allow cell attachment to 
the silicone. After the attachment phase, the silicone squares were washed twice with 1ml 
PBS to remove any unattached cells and transferred to 1ml RPMI-1640 media (Sigma-Aldrich, 
R8755). They were then incubated at 37oC (in either 0.03% CO2 or 5% CO2) without shaking 
for 48h to allow biofilm maturation.  
 
3.4.3 Biofilm quantification via XTT assay     
Biofilm growth was quantified using an XTT assay [237]. Biofilms were washed twice with 1ml 
PBS to remove any planktonic cells before proceeding to quantification. After washing, the 
biofilms were transferred to a new pre-sterilised 24-well plate (Greiner Bio-one, CELLSTAR, 
662160) containing 30µg/ml XTT labelling reagent (Roche, 11465015001) and incubated at 
37oC for 4h. After incubation, the biofilms were removed from the 24-well plate and the 
absorbance of the remaining XTT labelling reagent was measured at 492nm using a BMG 
LABTECH FLUOstar Omega plate reader machine.  
 
3.4.4 C. albicans transcription factor knockout (TFKO) screen  
Biofilms using mutants from a C. albicans TFKO library [269] were seeded and grown for 48h 
on a PDMS silicone elastomer (Provincial Rubber, S1) as described above. Biofilm growth was 
quantified using the XTT assay. Experiments were performed in biological triplicate.   
 
3.4.5 Iron starvation of C. albicans biofilms 
Biofilms were set up as described previously except they were incubated at 37oC in either 
0.03% CO2 or 5% CO2 for 48h in RPMI-1640 containing varying concentrations of the Fe2+ 
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chelator 3-(2-Pyridyl)-5,6-diphenyl-1,2,4-triazine-p,p’-disulfonic acid monosodium salt 
hydrate (Ferrozine – Sigma-Aldrich, 160601) or the Fe3+ chelator Deferasirox (Cambridge 
Bioscience, CAY16753-5). Ferrozine was made as a 100mM stock solution in sterile MQ H2O 
and diluted in RPMI-1640 to final concentrations of 250-500μM. Deferasirox was made as a 
20mg/ml stock solution in DMSO and diluted in RPMI-1640 to final concentrations of 70-
210µg/ml. A 1% DMSO vehicle control was included in the experiment. Final biofilms were 
quantified using the XTT assay. Ferrozine experiments were performed in 6 biological 
replicates each in technical triplicate. Deferasirox experiments were performed in biological 
duplicate and technical triplicate.      
 
3.4.6 Preparation of PDMS-coated microscope slides 
To prepare PDMS for coating microscope slides 16g (6.16 x 10-4 mol) silanol-terminated PDMS 
(cSt 1000, MW 26000, from Fluorochem Ltd.) and 0.26g (12.48 x 10-4 mol, 1:4 stoichiometric 
ratio) cross-linking agent tetraethyl orthosilicate (TEOS – Sigma-Aldrich, 131903) were mixed 
at 3500rpm for 60 secs using a DAC 150FV2-K speedmixer. At this point, 720µl tin(II) 
ethylhexanoate (Sigma-Aldrich, S3252) made up at a concentration of 0.6M in toluene was 
added as a catalyst and the mix spun for a further 60 secs at 3500rpm. The elastomer mixture 
was then doctor bladed onto microscope slides using an automatic precision film applicator 
MTCX4 (Mtv-Messtechnik – blade width = 70mm, thickness adjustability 0-3000µm). The 
doctor blade height was set 10µm higher than the thickness of the microscope slide. The 
elastomer mix was poured over the top of the slide (with a bias towards the side of the 
microscope slide closest to the doctor blade), and then the doctor blade is moved at a 
constant speed over the substrate. The microscope slide was then air cured for 2h before 
being heat cured for 18h in a 70oC oven.  
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3.4.7 Preparation of C. albicans biofilms on silicone coated slides for microscopy 
Biofilms were grown directly on microscope slides that had been pre-coated with a PDMS 
silicone polymer (see above) for confocal imaging. Biofilms were grown with a prefabricated 
well. PDMS-coated microscope slides were incubated with 400µl 50% Donor Bovine Serum 
(DBS) (Gibco, 16030074) in the wells for 30 min at 30oC and washed twice with 400µl PBS. C. 
albicans overnight cultures were grown in YPD at 30oC and washed in PBS as described 
previously. 400µl of the OD600 1.0 standard cell suspension was added to the wells and 
incubated at 37oC (in either 0.03% CO2 or 5% CO2) without shaking for 90 min to allow cell 
attachment to the silicone surface of the microscope slide. After the attachment phase, the 
microscope slides were washed twice with 400µl PBS to remove any unattached cells and 
then incubated at 37oC with 400µl RPMI-1640 media in the wells for 6h, 24h or 48h (in either 
0.03% CO2 or 5% CO2). Biofilms were washed twice with 400µl PBS and then incubated in the 
dark for 45 min at 30oC in 400µl PBS containing 50µg/ml ConA-FITC (Sigma-Aldrich, C7642) 
and 20µM FUN-1 (Invitrogen Molecular Probes, F7030). After incubation with the dyes, the 
stained biofilms were washed again with 400µl PBS to remove any residual dye. The well was 
removed and 2 drops of ProLongTM Diamond Antifade Mountant (Invitrogen, P36965) was 
added to each stained biofilm. A cover slip was placed on top and the microscope slides were 
incubated in the dark at room temperature overnight to allow the mountant to cure.   
 
3.4.8 Confocal scanning laser microscopy (CSLM) of C. albicans biofilms on silicone slides 
Stained biofilms grown on silicone coated slides were imaged using a Zeiss LSM880/Elyra/Axio 
Observer.Z1 Confocal Microscope (Carl Zeiss Inc.) using the 488nm argon and the 561nm 
DP55 lasers. Images of the green (ConA-FITC) and the red (FUN-1) were taken simultaneously 
using a multitrack mode. Z-stacks were taken using the inbuilt ‘optimal’ settings to determine 
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the optimal intervals (typically 1.5-2.0µm slices) based upon sample thickness and 
magnification. The 20x and oil-immersion 40x objective lenses were used throughout. The 
image acquisition software used was ZENBlack and the image processing software was 
ZENBlue. 
 
3.4.9 RNA isolation from C. albicans biofilms 
Total RNA was extracted in biological triplicate per condition (0.03% and 5% CO2) using the 
E.Z.N.A.TM Yeast RNA Kit (Omega Bio-Tek, R6870-01) as per the manufacturer’s instructions 
with a few modifications. Specifically, C. albicans CAI-4 biofilms were seeded and grown in 
0.03% and 5% CO2 as described for in vitro biofilm growth assays. Mature biofilms were 
washed twice with 1ml ice-cold PBS to remove any planktonic cells. Biofilm cells were 
harvested by transferring silicone squares upon which the biofilms were growing into 5ml 
cold SE buffer/2-mercaptoethanol (provided in the E.Z.N.A.TM Yeast RNA Kit) and vortexing at 
2500rpm for 1 min. The resulting biofilm cell suspension was pelleted by centrifugation at 
4000rpm for 10 min at 4oC. The supernatant was discarded and the cells re-suspended in fresh 
1ml cold SE buffer/2-mercaptoethanol, this cell suspension was transferred to a 2ml 
Eppendorf tube. The cell suspension was centrifuged again for 10 min at 4oC, the supernatant 
discarded and the pellet re-suspended in 480µl fresh SE buffer/2-mercaptoethanol. The 
biofilm cell suspension was incubated with 80µl lyticase stock solution (5000units/ml in SE 
buffer) at 30oC for 90 min. The resulting spheroplasts were pelleted by centrifugation at 
2900rpm for 10 min at 4oC and the supernatant aspirated and discarded. The spheroplasts 
were gently re-suspended in 350µl YRL buffer/2-mercaptoethanol (provided in the E.Z.N.A.TM 
Yeast RNA Kit). The rest of the RNA extraction proceeded as per the manufacturer’s 
instructions including the optional DNase digestion step. RNA was eluted in 30µl DEPC water, 
 125 
 
the concentration and purity established using a NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies) and stored at -80oC.         
 
3.4.10 Library Preparation and RNA Sequencing  
RNA samples were sent to the Centre for Genome Enabled Biology and Medicine (Aberdeen, 
UK) for library preparation and sequencing. Before library preparation, the quality and 
quantification of RNA samples were evaluated with TapeStation (Agilent) and Qubit (Thermal 
Fisher). Samples with a minimum RIN of 8.0 proceeded to library preparation. The input of 
RNA was based on the specifically measured RNA concentration by Qubit. The mRNA-Seq 
libraries were prepared using TruSeq™ Stranded mRNA Sample Preparation Kit (Illumina) 
according to the manufacturer’s instructions. Briefly, Poly-A RNA were purified from 500ng of 
total RNA with 1ul (1:100) ERCC spike (Thermal Fisher) as an internal control using RNA 
purification oligo(dT) beads, fragmented and retrotranscribed using random primers. 
Complementary-DNAs were end-repaired, and 3-adenylated, indexed adapters were then 
ligated. 15 cycles of PCR amplification were performed, and the PCR products were cleaned 
up with AMPure beads (Beckman Coulter). Libraries were validated for quality on Agilent 
DNA1000 Kit and quantified with the qPCR NGS Library Quantification kit (Roche). The final 
libraries were equimolar pooled and sequenced using the High Output 1X75 kit on the 
Illumina NextSeq500 platform producing 75bp single-end reads. For each library a depth 50-
70M reads were generated.  
 
3.4.11 Analysis of RNA-Seq data 
Analysis of RNA-Seq data was performed using the Galaxy web platform [270]. The quality of 
the RNA sequencing reads was checked using FastQC v0.11.5 [271] with default settings. Low 
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quality ends (Phred score < 20) and any adaptor sequences were trimmed using TrimGalore! 
v0.4.3 [272]. Reads which became shorter than 40bp after trimming were removed from 
further analysis. After trimming, 97.7% of initial reads remained and the quality was checked 
again using FastQC v0.11.5 [271] to ensure the trimming had worked correctly. There were 
no Poly-A reads (more than 90% of the bases equal A), ambiguous reads (containing N) or low 
quality reads (more than 50% of the bases with a Phred score < 25). After processing, the 
mean Phred score per read was 35. Processed reads were aligned with the reference C. 
albicans genome SC5314 version A21-s02-m09-r10 using HISAT2 v2.1.0 [273] with single-end 
reads and reverse strand settings (rest of the settings were default). After alignment, the 
number of mapped reads which overlapped CDS features in the genome (using the C. 
albicans_SC5314_version_A21-s02-m09-r10_features.gtf annotation file [274]) were 
determined using htseq-count v0.9.1 [275] with default settings. Reads aligning to multiple 
positions or overlapping more than one gene were discarded, counting only reads mapping 
unambiguously to a single gene. Differential gene expression analysis between conditions 
(0.03% and 5% CO2) was performed using DESeq2 v1.18.1 [276] with default settings.  
 
3.4.12 Gene Set Enrichment Analysis of transcription profiles 
Downstream analysis of RNA Sequencing data was performed using the PreRanked tool of 
Gene Set Enrichment Analysis (GSEA; Broad Institute) [277] which compares a pre-ranked 
significantly differentially expressed gene list to a functional gene set database. False 
discovery rate (FDR) q-values were calculated based upon 1000 permutations. The gene set 
database used was assembled by Sellam, A. et al. as described in [278], which is based upon 
experimental analyses from published studies, Gene Ontology (GO) term categories curated 
by the Candida Genome Database [279] and protein-protein interaction information derived 
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from Saccharomyces cerevisiae data curated by the Saccharomyces Genome Database [280]. 
Gene set networks were generated in Cytoscape 3.7.1 (Available at: https://cytoscape.org/) 
[281] using the EnrichmentMap plug-in (Available at: 
http://apps.cytoscape.org/apps/enrichmentmap). Gene expression heat maps based on GO 
term categories were created using the Pheatmap package in R Studio.     
 
3.4.13 Antifungal treatment of C. albicans biofilms 
Biofilms were set up as described previously and grown in RPMI-1640 for 24h at 37oC. The 
biofilms were then transferred to fresh RPMI-1640 media containing a select antifungal. 
Three antifungals were tested; fluconazole, miconazole and nystatin. Fluconazole (Santa Cruz 
Biotechnology, sc-205698) was made as a 50mg/ml stock solution in ethanol and diluted in 
RPMI-1640 final concentrations ranging from 8-256µg/ml. Miconazole (Santa Cruz 
Biotechnology, sc-205753) was made as a 50mg/ml stock solution in DMSO and also diluted 
in RPMI-1640 to final concentrations ranging from 8-256µg/ml. Nystatin (Santa Cruz 
Biotechnology, sc-212431) was made as a 5mg/ml stock solution in DMSO and diluted in 
RPMI-1640 to final concentrations ranging from 1-8µg/ml. Drug vehicle controls (0.5% 
ethanol for Fluconazole, 0.5% DMSO for Miconazole and Nystatin) were used in all cases. The 
biofilms matured in the RPMI-1640 media containing the select antifungal for a further 24h 
at 37oC in both 0.03% and 5% CO2 before proceeding to quantification via the XTT assay. 







3.4.14 C. albicans attachment assay   
CAI-4 cells were seeded onto silicone-coated microscope slide for 90 min as described 
previously for growing biofilms for confocal microscopy, except here an OD600 of 0.1 was used 
instead of 1.0 and the silicone-coated microscope slides were not pre-incubated with DBS. 
The slide surface was washed twice with 400µl PBS to remove any unattached cells. Images 
were taken using a Leica DMR fitted with a Leica DFC9000 GT camera using a 20x objective 
lens and brightfield settings. The image acquisition software used was the Leica Application 
Suite X package. Using identical microscope settings throughout, five images were taken of 
each of three biological replicates in both 0.03% and 5% CO2 and the cells per image counted 
using the ‘Cell Counter’ function in ImageJ.    
 
3.4.15 2-deoxyglucose (2-DG) treatment of C. albicans biofilms 
Biofilms were set up as described previously except they were incubated at 37oC in either 
0.03% CO2 or 5% CO2 for 48h in RPMI-1640 containing varying concentrations of 2-DG. 2-DG 
(Sigma-Aldrich, D6134) was made up as a 20% stock solution in sterile MQ H2O and diluted in 
RPMI-1640 to final concentrations of 0.25-1%. Biofilms were quantified using XTT assays and 
images were also taken. Experiments were performed in biological and technical triplicate. 
 
3.4.16 C. albicans biofilm dispersion assay 
Biofilms were set up as described previously and grown in RPMI-1640 for 48h at 37oC. The 
spent media, containing dispersed cells, was sonicated at amplitude 4µm for 10 secs to 
separate clumps of hyphal cells (previous work in our lab has demonstrated these sonication 
settings do not affect viability). After sonication, the dispersed cells were diluted 1 in 10 and 
200µl of this suspension was plated on YPD agar plates in triplicate. YPD plates were 
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incubated for 48h at 37oC to allow colonies to form, at which point the number of colonies 
were manually counted using a Stuart Scientific Colony Counter. Experiments were performed 




3.5.1 High CO2 enhances C. albicans biofilm growth                                                                                      
C. albicans biofilms were seeded and grown on silicone in both levels found in exhaled air 
(5%) and normal air (0.03%) CO2 conditions for 24 and 48 hours. Biofilms were quantified 
using the XTT assay which acts as a readout of cell number [237]. After 24 hours of growth, 
both CAI4pSM2 and SN152 C. albicans strains assayed exhibited a significantly higher cell 
number within biofilms grown in a 5% CO2 environment compared to 0.03% CO2. However, 
after 48 hours, cell numbers within biofilms grown in both CO2 conditions appeared equal 
(Figure 3.1A). Biofilms formed from clinical isolates isolated from failed voice prostheses 
displayed a similar effect with significantly higher cell numbers within biofilms grown in 5% 
CO2. Interestingly, although cell number appeared equivalent at 48h, the resultant biofilm 
mass appeared noticeably larger in biofilms grown under elevated CO2 conditions (Figure 
3.1B). This CO2-mediated increase in biofilm growth is specific to the biofilm scenario as 
planktonic C. albicans cells exhibited no significant difference in growth rate in RPMI-1640 



































Figure 3.1: The effect of high CO2 (5%) on C. albicans biofilm formation. (A) Biofilm growth assay using two 
laboratory strains. Biofilms were seeded and grown for 24h or 48h, the resulting biofilms were quantified 
using the XTT assay. Control wells with no cells were set up as media controls to monitor for contamination 
as well as to ensure there was no reaction of the silicone squares with the XTT reagents. The graph represents 
three biological replicates each containing technical triplicates, error bars denote Standard Deviation. Paired 
two-tail t-tests were carried out: *p<0.05, **p<0.01, ***p<0.001, n.s. = not significant. (B) Representative 
images of SN152 biofilms grown in 0.03% and 5% CO2 for 48h (red coloration due to XTT assay).          
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3.5.2 Analysis of the effects of CO2 on phases of C. albicans biofilm growth   
We sought to determine which phases of biofilm growth were influenced by CO2 elevation. 
To investigate the attachment phase C. albicans cells were seeded for 90 min onto silicone-
coated microscope slides under 0.03% CO2 or 5% CO2 levels. We observed that exposure to 
elevated CO2 led to a significant increase in the number of cells that attached to silicone 
(mean of 2108 cells in 0.03% vs. a mean of 7033 cells in 5% CO2) (Figure 3.2A). Cells also 
appeared to attach as larger aggregations in 5% CO2 when compared to those in 0.03% CO2 
(Supplementary Figures S3.1A and B) indicating that both cell-substrate and cell-cell 
attachments may be enhanced.  
 
Confocal scanning laser microscopy (CSLM) was used to investigate the effects of CO2 on 
biofilm growth during maturation. C. albicans biofilms were seeded on silicone-coated 
microscope slides and images were taken at 6h, 24h and 48h of growth under either 0.03% 
or 5% CO2 growth conditions (Figure 3.2B). Biofilm images are displayed as maximum intensity 
ortho-projections of Z-stacks to give a view of the overall structures of the biofilms. Green 
fluorescence resulted from ConA conjugated to FITC (green) binding to the polysaccharides in 
the cell wall. Red fluorescence was due to FUN-1 forming aggregates in the cytoplasm of 
metabolically active cells. After 6h growth in 0.03% CO2, the majority of cells were found in 
the yeast form with some visibly initiating hyphae. In comparison, biofilms grown in 5% CO2 
appeared to consist of a high proportion of hyphal cells, were visibly denser and had begun 
to exhibit an ordered structure in the Z-plane (Figure 3.2B). After 24h growth in 0.03% CO2, 
biofilms were progressing through the maturation stage with the appearance numerous 
hyphal cells. However, the 5% CO2 biofilms displayed a fully mature biofilm organisation 
displaying hyphal cells organised in a brush-like structure above a basal layer of yeast cells 
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(Figure 3.2B). At 48h, biofilms grown in both 0.03% and 5% CO2 appeared as dense mature 
structures, however, biofilms grown under elevated CO2 were generally deeper (Figure 3.2B).  
 
Dispersion is the final stage of biofilm formation, we therefore investigated whether CO2 
elevation resulted in increased levels of cell shedding. We routinely observed that spent 
RPMI-1640 media isolated after biofilm growth in 5% CO2 contained more cells than that of 
taken from biofilms grown in 0.03% CO2 (Supplementary Figure S3.2A). We quantified this by 
seeding and growing C. albicans biofilms for 48h in 0.03% and 5% CO2 and conducting colony 
forming unit (CFU) assays using the spent RPMI-1640 media (Figure 3.2C and Supplementary 
Figure S3.2B). Our results showed an approximate four-fold increase in cell number released 
from mature biofilms when grown under elevated CO2 conditions, consistent with an increase 
in dispersal. Overall, these data demonstrate that the elevation of CO2 enhances each stage 








































3.5.3 Identification of the regulatory mechanisms that govern CO2 acceleration of C. 
albicans biofilm formation 
CO2 is sensed by C. albicans cells, in the form of bicarbonate ions (HCO3-), via the adenylate 
cyclase Cyr1 (Cdc35) [69] within the context of the Ras-cAMP-PKA pathway. We investigated 
whether CO2 elevation may drive biofilm formation via the same mechanism. We conducted 
biofilm growth assays using C. albicans mutants lacking key components of the Ras1-Cyr1-
PKA pathway; ras1Δ/Δ, cdc35Δ/Δ, CDC35ΔRA (adenylate cyclase missing the Ras1 interacting 
domain), tpk1Δ/Δ (missing a catalytic subunit isoform of PKA), and tpk2Δ/Δ (missing the other 
catalytic subunit isoform of PKA). Biofilm formation was quantified via XTT assay after 48h 
and compared to an isogenic wild type control. The ras1Δ/Δ mutant displayed significantly 
attenuated biofilm growth in 0.03% CO2 but this was rescued to wild type levels in 5% CO2 
(Figure 3.3A), indicating that Ras1 function is dispensable for biofilm formation under 
conditions of elevated CO2. The cdc35Δ/Δ and CDC35ΔRA mutants both exhibited significantly 
reduced biofilm growth when grown under either atmospheric or elevated CO2 conditions 
(Figure 3.3A). Conversely, both tpk1Δ/Δ and tpk2Δ/Δ mutants exhibited biofilm growth 
Figure 3.2: The effects of high CO2 (5%) on different stages of C. albicans biofilm growth. (A) Attachment: 
C. albicans CAI-4 cells were seeded onto silicone-coated microscope slides in 0.03% or 5% CO2 and images 
taken at 20x objective magnification (Supplementary Figure S2). Cells per image were counted using the 
‘Cell Counter’ function in ImageJ and the mean number of cells per image in the two conditions were 
calculated across three biological replicates (five images per replicate). A paired two-tail t-test was carried 
out: **p<0.01. Error bars denote Standard Deviation. (B) Maturation: Biofilms were seeded on silicone-
coated microscope slide and grown for 6h, 24h and 48h. Biofilms were stained with ConA-FITC (green) 
and FUN-1 (red). Images were taken using 20x and 40x objective magnifications. Experiments were 
repeated in triplicate and representative images are presented. (C) Dispersion: Mean number of colonies 
per plate from a 1:10 dilution of the spent RPMI-1640 media after 48h biofilm growth in 0.03% and 5% 
CO2. Graph represents three biological replicates each containing technical triplicates, error bars denote 







equivalent to the wild type under both CO2 conditions (Figure 3.3A). Taken together, this data 
implies the CO2-mediated effect on C. albicans biofilm growth is reliant on Cyr1 but can bypass 
a requirement for Ras1 and that the PKA isoforms Tpk1 and Tpk2 are functionally redundant 
with respect to cAMP activation of the biofilm programme. Our findings are however 
consistent with the adenylate cyclase Cyr1 as a key CO2 sensor in the enhanced biofilm growth 
observed under elevated CO2 conditions. 
 
To investigate the molecular basis of the activation of C. albicans biofilm formation in 5% CO2, 
we conducted a screen of a transcription factor knockout (TFKO) library [269] containing 146 
mutants each lacking a non-essential transcription factor for biofilm-forming ability. This 
screen identified 121 deletions that had no effect upon biofilm formation in either CO2 
condition (Supplementary Figure S3.3). The screen identified 21 transcription factors which, 
upon their deletion, resulted in attenuated biofilm formation (Supplementary Table S3.2). 
Specifically, 5 TFKO mutants (tup1Δ/Δ, sef1Δ/Δ, swi4Δ/Δ, pho4Δ/Δ and efg1Δ/Δ) had 
diminished biofilm growth in both 0.03% and 5% CO2, 12 had reduced biofilm formation only 
in 0.03% CO2 (hap2Δ/Δ, rbf1Δ/Δ, rob1Δ/Δ, fgr15Δ/Δ, dal81Δ/Δ, mig1Δ/Δ, brg1Δ/Δ, 
C4_00260WΔ/Δ, zcf27Δ/Δ, C1_13880CΔ/Δ, crz1Δ/Δ, and hap43Δ/Δ), and 4 TFKOs had 
reduced biofilm formation only in 5% CO2 (leu3Δ/Δ, mbp1Δ/Δ, bas1Δ/Δ, and try6Δ/Δ) 
(Supplementary Table S3.2 and Supplementary Figure S3.3). Intriguingly, 3 additional 
mutants, zcf17Δ/Δ, zcf30Δ/Δ and mac1Δ/Δ, displayed increased biofilm growth in 0.03% CO2 
but no significant difference in 5% CO2.    
 
We performed gene ontology enrichment analysis on the genes encoding the 24 transcription 
factors whose loss impacted upon biofilm growth to group them according to biological 
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processes. This revealed that 6 of these transcription factors – Brg1, Dal81, Efg1, Leu3, Rob1 
and Try6 – were already known to be involved in the regulation of single-species biofilm 
formation within C. albicans (Supplementary Table S3.2). Interestingly, out of these, only the 
efg1Δ/Δ mutant exhibited attenuated biofilm growth in both 0.03% and 5% CO2. The brg1Δ/Δ, 
dal81Δ/Δ, and rob1Δ/Δ mutants had significantly reduced biofilm growth in 0.03% CO2 but 
this was rescued in the 5% CO2 environment (Supplementary Table S3.2), possibly indicating 
a redundancy of these when cells are exposed to high CO2. This important finding suggests 
that CO2 elevation can bypass the requirement for some of the key transcriptional regulators 
of biofilm formation (Figure 3.3B). The leu3Δ/Δ and try6Δ/Δ mutants had significantly reduced 
biofilm growth in 5% CO2 but no significant difference in 0.03% CO2.  
 
Moreover, 8 of the transcription factors – Brg1, Crz1, Efg1, Mac1, Mig1, Rob1, Zcf27, Zcf30 – 
are associated with the positive regulation of filamentous growth and Tup1 is involved in the 
negative regulation of filamentous growth. C. albicans biofilm formation is strongly linked 
with the yeast-to-hyphal switch, with mutants unable to perform this switch have previously 
been shown to be deficient in biofilm growth [142]. Our results are consistent with this, 
demonstrating that perturbation of the hyphal programme in C. albicans can have significant 























Figure 3.3: Biofilm growth assays of C. albicans Ras1-Cyr1-PKA pathway and central biofilm regulator 
null mutants. Mutants were seeded and grown as biofilms for 48h before XTT quantification. (A) Graph 
represents three biological replicates each containing technical triplicates, error bars denote Standard 
Deviation. Two-way ANOVAs followed by Tukey tests for multiple comparisons was carried out: *p<0.05, 
**p<0.01, ***p<0.001, n.s. = not significant. Stars directly above the bars indicate a significant difference 
to the CAI4 wild type in the same CO2 environment. (B) Graphs represent biological triplicates, error bars 
denote Standard Deviation. XTT readouts for the TFKO mutants in 0.03% and 5% CO2 have been normalised 
to the 0.03% and 5% CO2 SN152 wild type controls respectively. One-way ANOVAs followed by Dunnett’s 
Tests for multiple comparisons to a control were performed to compare the TFKO mutant biofilms to the 
SN152 wild type controls (for both 0.03% and 5% CO2). *p<0.05, **p<0.01, ***p<0.001, n.s. = not 




The TFKO screen also revealed that mutants lacking transcription factors associated with 
metal ion homeostasis, specifically iron homeostasis, had altered biofilm-formation in 0.03% 
and/or 5% CO2 (Figure 3.4A and Supplementary Table S3.2). Mutants lacking genes expressing 
components of the HAP complex; hap2Δ/Δ, hap3Δ/Δ, hap5Δ/Δ, and hap43Δ/Δ, exhibited 
significantly reduced biofilm growth after 48h compared to wild type in 0.03% CO2. However, 
their biofilm growth was significantly higher in 5% CO2, reaching wild type levels in the cases 
of the hap3Δ/Δ, hap5Δ/Δ, and hap43Δ/Δ mutants (Figure 3.4A). This is an important 
observation as it indicates that an increase in CO2 concentration is sufficient to compensate 
for the loss of these transcription factors. The HAP complex in C. albicans is responsible for 
the regulation of iron homeostasis [57]. Sef1 acts downstream of this complex and the 
sef1Δ/Δ mutant displayed significantly reduced biofilm growth in both 0.03% and 5% CO2 after 
48h growth (Figure 3.4A). These data suggest that the elevation of CO2 can bypass the 
requirement for HAP complex activity in biofilm formation in a Sef1 dependent manner. 
 
To further determine whether elevated CO2 enhanced C. albicans ability to appropriate iron 
from the environment biofilms were grown in the presence of the Fe2+ chelator 3-(2-Pyridyl)-
5,6-diphenyl-1,2,4-triazine-p,p’-disulfonic acid monosodium salt hydrate (Ferrozine). Iron 
chelation was observed to have a marked effect on biofilm growth at and above 350μM 
Ferrozine (Figure 3.4B). As had been observed with TFKO strains of the HAP complex, the 
elevation of CO2 counteracted the effects of iron limitation (Figure 3.4B) providing further 
evidence of a role for CO2 in enhancing iron uptake or utilisation capability. This tolerance to 
iron sequestration of C. albicans biofilms grown in 5% CO2 was also exhibited by tpk1Δ/Δ and 
tpk2Δ/Δ mutants (Supplementary Figure S3.4), indicating these PKA isoforms are functionally 
redundant with respect to iron homeostatic pathways. Clinical strains of C. albicans isolated 
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from failed voice prostheses displayed the same phenotype with biofilm formation rescued 
in 5% CO2 when grown in the presence of 500μM Ferrozine (Figure 3.4C). A transcriptomic 
analysis comparing biofilms grown in 0.03% and 5% CO2 (described below) revealed that 
several genes related to iron acquisition were upregulated in 5% CO2 CAI-4 biofilms after 48h, 
possibly explaining the tolerance to iron sequestration in high CO2 (Figure 3.4B and 3.4C). 
FTR2, which encodes the high affinity iron permease Ftr2, had increased expression (0.97 log2 
fold change). In addition, CFL4 which encodes a putative ferric reductase, is regulated by Sef1 
and induced in low-iron conditions [56] was upregulated (2.29 log2 fold change) in high CO2 
biofilms after 48h. Finally, the CSA2 and RBT5 genes, which encode proteins involved in the 
acquisition of iron from haem groups, were also upregulated (2.95 and 0.95 log2 fold changes 
respectively). Csa2 and Rbt5 have both previously been found to be required for normal 





































Figure 3.4: The effect of high (5%) CO2 on iron homeostasis in C. albicans biofilms. Biofilms were seeded and grown 
for 48h before XTT quantification. Control wells with no cells were set up as media controls to monitor for 
contamination as well as to ensure there was no reaction of the silicone squares with the XTT reagents. (A) Biofilm 
growth assay using TFKO mutants lacking iron homeostatic transcription factors. Graph represents three biological 
replicates each containing technical triplicates, error bars denote Standard Deviation. (B) Iron starvation biofilm 
growth assay of SN152 in the presence of the Fe2+ chelator Ferrozine. Graph represents six biological replicates each 
containing technical triplicates, error bars denote Standard Deviation. (C) Iron starvation biofilm growth assay of 
clinical isolates in the presence of Ferrozine. Graph represents two biological replicates each containing technical 
triplicates, error bars denote Standard Deviation. Two-way ANOVAs followed by Tukey tests for multiple comparisons 
were carried out: *p<0.05, **p<0.01, ***p<0.001, n.s. = not significant. Stars directly above the bars indicate a 




3.5.4 Transcriptome analysis of C. albicans biofilms grown in high and low CO2 
To further investigate the effect of high CO2 on C. albicans biofilm growth, we performed a 
genome-wide transcriptome analysis of C. albicans biofilms grown in 0.03% and 5% CO2 to 
evaluate gene expression patterns in the two conditions. C. albicans biofilms were grown in 
biological triplicate in both 0.03% and 5% CO2 for 48h. RNA was isolated and sequenced, 
generating an average of 58M reads per sample. Quality control analyses of the RNA-Seq 
reads were performed using FastQC and these can be found in Appendix 1. Using DESeq2 
[276], the expression levels of each gene in the 5% CO2 samples was compared to those in the 
0.03% CO2 samples. Growth in 5% CO2 led to a global response resulting in the significant 
differential expression (false-discovery-rate adjusted p-value (q) ≤ 0.05) of 2875 genes, with 
roughly equal numbers of genes up- and downregulated (1441 up and 1434 down) (Figure 
3.5A). 80 genes were strongly (log2 fold change >2) upregulated and 25 were strongly (log2 
fold change <-2) downregulated. To investigate the cellular pathways which these 
differentially expressed genes are within we conducted Gene Set Enrichment Analysis (GSEA; 
Broad Institute) [277]. Briefly, GSEA takes a list of significantly (q ≤ 0.05) differentially 
expressed genes, ranked from the most upregulated to the most downregulated, and 
compares them to a gene set database [278] to determine whether the members of each 
gene set are randomly distributed throughout the ranked list or significantly overrepresented 
(enriched) at the top or the bottom. Gene sets with genes enriched at the top of the ranked 
list have a positive normalised enrichment score (NES) and gene sets with genes enriched at 
the bottom have a negative NES. This makes it possible to draw conclusions about biological 
processes/pathways which were up- or downregulated between the two conditions. Gene 
sets along with the position of the genes in the ranked list of significantly differentially 
expressed genes and the running enrichment scores can be found in Appendix 2.        
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GSEA revealed that biofilm formation pathways controlled by four of the nine ‘core’ biofilm 
regulator transcription factors [127][128] were upregulated in 5% CO2 biofilms at 48h (Figure 
5B). Genes downstream of Brg1, Efg1, Ndt80 and Bcr1 are enriched in the upregulated genes 
at the top of the ranked list of differentially expressed genes (NES = +2.79, +2.66, +2.56, and 
+2.60 respectively) (Figure 3.5B), indicating high CO2 drives expression of genes previously 
described as important in the biofilm-forming ability of C. albicans.  
 
As GSEA can show enrichment profiles exhibiting correlations with several overlapping gene 
sets, we visualised networks of similar gene sets using the Cytoscape 3.7.1 EnrichmentMap 
plug-in [281]. Upregulated gene sets included those encoding membrane transporters, 
ribosome biogenesis, peroxisomal β-oxidation and white-opaque switching (Figure 3.5C). 
Pathways involved in cytoskeleton organisation, cell-cycle progression and membrane 
biosynthesis were downregulated in high CO2 conditions (Figure 3.5C), indicating cells within 
biofilms in high CO2 may have stopped dividing, consistent with such biofilms having moved 



































Figure 3.5: Global gene expression changes in 5% CO2 vs. 0.03% CO2 C. 
albicans biofilms. (A) Volcano plot of log2 fold changes (5% CO2 vs. 0.03% 
CO2 biofilms) against mean of normalised counts for each gene; red dots 
= significantly differentially expressed (q≤0.05) genes, grey dots = not 
significant. 2875 genes showed significant differential expression. 
Normalised counts are the number of reads a particular gene has, thus 
the higher the mean of normalised count, the higher the expression of 
that gene. (B) GSEA enrichment plots of central biofilm regulator gene 
sets containing genes whose promoters have been shown by ChIP-chip 
experiments to be bound during biofilm formation by one or more of four   
 
(Brg1, Efg1, Ndt80, and Bcr1) of the nine ‘core’ biofilm regulators [27]. Vertical black lines represent individual genes 
in the significantly differentially expressed ranked gene list from upregulated (left) to downregulated (right). The 
enrichment score increases if there are lots of genes towards the beginning of the ranked list (upregulated). NES = 
normalised enrichment score, positive NES indicates enrichment in the upregulated group of genes. (C) Gene set 
cluster map showing the most upregulated and downregulated gene sets as determined by GSEA along with their 
cellular functions. Each circle is a gene set and the lines between them depict how much they overlap, thicker line = 
more genes in common.   
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GSEA suggested that cell adhesion processes were upregulated in high CO2 biofilms (NES = 
+2.13) (Figures 3.6Ai). GO Slim process analysis also highlighted many genes associated with 
cell adhesion were upregulated in C. albicans biofilms grown in 5% CO2 after 48h (Figure 
3.6Bi). The second highest upregulated gene in 5% CO2 biofilms compared to 0.03% CO2 
biofilms was ALS1 with a 3.77 log2 fold change (Figure 3.6Bi). The Als1 cell surface adhesin 
has previously been shown to have important roles in biofilm formation [284], and its 
expression is controlled by the biofilm transcription regulation network composed of Brg1, 
Rob1, Tec1, Ndt80, Bcr1 and Efg1 [127]. Other genes encoding cell surface adhesins such as 
ALS4 and ALS2 had log2 fold increases in expression of 1.87 and 1.46 respectively in 5% CO2 
biofilms after 48h (Figure 3.6Bi).    
 
GSEA has also identified genes involved in membrane transporter activity are enriched in the 
upregulated genes at the top of the ranked list of differentially expressed genes (NES = +2.22) 
(Figure 3.6Ai). Specifically, genes encoding amino acid transporters were enriched in the 
significantly upregulated genes of 5% CO2 biofilms (NES = +2.62) (Figure 3.6Aii). Likewise, 
significantly differentially expressed genes possessing the GO term ‘amino acid transport’ 
were primarily upregulated (Figure 3.6Bii). The most highly upregulated of these was GAP2 
which encodes a general amino acid permease [285]. GAP2 was in fact the highest 
upregulated gene of the entire RNA-Seq data set with a 4.60 log2 fold change. The basic amino 
acid permease genes CAN1, CAN2, and CAN3 were also upregulated (Figure 3.6Bii). 
     
Genes associated with carbohydrate transmembrane transport were also enriched in the 
significantly upregulated genes of 5% CO2 biofilms as revealed by GSEA (NES = +1.88) (Figure 
3.6Aii). Amongst these were 12 genes encoding putative major facilitator superfamily (MFS) 
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glucose transmembrane transporters present in the significantly differentially expressed gene 
list and these are almost all upregulated. The only exceptions are HGT9 and HGT18 with log2 
fold changes of -1.24 and -1.70 respectively (Figure 3.6Bii).  
 
Intriguingly, the TPK1 gene, which encodes the PKA catalytic subunit isoform Tpk1, was 
upregulated in 5% CO2 biofilms (1.04 log2 fold change) (Supplementary Figure S3.5B), 
whereas the other isoform encoding gene TPK2 was downregulated (-0.80 log2 fold change) 
(Figure 3.6Bi and Supplementary Figure S3.4B). This could suggest a preference for Tpk1 
instead of Tpk2 under high CO2 conditions, although there was not a significant biofilm growth 









































Figure 3.6: Adhesion and transport processes are predicted to be upregulated in 5% CO2 vs. 0.03% CO2 C. albicans 
biofilms. (Ai) GSEA enrichment plot of the BIOLOGICAL ADHESION_BIO gene set containing genes under the GO 
term ‘biological adhesion’. (Aii) Enrichment plots of the TRANSPORTER ACTIVITY_MOL, AMINO ACID 
TRANSPORT_BIO and CARBOHYDRATE TRANSPORTER ACTIVITY_MOL gene sets containing genes under the GO 
terms ‘transporter activity’, ‘amino acid transport’ and ‘carbohydrate transmembrane transporter activity’ 
respectively. NES = normalised enrichment score, positive NES indicates enrichment in the upregulated group of 
genes. (Bi) Heat map of significantly differentially expressed genes associated with cell adhesion as identified by GO 
Slim process analysis. The colours saturate at log2 fold change of 2 and -2; ALS1, C5_02110W, and WOR1 have log2 
fold changes of 3.77, 3.02 and 2.15 respectively. (Bii) Heat maps of significantly differentially expressed genes 
associated with amino acid and glucose transport as identified by GO Slim process analysis. The colours saturate at 
log2 fold change of 2 and -2; GAP2, CAN1, and AAP1 have log2 fold changes of 4.60, 2.34 and 2.32 respectively. 




The majority of gene sets predicted to be downregulated in 5% CO2 biofilms after 48h growth 
were associated with cytoskeletal organisation, hyphal growth and cell division 
(Supplementary Figure S3.5A). Genes previously identified to be involved in hyphal formation 
in response to foetal bovine serum (FBS) exposure or 37oC were enriched in the 
downregulated genes (NES = -3.41). Likewise, the majority of genes under the GO term 
‘hyphal growth’ in the significantly differentially expressed gene list were downregulated in 
5% CO2 biofilms at 48h growth (Supplementary Figure S3.5B). Significantly differentially 
expressed genes associated with the cytoskeleton, as identified by GO term analysis, were 
enriched in the downregulated genes (NES = -2.69) (Supplementary Figure S3.5A). 
Cytoskeleton reorganisation is important for the growth of C. albicans hyphal cells [286] as 
well as cell division [287][288], indicating cell growth is lower in 48h old C. albicans biofilms 
grown in 5% CO2 than in those grown in 0.03% CO2. Consistent with this, genes involved in 
the transition through the G1/S checkpoint were also enriched in the significantly 
downregulated genes (NES = -2.83) (Supplementary Figure S3.5A). Together, these data 
suggest C. albicans biofilm cells exhibit greater growth and division at 48h in 0.03% CO2 than 
in 5% CO2. Initially, this appears to be contradictory to the previous data highlighting the 
increased biofilm formation of C. albicans under high CO2 conditions. However, due to the 
increased biofilm formation in a 5% CO2 environment, C. albicans biofilms reach full maturity 
much quicker in high CO2, as observed via confocal microscopy (Figure 3.2B). Thus by 48h C. 
albicans biofilms grown in high CO2 have been fully mature for several hours, and hence 
would contain fewer dividing cells or cells extending hyphae in comparison to low CO2 





3.5.5 CO2 elevation enhances azole tolerance in C. albicans biofilms  
In addition to the observed increase in expression of genes that drive biofilm formation and 
we observed an elevation in certain stress response pathways in C. albicans biofilms grown in 
5% CO2. Gene sets involved in the response of C. albicans to antifungals such as Ketoconazole 
[289] (Figure 3.7A) were upregulated as well as several drug transporters (Figure 3.7B), 
indicating that CO2 elevation may lead to increased drug tolerance. Upregulated genes 
included the MDR1 gene (2.56 log2 fold change) which encodes the multidrug resistance 
pump Mdr1 and is associated with tolerance to several antifungals such as azoles [161]. To 
test this, C. albicans biofilms were seeded and grown for 24h in 0.03% and 5% CO2 before the 
addition of antifungals, after which they were grown for an additional 24h in both conditions 
to observe the effect of drug application. Antifungal concentrations were selected based upon 
previously reported MIC values for these antifungals against C. albicans biofilms [115]. 
Overall, Fluconazole and Miconazole treatment led to a significant reduction in biofilm growth 
in 0.03% CO2 (Figures 7C and Supplementary Figure S3.6). Treatment with Fluconazole and 
Miconazole also significantly reduced biofilm formation in 5% CO2, however, their 
effectiveness was markedly reduced (Figures 7C and Supplementary Figure S3.6). This 
suggests an increased tolerance of biofilms grown in 5% CO2 to azole treatment. Interestingly, 































Figure 3.7: Antifungal sensitivity of C. albicans biofilms grown in high (5%) CO2. (A) GSEA enrichment plot of the 
KETOCONAZOLE_UP gene set containing genes upregulated in C. albicans cells grown in the presence of 
Ketoconazole [62]. NES = normalised enrichment score, positive NES indicates enrichment in the upregulated group 
of genes. (B) Heat map of genes associated with drug transport, including the multidrug efflux pump gene MDR1. (C) 
Biofilm growth assay of CAI4pSM2 in the presence of Fluconazole. (D) Biofilm growth assay of CAI4pSM2 in the 
presence of Nystatin. Biofilms were seeded and grown for 24 hours before antifungal addition, they were then grown 
for a further 24 hours before quantification using the XTT assay. The relative XTT activity is presented with the 0.03% 
CO2 biofilms being normalised to the 0.03% CO2 untreated control and the 5% CO2 biofilms being normalised to the 
5% CO2 untreated control. This prevents the general higher growth of 5% CO2 biofilms impacting the analysis. Two-
way ANOVAs followed by Tukey tests for multiple comparisons were carried out: *p<0.05, **p<0.01, ***p<0.001, 
n.s. = not significant. Stars directly above the bars indicate a significant difference to untreated in the same CO2 
environment.       
    
 151 
 
3.5.6 Precision approaches to overcome CO2 acceleration of C. albicans biofilm formation 
Our data indicate that elevation of CO2 leads to an increase in the ability to scavenge for iron 
and glucose, both essential for biofilm formation and growth. We therefore wished to test 
whether these represented potential targets to combat C. albicans growth in high CO2 
environments such as the airway. An Fe3+ chelator called Deferasirox, which is approved for 
treating patients with iron overload, has recently been shown to reduce infection levels in a 
murine oropharyngeal candidiasis model [290]. With this in mind, we repeated our previous 
iron starvation biofilm growth assay (Figure 3.4B) using Deferasirox in place of Ferrozine. We 
observed that Deferasirox treatment completely eradicates C. albicans biofilm growth in 
0.03% CO2 but has little effect on biofilm growth in 5% CO2 (Figure 3.8A). Thus adding further 
evidence that exposure to high levels of CO2 can enable C. albicans biofilms to overcome the 
effects of iron starvation. Deferasirox does not therefore appear to be an effective treatment 
against C. albicans biofilms in high CO2 such as in the context of voice prostheses colonisation.  
 
C. albicans biofilms grown in 5% CO2 exhibited the upregulation of genes encoding glucose 
transporters. Accordingly, we contemplated whether treatment of C. albicans biofilms with 
the glucose analogue 2-deoxyglucose (a glycolytic inhibitor) may decrease biofilm growth in 
high CO2 environments. 2-deoxyglucose (2-DG) has previously made it to Stage II clinical trials 
as an anti-prostate cancer treatment and is considered safe for use in humans [291]. Thus, it 
could be a potential therapeutic option to combat C. albicans biofilm formation on medical 
devices, specifically on voice prostheses. C. albicans biofilm formation was significantly 
reduced in the presence of 2-DG regardless of CO2 environment (Figure 3.8B and 
Supplementary Figure S3.7). Interestingly, the biofilm reductions in all 2-DG concentrations 
were similar for biofilms in both low and high CO2, despite the fact several glucose 
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transporters were upregulated in 5% CO2 biofilms (Figure 3.6Bii). Treatment with 1% 2-DG 
reduced C. albicans SN152 biofilm formation by an average of 46% and 38% in 0.03% and 5% 
CO2 respectively (Figure 3.8B). Likewise, 1% 2-DG reduced C. albicans CAI4pSM2 biofilm 
formation by an average of 33% and 30% in 0.03% and 5% CO2 respectively (Supplementary 
Figure S3.7). This reduction was quite apparent and could be visually observed directly on the 

























Figure 3.8: Efficacy of potential treatments to combat C. albicans biofilms grown in high (5%) CO2. Biofilms were 
seeded and grown for 48h before XTT quantification. Control wells with no cells were set up as media controls to 
monitor for contamination as well as to ensure there was no reaction of the silicone squares with the XTT reagents. 
(A) Biofilm growth assay of SN152 in the presence of the Fe3+ chelator Deferasirox. Graph represents two biological 
replicates each containing technical triplicates, error bars denote Standard Deviation. (B) Biofilm growth assay of 
SN152 in the presence of the glycolytic inhibitor 2-DG. Graph represents three biological replicates each containing 
technical triplicates, error bars denote Standard Deviation. Two-way ANOVAs followed by Tukey tests for multiple 
comparisons were carried out: *p<0.05, **p<0.01, ***p<0.001, n.s. = not significant. Stars directly above the bars 
indicate a significant difference to the SN152 untreated in the same CO2 environment. (C) Representative images of 
SN152 biofilms grown in 5% CO2 ±2-DG for 48h (red coloration due to XTT assay). 




3.6.1 Physiological CO2 levels increase C. albicans biofilm formation 
Viewed together, the data presented here demonstrates for the first time that a 
physiologically relevant (5%) CO2 environment acts as a trigger to increase the biofilm-forming 
ability of C. albicans. CO2 is well established as a driver of the yeast-to-hyphal morphogenic 
switch in C. albicans [69][77][292], however, the effects of high CO2 levels on biofilm 
formation were hitherto unknown. CO2, in the form of bicarbonate ions (HCO3-), interacts with 
a lysine residue at position 1373 in the adenylate cyclase Cyr1 of the Ras1-Cyr1-PKA pathway, 
thereby activating it [77]. This Cyr1 activation is responsible for the CO2-driven yeast-to-
hyphal switch [69], and this morphogenesis is critical for biofilm formation [142]. A cdc35Δ/Δ 
null mutant is defective in hyphal formation [69], consistently our data demonstrates that this 
mutant was unable to make biofilms in either 0.03% or 5% CO2. The lack of CO2 response 
suggests Cyr1 is essential for the effect of CO2 on C. albicans biofilms that we have 
characterised in this study. Further evidence for this argument comes from the ras1Δ/Δ null 
mutant which is hyphal deficient [66] and was unable to form biofilms in 0.03% CO2 but 
formed equivalent biofilms to the wild type in 5% CO2. This suggests a redundancy of Ras1 in 
this scenario as the HCO3- ions are able to bypass Ras1 and activate Cyr1 directly [77], 
restoring the ability to form hyphae [69] and hence biofilms.  
 
Interestingly, from our data it appears that the ability of Cyr1 to respond to high CO2 levels is 
reliant on the presence of its Ras-interacting RA domain since a CDC35ΔRA mutant continued 
to have attenuated biofilm growth in 5% CO2. This is not due to a hyphal defect as the 
CDC35ΔRA strain displays normal hyphal growth in 5% CO2 [293]. Furthermore, as Ras1 is not 
required for hyphal formation [69] or biofilm formation in high CO2 (this study), the biofilm 
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deficiency of the CDC35ΔRA strain cannot be explained by a requirement for the RA domain to 
mediate an interaction with Ras1. The role of the RA domain in biofilm growth remains 
elusive. Overall, these data suggest the response of C. albicans biofilms to physiological (5%) 
levels of CO2 is dependent on Cyr1 but can bypass a requirement for Ras1. 
  
Phenotypic analyses identified that the elevation of CO2 enhances each stage of the C. 
albicans biofilm forming process, from attachment through maturation to dispersion. The 
observed increase in cell attachment is consistent with our transcriptome analysis as we 
observed an increase in the abundance of mRNA transcripts for ALS1, ALS2 and ALS4 which 
encode adhesins of the agglutinin-like sequence family that function in the cell-surface and 
cell-cell attachment of C. albicans [134]. Likewise, the increased dispersion also correlates 
with our transcriptome analysis since NRG1 was upregulated (1.76 log2 fold change) in 5% 
CO2 biofilms after 48h. Overexpression of NRG1 has previously been demonstrated to 
increase the dispersion of yeast cells from C. albicans biofilms [144], and so this possibly 
provides a mechanism to explain the increased dispersion from biofilms grown in high CO2. 
This amplified dispersion could have important clinical implications since it suggests biofilms 
may not only form more rapidly on medical devices (e.g. voice prostheses) in high CO2, but 
they may also have an increased propensity to disseminate and cause infection. Cells 
dispersing from mature biofilms have distinct characteristics compared to typical planktonic 
yeast cells; with enhanced adherence, an increased tendency to filament, and increased 
biofilm forming capability [126].  
 
Overall, our transcriptome analysis identified that a number of hallmarks of the biofilm mode 
of growth – including increased cell adhesion, increased transport activity, and increased drug 
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tolerance – were upregulated in biofilms grown in high CO2 conditions. Pathways governed 
by central regulators of biofilm formation – Efg1, Bcr1, Brg1, and Ndt80 [127] – were 
predicted by GSEA to be upregulated in C. albicans biofilms grown in 5% CO2, possibly 
explaining the increased expression of genes related to hallmarks of biofilm growth.  
 
Of the original 6 ‘core’ biofilm regulators (Efg1, Bcr1, Brg1, Rob1, Ndt80 and Tec1) only 3 (Efg1, 
Brg1 and Rob1) were identified as required for normal biofilm growth in our TFKO screen. The 
original 6 were identified in a similar screen to ours and used the same TFKO library, however, 
their study was carried out using polystyrene surfaces [127] whereas we used silicone. This 
may suggest that attachment to silicone requires a more limited set of core transcription 
factors reflecting the importance of surface upon biofilm formation as has been observed 
previously [128]. CO2 elevation appears to be able to compensate for the loss of some key 
regulators, as we observed its increase could bypass a requirement for Brg1 and Rob1. 
Intriguingly, of the four biofilm regulators whose gene sets were predicted to be upregulated 
in 5% CO2 biofilms, only Efg1 and Brg1 were identified in our TFKO screen, and only efg1Δ/Δ 
had reduced biofilm growth in both 0.03% and 5% CO2. This disparity may be explained by the 
degree of overlap in downstream target genes between the core regulators of biofilm 
formation [127] which implies significant potential for functional redundancy.      
 
Many of the genes significantly upregulated in biofilms grown in high CO2 after 48h were also 
found to be upregulated in other biofilm gene expression studies [130][294]. For instance, 
Nett, J. et al. observed an increase in the expression of adherence genes in an in vivo venous 
catheter biofilm model. Like us, this venous catheter biofilm study saw an increase in the 
transcript abundance of ALS1 and ALS2 however, this was only seen at earlier time point 
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biofilms [130]. This was also the case in a temporal gene expression analysis using in vitro 
denture and catheter models [294]. Interestingly, some pathways such as hexose transport, 
amino acid uptake, and stress responses that our differential gene expression analysis 
predicted to be upregulated in mature biofilms grown in high CO2 were concluded to be 
upregulated only in early phase biofilms (12h) in this denture and catheter study [294]. The 
authors concluded the result of the induction of these pathways is the increase of intracellular 
pools of pyruvate, pentoses and amino acids, preparing for the large increase in biomass that 
occurs later in biofilm development [294]. We hypothesise that high CO2 is stimulating these 
pathways and maintaining their activity even in mature biofilms, thus supporting the 
increased biomass and maturation rate of biofilms observed when grown in high CO2.  
 
Nearly all device-associated infections involve potential pathogens growing within a biofilm 
[4]. Previously, us and other laboratories have demonstrated C. albicans is the most prevalent 
fungal coloniser, in polymicrobial biofilms, of failed voice prostheses [195][204]. Due to the 
high CO2 content of exhaled air and the fact voice prostheses are situated in the throat, the 
responses of C. albicans to CO2 detailed here could provide an explanation for its competitive 
fitness in this scenario. More widely, this work could also be of importance to several C. 
albicans infections, for instance candidaemia, since CO2 levels within mammalian hosts are 
up to 150x higher (~5% vs. 0.03%) than in atmospheric air [222][268]. 
 
3.6.2 C. albicans biofilms grown in 5% CO2 exhibit increased drug tolerance 
We observed an increase in azole antifungal tolerance within C. albicans biofilms grown in 5% 
CO2. This, at least partly, could be explained by the increase in expression of drug transporter 
genes such as MDR1 in 5% CO2 biofilms which have previously been implicated in azole 
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tolerance [159][161]. However, mdr1Δ/Δ, as well as cdr1Δ/Δ and cdr2Δ/Δ, mutants only 
exhibit reduced azole tolerance in planktonic culture and early stage (6h) biofilms, while levels 
of tolerance are maintained in mature biofilms [161]. Therefore, we propose that it is more 
likely the increased azole tolerance phenotype of 5% CO2 biofilms displayed is contributed to 
via another mechanism, possibly increased ECM deposition. β-1,3-glucan, a major component 
of biofilm ECM, can bind to azole antifungals and sequester them to prevent passage to the 
cells [157]. We have observed that after 48h, 5% CO2 biofilms, while containing similar cell 
numbers to 0.03% CO2 biofilms, often appear larger to the eye with a more bulbous 
appearance. This could suggest more ECM material being produced in high CO2 environments, 
contributing to the increased azole tolerance. Furthermore, Miconazole treatment has been 
shown to generate superoxide radicals within C. albicans biofilms and leads to the increased 
expression of SOD5 and SOD6 (encode superoxide dismutase enzymes) in an attempt to 
protect against the toxic superoxides. A sod4Δ/Δsod5Δ/Δsod6Δ/Δ triple mutant is 
hypersensitive to Miconazole treatment when growing as a biofilm [183]. Our transcriptome 
analysis revealed SOD6 is upregulated with a 1.52 log2 fold change (also SOD4; 1.02 log2 fold 
change) in 5% CO2 biofilms, providing a potential further mechanism of the increased 
Miconazole tolerance.         
 
3.6.3 CO2 and iron homeostasis in C. albicans biofilms 
Our TFKO library biofilm formation screen identified transcription factors involved in iron 
homeostasis as important for C. albicans biofilm growth. Principal among these were the Hap 
transcription factors which come together to form the HAP complex, a CCAAT box-binding 
transcriptional regulator, under iron-limiting conditions. Genetic studies have revealed a 
requirement of HAP2, HAP3, HAP5 and HAP43 for growth in low-iron media [269][295]. Thus, 
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the biofilm formation defect exhibited by the hap2Δ/Δ, hap3Δ/Δ, hap5Δ/Δ, and hap43Δ/Δ 
mutants in 0.03% CO2 could be explained by this growth deficiency since RPMI-1640 media 
has a low iron content. Nevertheless, this makes it even more intriguing that simply an 
increase in ambient CO2 levels was able to significantly increase the biofilm growth of these 
mutants.  
 
The HAP complex represses a GATA-type transcription factor called Sfu1, Sfu1 is responsible 
for repressing iron-uptake genes along with SEF1 under iron-replete conditions. Sef1 activates 
iron-uptake genes as well as HAP43, HAP2 and HAP3 [56], in this way the HAP complex is able 
to induce iron-uptake pathways while repressing iron-utilisation genes [56][57]. Deletion of 
Sef1 results in the aberrant downregulation of all the major iron-uptake pathways of C. 
albicans in low iron conditions [56]. Due to the fact the sef1Δ/Δ mutant had defective biofilm 
growth in both CO2 conditions, we hypothesise that a high CO2 environment may influence 
Sef1 directly, causing the HAP complex to become at least partially redundant under these 
conditions. It should be noted that we did not observe a significant effect on SEF1 mRNA levels 
within 5% CO2 biofilms after 48h. Thus, if it is influencing Sef1 activity, CO2 must be acting at 
either the protein level or post-translational level as Sef1 is subject to a post-translational 
control loop consisting of Sfu1 and the cyclin-dependent kinase Ssn3 [58]. We do not believe 
the CO2 effect on iron homeostasis is mediated through Ssn3 as this protein has recently been 
found to be dephosphorylated and thus inactive in 5% CO2 [292]. Therefore, our current 
hypothesised model suggests that PKA can phosphorylate Sef1 and possibly also inhibit Sfu1 
(Figure 3.9). This is currently under investigation and may possibly explain the tolerance to 
iron sequestration exhibited by C. albicans biofilms grown in high CO2. We believe any 
potential phosphorylation of Sef1 by PKA to be Tpk1/Tpk2 redundant since the tpk1Δ/Δ and 
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the tpk2Δ/Δ mutants both exhibited a significant increase in biofilm growth in 5% CO2 when 
in the presence of 500µM Ferrozine compared to 0.03% CO2. This is supported by a Tpk1/Tpk2 
phosphoproteomic study which predicted Sef1 to be a potential PKA target that can be 





















Figure 3.9: Predicted model of the interplay between CO2 signalling and iron homeostasis in C. 
albicans biofilms on silicone surfaces. We hypothesise that the CO2-mediated activation of PKA via 
Cyr1 will result in increased activity of Sef1 (via its phosphorylation and possibly the inhibition of 
Sfu1), thus increasing the expression of iron-uptake genes.       
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The increased azole tolerance of C. albicans biofilms in 5% CO2 along with the observed iron 
starvation tolerance when treated with the Fe3+ chelator Deferasirox has important 
implications for the development of potential treatment strategies. This is especially true for 
those assessed in vitro, as it demonstrates that C. albicans can exhibit very different 
phenotypes in response to environmental changes, in our case CO2 concentration. At a clinical 
level, this also indicates the location of a C. albicans biofilm within the body should be taken 
into consideration when deciding upon the most effective treatment. Encouragingly, 2-
deoxyglucose (2-DG) was able to attenuate C. albicans biofilm growth in both 5% and 
atmospheric (0.03%) CO2 environments. 2-DG has exhibited antimicrobial effects against 
fungal moulds [296] and bacterial biofilms [297]. This, together with its action against C. 
albicans biofilms presented here, highlights the potential for 2-DG to be used an anti-biofilm 
therapeutic. It may be particularly useful for medical devices such as voice prostheses which 
are situated in CO2-rich environments in the body and are often colonised by a mixture of 
bacterial and fungal species [195][201][204]. It is important to note however that 2-DG was 
unable to eradicate C. albicans biofilm growth completely. It may be that 2-DG treatment is 
beneficial in combination with other compounds, such as iron chelators or traditional 
antifungals; this possibility is yet to be explored.  
 
In conclusion, our data and others’ indicate physiological (5%) levels of CO2 can act as an 
important pathogenic signal for C. albicans. CO2 drives many virulence factors such as yeast-
to-hyphal morphogenesis [69], biofilm growth (this study), and iron acquisition (this study). 
These CO2-mediated effects are likely to have important medical ramifications, primarily in 
the context of prosthetics as demonstrated with voice prosthetics, but also for host infections 
in CO2-rich environments in the body.     
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3.7 Supplementary Materials 
Strain Species Genotype/Parent Source/Reference 





CAI4 C. albicans ura3::imm434/ura3::imm434 
iro1/iro1::imm434 
Mühlschlegel Lab 
CAI4pSM2 C. albicans CAI4 transformed with pSM2, URA3 
integrating plasmid 
[77] 
TFKO Library C. albicans SN152 [269] 
CDH107 
(ras1Δ/Δ) 
C. albicans CAI4 [69] 
CR276 
(cdc35Δ/Δ) 
C. albicans CAI4 [298] 
WYF2 
(CDC35ΔRA) 
C. albicans CR276 transformed with pClp-
cdc35ΔRA  
[293] 
tpk1Δ/Δ C. albicans CAI4 Mühlschlegel Lab 
tpk2Δ/Δ C. albicans CAI4 Mühlschlegel Lab 
G-3065 C. albicans Clinical Isolate Failed Voice Prosthesis 
G-8424 C. albicans Clinical Isolate Failed Voice Prosthesis 






























Supplementary Table S3.2: Summary of the transcription factor knockout (TFKO) mutants which 
had significantly altered biofilm growth in 0.03% and/or 5% CO2 environments within our 
screen. Biofilms were quantified via XTT assays and normalised to the wild type XTT readout within 
each CO2 environment; ‒ ‒ ‒ <40% XTT activity relative to wild type, ‒ ‒ 40-70%, ‒ >70%, + >110% 
++ >130%, n.s. non-significant. Green indicates transcription factors previously known to have a 
role in biofilm regulation as per Gene Ontology analysis. Grey indicates transcription factors 




















Supplementary Figure S3.1: Attachment of C. albicans CAI-4 cells to a silicone surface in 0.03% and 
5% CO2. C. albicans CAI-4 cells were seeded for 90 mins onto silicone-coated microscope slides in 
0.03% CO2 or 5% CO2, unattached cells were washed off and images taken at 20x objective 
magnification. Several images were taken of both 0.03% and 5% CO2 slides and representative 
examples are shown. (A) Representative image of a slide section from 0.03% CO2. (B) Representative 






















Supplementary Figure S3.2: Dispersion of C. albicans CAI4pSM2 cells from biofilms grown in 
0.03% and 5% CO2. (A) Wells containing RPMI-1640 media after biofilm growth, C. albicans cells 
can be seen as white clumps formed from hyphal cells. (B) Representative CFU plates from a 1:10 









































Supplementary Figure S3.3: Transcription Factor Knockout Screen of C. albicans biofilm-forming ability. 
Biofilms were seeded and grown before quantification via XTT assay. Graphs represent three biological 
replicates for each mutant. The XTT assay absorbances at 492nm for the 0.03% and 5% CO2 biofilms have 
been normalised to the 0.03% and 5% CO2 SN152 wild type controls respectively. This removes any day-
to-day variation, thus allowing TFKO mutants grown on different days to be compared. One-way ANOVAs 
followed by Dunnett’s Tests for multiple comparisons to a control were performed to compare the TFKO 
mutant biofilms to the SN152 wild type controls (for both 0.03% and 5% CO2); *p<0.05, **p<0.01, 






















Supplementary Figure S3.4: The effect of high (5%) CO2 on tolerance to iron starvation in tpk1Δ/Δ and 
tpk2Δ/Δ PKA mutants. Biofilms using (A) tpk1Δ/Δ and (B) tpk2Δ/Δ mutants were seeded and grown for 
48h in the presence of the Fe2+ chelator Ferrozine before XTT quantification. Graphs represents two 
biological replicates each containing technical triplicates, error bars denote Standard Deviation. Two-way 
ANOVAs followed by Tukey tests for multiple comparisons were carried out: *p<0.05, **p<0.01, 
***p<0.001, n.s. = not significant. Stars directly above the bars indicate a significant difference to the 
























Supplementary Figure S3.5: Gene expression profiles of genes/gene sets downregulated in 5% CO2 
vs. 0.03% CO2 C. albicans biofilms. (A) GSEA enrichment plots of the HYPHAE_FBS_37_UP gene set 
containing genes upregulated after 6h of exposure to FBS and 37oC (hyphal inducing conditions), the 
CYTOSKELETON_CEL gene set containing genes under the GO term ‘cytoskeleton’, and the G1-S 
CLUSTER gene set containing genes involved in the transition through the G1/S checkpoint. Vertical 
black lines represent individual genes in the ranked gene list from upregulated (left) to 
downregulated (right). NES = normalised enrichment score, negative NES indicates enrichment in the 
downregulated group of genes. (B) Heatmap of genes associated with hyphal growth as identified by 
GO term analysis. Colours saturate at log2 fold change of 2 and -2; ALS1 actually has a log2 fold 






















Supplementary Figure S3.6: Miconazole sensitivity of C. albicans biofilms grown in high (5%) CO2. 
Biofilm growth assay of CAI4pSM2 in the presence of Nystatin. Biofilms were seeded and grown for 24 
hours before antifungal addition, they were then grown for a further 24 hours before quantification 
using the XTT assay. The relative XTT activity is presented with the 0.03% CO2 biofilms being normalised 
to the 0.03% CO2 untreated control and the 5% CO2 biofilms being normalised to the 5% CO2 untreated 
control. This prevents the general higher growth of 5% CO2 biofilms impacting the analysis. Two-way 
ANOVAs followed by Tukey tests for multiple comparisons were carried out: *p<0.05, **p<0.01, 
***p<0.001, n.s. = not significant. Stars directly above the bars indicate a significant difference to 























Supplementary Figure S3.7: Treatment of CAI4pSM2 C. albicans biofilms with 2-DG in 0.03% and 5% 
CO2. Biofilms were seeded and grown for 48h in the presence of the glycolytic inhibitor 2-DG before 
XTT quantification. Control wells with no cells were set up as media controls to monitor for 
contamination as well as to ensure there was no reaction of the silicone squares with the XTT reagents. 
Graph represents three biological replicates each containing technical triplicates, error bars denote 
Standard Deviation. Two-way ANOVAs followed by Tukey tests for multiple comparisons were carried 
out: *p<0.05, **p<0.01, ***p<0.001, n.s. = not significant. Stars directly above the bars indicate a 


























Within this study we confirmed that C. albicans is the most prevalent fungal microorganism 
isolated from early failing VPs within our patient cohort. From our study it appears that the 
yeast burden contributes most to the loss of mechanical function that underlies early VP 
failure. This is demonstrated by the success our novel VP treatment guidelines which focus 
on the attenuation of fungal colonisation. Implementation of this management strategy 
resulted in 2.7-fold increase in device overall lifespan in a 20 patient cohort. Our study also 
supports a major role for the environment in promoting yeast colonisation and in particular 
we observed that 5% CO2 (as found in exhaled breath) can drive the biofilm-formation of C. 
albicans. This may provide an explanation for its success in the VP setting. However, as 
expected, other bacterial (e.g. S. aureus and P. aeruginosa) and yeast (e.g. non-albicans 
Candida species) were also commonly found. Thus biofilms found on VPs represent complex 
and varied multi-species assemblies, each of which may contribute to VP deterioration.        
 
4.1 Polymicrobial Nature of Voice Prosthesis Biofilms 
Ours and previous studies [195][201][204] have observed the polymicrobial landscape of 
biofilms colonising failed VPs. The implications of polymicrobial biofilms and the interactions 
of the microbes within them in human disease are gaining increased interest [299]. Many 
diseases which were traditionally considered to be the result of a single microbial species, 
including infections of the oral cavity, otitis media and cystic fibrosis lung infections, have 
since been reassessed and recognised as true polymicrobial infections [299]. Interactions 
between microbes within polymicrobial infections can make them far more difficult to treat. 
For instance, it has been observed that physical interactions between yeast and hyphal C. 
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albicans cells and bacterial coccal cells in the oral mucosa result in increased antimicrobial 
tolerance of polymicrobial biofilms as well as enhanced biomass [299].   
     
The two most commonly isolated species in our study were S. aureus (found on 64.2% of VPs) 
and C. albicans (found on 56.0% of VPs). These two organisms are normal members of the 
oral microflora and synergistic relationships between them have previously been recognised. 
For instance, within polymicrobial biofilms S. aureus cells have been observed to be coated in 
C. albicans ECM material, increasing their tolerance to antibiotics such as Vancomycin [241]. 
In fact, S. aureus is poor at forming biofilms on abiotic surfaces on its own, however, it has 
been suggested that the hyphal C. albicans cells provide a scaffold on which the S. aureus cells 
can attach within a mixed species biofilm [247][300]. This is likely a major reason why S. 
aureus is found with C. albicans and other Candida species in such high frequencies on the 
same VP, as well as probably being very important to the success of our treatment startegy 
focussing on combatting the fungal colonisers.   
 
The attachment of S. aureus to C. albicans could also be a mechanism which the bacteria uses 
to invade human tissues during host infections, being carried on the hyphae as they penetrate 
the epithelial layers [258]. S. aureus is the third most commonly isolated organism with C. 
albicans in polymicrobial infections (a significant proportion of which are nosocomial 
infections) [257], demonstrating the importance of understanding interactions between 
these microorganisms. Carlson E. et al. demonstrated the potential dangers of co-infection 
with S. aureus and C. albicans over 30 years ago; intraperitoneal co-innoculation of 
immunocompetent mice with sublethal doses of C. albicans and S. aureus resulted in 100% 
mortality [259]. A further study discovered up to a 70000-fold decrease in the LD50 (inoculum 
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dose required to kill 50% of mice) for some S. aureus strains when co-innoculated with C. 
albicans compared to innoculation with S. aureus alone [260].  
 
The second most common bacterial species isolated from early failing voice prostheses in our 
study was P. aeruginosa. In a previous study, P. aeruginosa was found to be the most 
prevalent bacteria on failed VPs [201]. Traditionally, P. aeruginosa and C. albicans were 
considered to have an antagonistic relationship because in vitro experiments have 
demonstrated P. aeruginosa is capable of binding to the surface of C. albicans hyphal cells 
and induce cell lysis [301]. Moreover, P. aeruginosa and Candida species exhibited a mutual 
inhibition of biofilm formation in dual-species biofilms in vitro [302]. However, it may not be 
this simple as they have been found together in polymicrobial biofilms on medical devices 
such as VPs (this study – all VPs with P. aeruginosa also had one or more Candida species), as 
well as being commonly co-isolated in the sputum of cystic fibrosis patients [303]. In fact, the 
presence of C. albicans in cystic fibrosis sputum is a strong predictor of co-colonisation with 
Pseudomonas species [304]. Similar to S. aureus and C. albicans, co-infection of murine 
models with sublethal doses of P. aeruginosa and C. albicans resulted in significantly higher 
mortality than either species alone [305]. The discrepancies between in vitro and in vivo 
findings with regards to interactions between P. aeruginosa and Candida are not fully 
understood, but are likely to be a result of host interactions as well these species’ abilities to 
adapt to a variety of different niches. In vivo interactions between P. aeruginosa and C. 
albicans on medical devices and within polymicrobial biofilm infections are clinically very 




We identified many other Candida species in addition to C. albicans colonising failed VPs; C. 
glabrata, C. tropicalis, and C. parapsilosis were the third, fourth and fifth most commonly 
isolated species respectively. With the exception of C. parapsilosis, which was only co-isolated 
with another Candida species on one occassion, the other Candida species were commonly 
found together - most often C. albicans with one or more of the others. There has been limited 
work investigating potential synergistic/anatagonistic interactions within the Candida genus. 
We investigated whether the lack of Candida co-isolation with C. parapsilosis was due to a 
competitive advantage of C. parapsilosis over C. albicans. However, we found that in vitro C. 
albicans made much larger biofilms and outcompeted C. parapsilosis in a mixed biofilm, 
indicating other factors, such as patient diet, flora, and lifestyle which we were unable to 
mimic in our in vitro assay, are probably contributing to the success of C. parapsilosis in vivo. 
This is similar to previous studies; Kuhn, D. et al. found C. albicans isolates formed larger 
biofilms than C. parapsilosis isolates on silicone in vitro [237], whereas an investigation into 
Candida biofilms grown on catheters in vivo found little difference between C. albicans and 
C. parapsilosis biofilms [306].  
 
C. glabrata was the second most common fungal species; it was isolated from 23 failed VPs 
and 19 of these had another Candida species present, most commonly C. albicans. This 
implies a potential synergistic relationship between these species. It has previously been 
observed that C. glabrata and C. albicans are frequently co-isolated from patients with 
denture stomatitis and their combined presence was often associated with severe 
inflammation [307]. Unlike C. albicans, C. glabrata is unable to form hyphae, and as a result 
forms smaller biofilms composed solely of yeast cells [308]. The authors of the denture 
stomatitis study hypothesised that the hyphal cells of C. albicans help to maintain the 
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structural integrity of denture-associated biofilms and provide a protective network for the 
smaller C. glabrata cells [307]. This may also be the case with VP-associated biofilms. Further 
evidence for a possible synergy between C. albicans and C. glabrata during infection comes 
from experiments which demonstrated C. albicans was able to enhance the invasiveness of 
C. glabrata in a RHE model, possibly as a result of C. glabrata ‘hitchhiking’ on C. albicans 
hyphae [309]. For most strains tested, tissue damage was also significantly increased during 
co-infection compared to single infection with either species [309].   
 
We have demonstrated C. albicans biofilm growth in enhanced within a 5% CO2 environment 
(see Section 4.2). It is possible that metabolically derived CO2 generated by microorganisms 
in polymicrobial biofilms could create a microenvironment which supports biofilm formation. 
Hall, R. et al. observed that metabolic CO2 within C. albicans biomasses can accumulate to 
induce filamentous growth via activation of Cyr1 [77]. The work presented here shows that 
CO2 activation of Cyr1 also stimulates C. albicans biofilm growth. Thus, it is likely that once a 
polymicrobial biofilm reaches a critical size it enters a positive-feedback scenario where self-
derived CO2 drives further expansion which in turn provides more CO2. Furthermore, C. 
albicans biofilms create a hypoxic microenvironment which can support the growth of 
anaerobic bacteria such as Clostridium perfringens and Bacteroides fragilis; C. perfringens is 
even able to induce C. albicans cells to form biofilm-like aggregations in liquid culture where 
it can survive in the normally toxic aerobic environment [310]. The combination of 
metabolically-derived CO2 and hypoxia within growing biofilms is likely to substantially 





While our antifungal treatment strategy was successful at extending VP in situ lifespans, inter-
species interactions should not be underestimated. In addition to the interactions discussed 
above, it would also be interesting to explore possible viral or phage influences as these are 
not often considered in polymicrobial studies. This is also the case with non-fungal eukaryotic 
microorganisms such as protozoa. It is important to understand the synergistic and 
antagonistic relationships between microorganisms in this setting as they could provide 
insights for the development of further therapeutic strategies. These strategies could 
potentially be beneficial, not just for VP management, but also in the context of other 
prosthetic devices as well as polymicrobial host infections in general which are associated 
with enhanced pathogenicity.   
   
4.2 Physiological Levels of CO2 (5%) Enhance the Biofilm-Forming Ability of 
Candida albicans 
A key finding in our study is that a CO2 concentration of 5% increases the biofilm-forming 
ability of C. albicans. It has been well established that 5% CO2 is a morphogenic signal for C. 
albicans, driving the yeast-to-hyphal switch via the Ras1-Cyr1-PKA pathway [69][77]. Despite 
this switch being known to be central to C. albicans biofilm formation, the effects of 5% CO2 
on C. albicans biofilm formation hitherto had not been explored. We demonstrate that all 
aspects of C. albicans biofilm growth – adhesion, maturation and dispersal – are enhanced in 
5% CO2. This CO2-mediated increase in biofilm growth is specific to the biofilm scenario as 
planktonic C. albicans cells exhibited no significant growth rate difference in RPMI-1640 
between 0.03% and 5% CO2 environments (Figure 4.1). Transcriptome analysis revealed that 
several pathways governed by key regulators of C. albicans biofilm growth (Efg1, Brg1, Bcr1, 
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and Ndt80) were upregulated in biofilms grown in 5% CO2. This provides an explanation for 
C. albicans success in colonising VPs, as observed in this study and others [195][201][204], 
since the CO2 content of exhaled breath which the VP is consistently exposed to when in situ 
is approximately 5%. In mammals, physiological concentrations of CO2 are up to 150x higher 
than atmospheric air [222][268], thus this data could have wider implications with regards to 
colonisation of other medical prosthetic devices, several of which are commonly colonised 















In addition to C. albicans, we also frequently isolated several non-albicans Candida species, 
including C. dubliniensis, C. glabrata, C. parapsilosis and C. krusei, from failed VPs. This is 
consistent with other studies [195][201][204]. However, these other Candida species, do not 
Figure 4.1: Planktonic growth of C. albicans CAI-4 in RPMI-1640 in 0.03% and 5% CO2. Overnight 
cultures were inoculated to OD600 0.1 in RPMI-1640 in 24-well plates. They were grown for 48 hours 
with 400rpm double orbital shaking in a BMG LABTECH SPECTROstarNano plate reader for 0.03% CO2 
conditions and a BMG LABTECH CLARIOstar plate reader for 5% CO2 conditions. Growth was 
measured by OD600 readings taken every 10 mins. Graph represents three biological replicates each 
containing technical triplicate. A paired two-tail t test was carried out; n.s. = not significant.   
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undergo a yeast-to-hyphae transition in response to elevated CO2 levels [78]. In fact, other 
than C. dubliniensis, they do not form true hyphae at all and have been shown to form biofilms 
composed solely of yeast cells in vitro [237] and in vivo [306]. Therefore, elevated CO2 is 
unlikely to directly explain their prevalence on VPs, though we cannot rule out that the 
adenylate cyclase of these latter species is activated by CO2/bicarbonate ions. We did not 
observe an increase in the biofilm-forming ability of C. parapsilosis in 5% CO2, although this 
may simply be due to the fact that the C. parapsilosis isolate we used generally did not form 
biofilms well in our in vitro model. One hypothesis is that the effect CO2 has on species such 
as C. albicans can aid colonisation by other species – C. glabrata and the bacteria S. aureus 
have both been observed to attach to C. albicans hyphal cells in biofilms [247][300][309]. As 
discussed in Section 4.1, further investigations into interactions between species on medical 
devices are necessary and it would be interesting to determine if CO2 has any effect on these.   
 
4.2.1 The effect of high CO2 on C. albicans biofilm growth relies on the adenylate kinase 
Cyr1  
The Ras1-Cyr1-PKA pathway is crucial for the transduction of environmental cues from the 
exterior to the interior of the cell and integrates these signals with morphogenesis [6]. As 
discussed in Paper 2, CO2 is able to directly activate the adenylate cyclase Cyr1 (Cdc35) and 
this Cyr1 activation is responsible for the CO2-driven yeast-to-hyphal switch [69]. A cdc35Δ/Δ 
null mutant is defective in hyphal formation [69], consistently we found this mutant was 
unable to make biofilms in either 0.03% or 5% CO2. The ras1Δ/Δ null mutant is also hyphal 
deficient [66] and was unable to form biofilms in 0.03% CO2 but formed equivalent biofilms 
to the wild type in 5% CO2. Overall, our data suggests the response of C. albicans biofilms to 
physiological (5%) levels of CO2 is dependent on Cyr1 but can bypass a requirement for Ras1. 
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Our transcriptome analysis revealed the RAS1, CYR1 (CDC35), and TPK2 (encodes a catalytic 
subunit isoform of PKA) genes are significantly downregulated after 48 hours within 5% CO2 
biofilms in comparison to 0.03% CO2. This could be explained by the fact the Ras1-Cyr1-PKA 
pathway can be considered most important for the earlier stages of biofilm formation when 
hyphal cells begin to form; indeed the Efg1 transcription factor, a key effector downstream of 
the pathway, principally functions in the initiation stage of biofilm growth [129]. We propose 
that C. albicans biofilms mature quicker in high CO2 compared to low CO2. Thus, as the 5% 
CO2 biofilms have reached full maturity faster, the Ras1-Cyr1-PKA signalling pathway may be 
more active in the 0.03% CO2 biofilms after 48h growth as they are still maturing or have 
matured more recently. The enrichment of hyphal related genes in the significantly 
downregulated genes in 5% CO2 biofilms as revealed by GSEA is consistent with this. 
Moreover, upon progression to dispersion, the final stage of biofilm formation, several 
hyphal-specific genes downstream of Ras1-Cyr1-PKA pathway signalling are actively 
suppressed by transcriptional repressors such as Nrg1 [102]. Nrg1 is a positive regulator of 
biofilm dispersion and the NRG1 gene was upregulated in 5% CO2 biofilms, providing one 
explanation of hyphal gene repression and adding further evidence to the increased C. 
albicans biofilm maturation rate in 5% CO2.          
 
Finally, unlike other components of the Ras1-Cyr1-PKA pathway, TPK1 is significantly 
upregulated (1.04 log2 fold change) in 5% CO2 biofilms. The Tpk1 and Tpk2 isoforms have 
some redundant functions in C. albicans, demonstrated by no difference in biofilm formation 
compared to wild type of either the tpk1Δ/Δ or the tpk2Δ/Δ mutant (this study). However, 
they have also been shown to have specific roles, for example, recent transcriptomic and 
phosphoproteomic analyses using tpk1Δ/Δ, tpk2Δ/Δ and tpk1Δ/Δtpk2Δ/Δ mutants predicted 
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31 phosphorylation target sites specifically mediated by Tpk1 and 27 by Tpk2. Cell wall, 
membrane and signalling-related proteins were enriched in the Tpk1-specific targets, 
whereas filamentation and transporter-related proteins were enriched in the Tpk2-specific 
targets [75]. Given the apparent roles of Tpk2 in filamentation and transport, two very 
important processes for biofilm formation, it is quite surprising that TPK1 expression is up and 
TPK2 down in 5% CO2 biofilms. However, the downregulation of TPK2 is consistent with the 
enrichment of hyphal related genes in the significantly downregulated genes in 5% CO2 
biofilms which we propose is due to the faster maturation rate of high CO2 biofilms. We 
should also highlight that the surface upon which a C. albicans biofilm is forming appears to 
exert a major influence on which signalling pathways are utilised. Indeed, a tpk2Δ/Δ mutant 
has exhibited attenuated adhesion and biofilm formation on a polystyrene surface [74], 
whereas on a silicone surface we observed tpk2Δ/Δ biofilm formation equivalent to an 
isogenic wild-type. This has previously been observed in C. albicans gene expression profiles 
using different biofilm models [294].      
 
4.2.2 CO2 and iron homeostasis in C. albicans biofilms 
Our TFKO library biofilm formation screen identified iron homeostatic transcription factors 
including Sef1, and the HAP complex components Hap2, Hap3, Hap5, and Hap43. All four of 
the hap mutants – hap2Δ/Δ, hap3Δ/Δ, hap5Δ/Δ, and hap43Δ/Δ – exhibited a biofilm growth 
defect in 0.03% CO2 but intriguingly had significantly higher biofilm growth in 5% CO2. 
However, the sef1Δ/Δ mutant had defective biofilm growth in both CO2 conditions. Since Sef1 
functions downstream of the HAP complex, we hypothesise that a high CO2 environment may 
influence Sef1 directly, causing the HAP complex to become at least partially redundant under 
these conditions.  
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It should be noted that we did not observe a significant effect on SEF1 mRNA levels within 5% 
CO2 biofilms after 48h. Thus, if it is influencing Sef1 activity, CO2 must be acting at either the 
protein level or post-translational level as Sef1 is subject to a post-translational control loop 
consisting of Sfu1 and the cyclin-dependent kinase Ssn3 [58]. We do not believe the CO2 effect 
on iron homeostasis is mediated through Ssn3 as this protein has been recently found to be 
dephosphorylated and thus inactive in 5% CO2 [292]. Therefore, our current hypothesised 
model suggests that PKA, in a Tpk1/Tpk2 redundant manner can phosphorylate Sef1 and 
possibly also inhibit Sfu1. Our model is supported by the Tpk1/Tpk2 phosphoproteomic study 
discussed previously as it predicted Sef1 to be a potential PKA target that can be 
phosphorylated by both Tpk1 and Tpk2 [75].  
 
The influence of CO2 on the iron status of C. albicans cells could have wider implications 
regarding host infections and nutritional immunity. The transition from a commensal to a 
pathogenic lifestyle, especially in regards to entry into the bloodstream, is associated with 
rapid cellular reprogramming to adapt to the new environment [56]. A critical challenge C. 
albicans must overcome during infection is the maintenance of adequate iron levels, 
demonstrated by the high induction of several iron homeostatic genes in animal-infection 
models [311]. Most iron within the host is sequestered from potential pathogens either in the 
form of haemoglobin, bound to transferrin in the blood or bound to ferritin in tissues [44]. 
This provides a ‘nutritional immunity’ to combat infection with iron-dependent pathogens 
[38][312].  
 
We observed C. albicans biofilms in high CO2 overcoming the effects of iron 
starvation/sequestration in vitro. While in situ in the throat, VPs are coated in saliva which 
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contains the iron-chelating protein lactoferrin. Through its iron-sequestration properties, as 
well as other more direct antimicrobial actions, lactoferrin forms an important part of innate 
immune defence [313]. Consequently, it’s possible that the CO2 content of exhaled breath 
that VPs are exposed to could provide a competitive advantage to C. albicans in coping with 
lactoferrin-mediated iron-sequestration. Furthermore, the blood contains relatively high 
levels of CO2 [222], and thus it is possible that high CO2 is one (of many) signals C. albicans 
uses to increase iron acquisition in this environment. Consistent with this, our transcriptome 
analysis revealed mRNA transcript levels of CSA2 and RBT5 which encode proteins involved in 
the acquisition of iron from haem groups [41][314] were significantly increased in biofilms 
grown in 5% CO2. Rbt5 in particular appears to be important in the acquisition of iron during 
host blood infection as RBT5 is one of the most highly induced genes in murine and Galleria 
mellonella infection models [311], and anti-Rbt5 antibodies are prominent in the serum of 
patients following candidaemia [315]. 
 
In conclusion, our data and others’ indicate physiological (5%) levels of CO2 can act as an 
important pathogenic signal for C. albicans. CO2 drives many virulence factors such as yeast-
to-hyphal morphogenesis [69], biofilm growth (this study), and iron acquisition (this study). 
These CO2-mediated effects are likely to have important medical ramifications, primarily in 
the context of prosthetics as demonstrated with voice prosthetics, but also for host infections 







4.3 Potential Therapeutic Options to Combat Candida albicans Biofilms 
In light of the characterised CO2 effect on C. albicans biofilm formation, we investigated some 
potential therapeutic options for biofilms grown in high CO2 environments which could be 
useful for VP management in the future.  
 
We have demonstrated that 2-deoxyglucose (2-DG) is able to attenuate C. albicans biofilm 
growth in both 5% and atmospheric (0.03%) CO2 environments. A 2-DG concentration of 1% 
reduced biofilm growth of the SN152 wild-type strain by 46% and 38% in 5% and 0.03% CO2 
respectively. 2-DG is actively taken up by hexose transporters on eukaryotic cell surfaces and 
our transcriptome analysis showed genes encoded several of these were upregulated in 5% 
CO2 biofilms. Upon its phosphorylation, the resulting 2-DG-6-phosphate is a glycolytic 
inhibitor, inhibiting phosphoglucose isomerase and hexokinase in a competitive and non-
competitive manner respectively [316][317]. Although more recent studies using S. cerevisiae 
have proposed that a glycolytic block does not sufficiently explain its growth inhibition effects, 
concluding the interplay between glycolysis and the pentose phosphate pathway is important 
as the separation of these pathways through genetic deletions results in increased 2-DG 
resistance [318]. 2-DG has been widely studied as a potential anti-cancer drug to combat 
Warburg metabolism; it has previously reached Stage II clinical trials as an anti-prostate 
cancer drug but was ultimately deemed unsuccessful [291]. The potential of repurposing 2-
DG as a biofilm-treating antifungal agent for pathogenic yeasts has not previously been 
explored. 2-DG has exhibited antifungal effects against the moulds Botrytis cinerea, 
Penicillium expansum, and Rhizopus stolonifer [296]. It has also been observed to inhibit 
biofilm growth of Escherichia coli [297]. This, together with its action against C. albicans 
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biofilms presented in our study, could mean it is particularly useful against VP-associated 
biofilms which as we have demonstrated are often a mixture of bacterial and fungal species.   
    
2-DG is considered safe for use in humans at low doses and besides we would envisage it to 
be applied directly to the VP surface in a similar way to the antifungals in our newly 
implemented treatment guidelines so host cell exposure would be minimal. It is important to 
note that 2-DG treatment was unable to eradicate C. albicans biofilm formation entirely, 
although it is encouraging that it is equally effective against both high and low CO2 biofilms. 
Combination therapy using traditional antifungals and other compounds has previously been 
demonstrated to be effective against C. albicans biofilms [178][180][181]. It may be that 2-
DG treatment is beneficial in combination with other compounds, such as iron chelators (see 
below) or traditional antifungals; this possibility is yet to be explored.    
 
We also explored the possibility of using the Fe3+ chelator Deferasirox, which is an approved 
drug for treating patients with iron overload, as a therapeutic to combat C. albicans biofilms 
on silicone surfaces. It was recently revealed that treatment with Deferasirox significantly 
reduced salivary iron levels in a murine oropharyngeal model and resulted in a reduction in 
oral fungal burden [290]. Moreover, Deferasirox treated C. albicans cells had reduced survival 
in phagosomes after phagocytosis by human neutrophils, as well as decreased adhesion and 
invasion of oral epithelial cells in vitro [290]. In our study, Deferasirox completely prevented 
C. albicans biofilm formation in atmospheric CO2 conditions but had very little effect in 5% 
CO2. This demonstrates that Deferasirox has potential as a fungal biofilm therapeutic, 
however, not in high CO2 environments and consequently is probably not useful for the 
management/treatment of VP-associated biofilms. This data also highlights that the 
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environment where a C. albicans biofilm is found can have crucial implications regarding 
which treatments will be most effective, and hence should influence the choice of treatment.    
 
Within our study, we have focussed on the potential for repurposing currently available 
compounds which are approved for human use. We believe that this is an important avenue 
to explore as already approved compounds will be able to be implemented in treatments 
significantly quicker than completely new antifungal compounds (although these of course 
need to be discovered too). We have also highlighted the importance of external factors such 
as CO2 environment when testing potential antifungals; adding additional complexity such as 
this to in vitro tests will hopefully give a more representative account of the efficacy in vivo. 
 
4.4 Candida albicans Biofilm Formation on Other Medical-Implant Devices 
The findings we have detailed within this study could be more generally applicable to the 
colonisation of several implanted medical devices. In addition to VPs, C. albicans is a common 
coloniser of many medical devices including central venous catheters, dentures, 
tracheostomy tubes, and urinary catheters [4]. We hope that the findings detailed in our study 
can be applicable to other scenarios of C. albicans colonisation. Catheters such as central 
venous catheters are typically made of silicone and so these represent the most likely 
candidates for similar C. albicans interactions. Moreover, the CO2 content of venous blood is 
relatively high [222], meaning some of the CO2-mediated effects may also be relevant here. 
A study investigating denture stomatitis and the associated fungal colonisation found that C. 
albicans and C. glabrata were the two most frequently isolated yeasts [307]. Likewise, C. 
albicans and C. glabrata were also the two most common fungal VP colonisers isolated in this 
study. This overlap is expected due to the similar locations of the devices within the body and 
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hence dentures and VPs are exposed to the same oral cavity microflora. However, it is 
possible that although they are not made of silicone, denture colonisation could be influenced 
by the CO2 content of exhaled breath in a similar way to what we are proposing for VPs.         
 
4.5 Future Investigations  
The results presented here confirm C. albicans as the most prevalent coloniser of VPs, often 
in a polymicrobial biofilm. A drawback of the microbiology data we and others present is that 
it is qualitative rather than quantitative as it relies on pre-culturing before species 
identification. While these data give a very good overview of the microbial landscape on early 
failing VPs, we should follow up these studies with assessments of the microorganisms 
directly from the VP surface. These future studies could utilise new sequencing technologies, 
such as NanoPore DNA sequencing, for microbial identification [319]. This would give a 
quantitative readout of the relative abundance of different microorganisms, as well as 
allowing the identification of species which cannot be cultured under laboratory conditions 
and so are often overlooked with traditional identification methodology.   
 
In addition, further polymicrobial investigations should be carried out to investigate 
interactions between species in mixed biofilms as well as the order of colonisation of these 
species on voice prosthetic surfaces. Due to the success of our antifungal treatment guidelines 
we hypothesised that Candida species, particularly C. albicans, are likely to be early colonisers 
which enable colonisation with other species. However, we did not directly test this and so it 
would be interesting to determine if this is indeed true. The influence of patient diet on 
colonisation would also be useful to examine as this would enable clinicians to give evidence-
based patient advice to hopefully aid in VP lifespan management. Preliminary experiments 
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exploring the effect of alcohol and glucose levels have been carried out within our laboratory 
but further investigations are needed.   
  
We have shown that 5% CO2 can drive the biofilm growth phenotype in C. albicans and 
increase its tolerance to iron starvation. We have proposed a model whereby PKA in the Ras1-
Cyr1-PKA pathway (known to be activated by 5% CO2 [69][77]) may possibly phosphorylate 
and activate the iron-uptake regulator Sef1. This can then increase the expression of iron-
uptake genes to circumvent iron starvation, as well as causing a redundancy of the HAP 
complex. We are currently investigating the phosphorylation of Sef1 in 5% CO2 through the 
use of Phos-tag SDS-PAGE gels which can detect the phosphorylation state of proteins [320]. 
Finally, we identified 2-DG as a potential therapeutic for C. albicans biofilms in high CO2 
environments. Further investigations into its use as a viable antifungal are warranted, along 
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Appendix 1 – Quality control analysis of RNA-Seq reads 
Total RNA was extracted in biological triplicate from C. albicans CAI-4 biofilms grown for 48h 
in both 0.03% and 5% CO2 using the E.Z.N.A.TM Yeast RNA Kit as per the manufacturer’s 
instructions with a few modifications as detailed in the Paper 2 Materials and Methods. After 
extraction, RNA purity was estimated using a NanoDrop ND-1000 spectrophotometer and 
sent to the Centre for Genome Enabled Biology and Medicine (Aberdeen, UK) for library 
preparation and sequencing. Sequencing was performed on the Illumina NextSeq500 
platform, producing 75bp single-end reads. 
 
The quality of the RNA sequencing reads was checked using FastQC [271] on the Galaxy web 
platform [270]. FastQC provides visual readouts of the quality of raw sequencing data; giving 
information on basic statistics (average sequence length, number of sequences and number 
of poor quality sequences), Phred score (the probability of a base being wrong), and adaptor 
content (the amount of adaptor contamination in the reads), among others. The information 
obtained from FastQC was used to determine if any trimming of the sequencing reads was 
required before further analysis. For all samples, low quality ends (Phred score < 20) and any 
adaptor sequences were trimmed using TrimGalore!. After trimming, 97.7% of initial reads 
remained and FastQC was run again to confirm the quality. Below are the FastQC outputs 








The basic statistics reveal an average sequencing depth of 58M reads across the 3 replicates 
in each condition. They also conclude that there were no sequences flagged as poor quality 
in any of the samples after trimming. The sequence length of the reads after trimming was 









The Phred score is a measure of the probability that a base within a sequencing read has been 
called wrong, thereby giving an estimation of the quality of the sequencing reaction and 
hence resulting reads. It is a logarithmic scale from 1-40, the higher the number the lower the 
probability of the base being wrong. A base with a Phred score of 30 indicates a 1 in 1000 
probability of that base being identified incorrectly during the Illumina sequencing reaction. 
This corresponds to an accuracy of 99.9% and thus reads with Phred scores above 30 are 
generally considered good quality for next-generation sequencing (NGS) applications such as 
RNA-Seq [321]. For all 6 samples, the Phred scores were very high throughout the whole 
length of all the reads (Appendix Figure 1.1B). There is a natural reduction in Phred score 
Appendix Table 1.1: Basic statistics output from FastQC analysis of the RNA sequencing reads 
from the 0.03% CO2 biofilm replicate 1 sample. This table is representative of all the samples. 
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across the length of the read as an artefact of the sequencing reaction and this cannot be 
avoided. Despite this, even the last few bases in each read still had Phred scores above 30 





























Appendix Figure 1.1: Phred score visualisations giving the average Phred score for each base across 
the length of the sequencing reads. (A) Average Phred scores for bases within reads in the 0.03% CO2 
biofilm replicate 1 sample. (B) Average Phred scores for bases within reads for all 6 samples. Note: 

















The N content gives an indication of the number of ambiguous reads present in a sample, i.e. 
the number of reads which contain at least one base which was unable to be called and hence 

















The adaptor content gives a quantification of any contamination of reads with adaptor 
sequences originating from the library preparation. Adaptor contamination can lead to 
alignment errors when aligning to a reference genome since the adaptor sequences will not 
appear in the genome. Thus, it is important to trim reads to remove any adaptor sequences 
Appendix Figure 1.2: N content across all bases within the reads of the 0.03% CO2 biofilm replicate 
1 sample. Graph was identical to that above for all samples.  
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which could influence steps downstream. After trimming, there were no adaptor sequences 















Principal Component Analysis 
Principal component analysis (PCA) is a useful method for visualising large data sets to 
determine how similar biological replicates of a sample are to each other, and how different 
they are to samples from other conditions. PCA was carried out within the DESeq2 package 
[276] as part of the differential gene expression analysis. The PCA reduces the dimensionality 
of the data by identifying directions (principal components) along which most variation 
occurs, simplifying very large data sets while retaining as much information as possible [322]. 
This allows for easier comparisons. The first principal component, PC1, is the direction along 
Appendix Figure 1.3: Adaptor content across bases within the reads of the 0.03% CO2 biofilm 
replicate 1 sample. Graph was identical to that above for all samples.  
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which most of the variation occurs. The second principal component, PC2, covers as much as 
possible of the remaining variation.  
 
Samples are displayed on a graph based on the two principal components (Figure 4); 
clustering indicates similarity, thus, the closer two points are together, the greater the 
similarity between those two samples. The biological replicates of the two conditions cluster 
well along the PC1 axis. The biological replicates of the 5% CO2 biofilms also cluster well along 
the PC2 axis, whereas the 0.03% CO2 Biofilm 2 and 0.03% CO2 Biofilm 3 samples cluster along 
the PC2 axis but the 0.03% CO2 Biofilm 1 sample does not (Appendix Figure 1.4). The reasons 
for this lack of clustering are unclear. However, we decided to retain the 0.03% CO2 biofilm 1 
sample in subsequent differential gene expression analysis because it still clusters with the 
other 0.03% CO2 replicates along the PC1 axis which is the direction where most variation 
occurs. Thus, the 0.03% CO2 biofilm 1 sample is still closer to the other 0.03% CO2 replicates 









Appendix Figure 1.4: Principal component analysis of 0.03% CO2 and 5% CO2 RNA-Seq samples. Principal 




Appendix 2 – Ranked GSEA gene set lists  
Below are lists of genes which are significantly differentially expressed, false-discovery-rate 
(q) values ≤ 0.05, in C. albicans biofilms grown in 5% CO2 compared to those grown in 0.03% 
CO2 (atmospheric air). The genes are organised into the gene sets in which they appear 
within the gene set database used for Gene Set Enrichment Analysis.  
 
Gene sets with genes enriched in the upregulated group of differentially expressed genes 
These gene sets are for pathways which the GSEA concluded are significantly upregulated 
within 5% CO2 biofilms. The rank in gene list refers to the position of the gene in the overall 
list of significantly differentially expressed genes in this study ranked with regards to log2 fold 
change. The running enrichment score is a running tally as a quantitative measure of how 
much each gene contributes to the overall gene set/pathway being upregulated as measured 
via GSEA. Genes which cause the running enrichment score to increase, known as the leading 
edge subset (green – prior to the highest score), are those which have the greatest 









1 orf19.5741 ALS1 3.7669 0.0145 
4 orf19.4934 OP4 3.3214 0.0268 
5 orf19.4211 FET31 3.1690 0.0393 
7 orf19.5267 C1_11990W_A 3.1051 0.0512 
8 orf19.4438 RME1 3.0969 0.0634 
9 orf19.3643 C6_00810C_A 3.0665 0.0755 
13 orf19.849 MNN41 2.9716 0.0861 
21 orf19.5728 C6_03600C_A 2.6549 0.0939 
22 orf19.6715 C3_07720C_A 2.6148 0.1042 
23 orf19.1286 C5_04040C_A 2.6036 0.1145 
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25 orf19.5604 MDR1 2.5564 0.1242 
26 orf19.851 MNN42 2.5559 0.1343 
30 orf19.4933 FAD3 2.4966 0.1430 
37 orf19.6713 WOR4 2.4007 0.1502 
39 orf19.2023 HGT7 2.3851 0.1592 
40 orf19.7218 RBE1 2.3719 0.1686 
41 orf19.97 CAN1 2.3381 0.1778 
46 orf19.1932 CFL4 2.2907 0.1853 
49 orf19.7094 HGT12 2.2631 0.1935 
50 orf19.2332 C1_10850W_A 2.2465 0.2024 
54 orf19.54 RHD1 2.2299 0.2100 
55 orf19.2725 C4_02730C_A 2.2163 0.2188 
59 orf19.6547 C7_01770W_A 2.1587 0.2262 
60 orf19.4884 WOR1 2.1534 0.2347 
62 orf19.2738 SUL2 2.1449 0.2427 
65 orf19.5933 C3_04730C_A 2.1167 0.2503 
69 orf19.218 BUD20 2.1019 0.2575 
81 orf19.454 SFL1 1.9628 0.2611 
83 orf19.3674 GAL102 1.9457 0.2684 
85 orf19.6276 C1_06350W_A 1.9402 0.2757 
86 orf19.6983 C3_05450C_A 1.9390 0.2833 
92 orf19.4231 PTH2 1.8930 0.2889 
93 orf19.2356 CRZ2 1.8902 0.2964 
99 orf19.4555 ALS4 1.8730 0.3019 
102 orf19.935 AGA1 1.8553 0.3084 
103 orf19.5625 C6_03360C_A 1.8474 0.3157 
104 orf19.258 C3_02660W_A 1.8340 0.3229 
116 orf19.7150 NRG1 1.7552 0.3257 
118 orf19.3668 HGT2 1.7445 0.3322 
122 orf19.1743 ACS1 1.7279 0.3379 
127 orf19.5908 TEC1 1.6893 0.3431 
136 orf19.3182 GIS2 1.6607 0.3466 
142 orf19.7054 C7_00650W_A 1.6351 0.3512 
145 orf19.5302 PGA31 1.6212 0.3568 
148 orf19.6488 C7_02250W_A 1.6081 0.3624 
157 orf19.5307 JEN2 1.5563 0.3655 
164 orf19.5070 C1_07990C_A 1.5436 0.3693 
167 orf19.1224 FRP3 1.5343 0.3746 
176 orf19.3368 C4_03420C_A 1.4951 0.3775 
209 orf19.3675 GAL7 1.3944 0.3710 
210 orf19.6736 C3_07550C_A 1.3852 0.3764 
225 orf19.450 C1_05150C_A 1.3508 0.3765 
229 orf19.5032 SIM1 1.3375 0.3806 
231 orf19.7436 AAF1 1.3322 0.3855 
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240 orf19.1189 C6_00290W_A 1.3141 0.3877 
241 orf19.5475 C3_00020W_A 1.3109 0.3928 
246 orf19.3795 AGP3 1.2958 0.3965 
258 orf19.7151 C7_04220W_A 1.2797 0.3974 
271 orf19.3672 GAL10 1.2536 0.3978 
279 orf19.723 BCR1 1.2419 0.4000 
283 orf19.2781 C1_07640C_A 1.2380 0.4038 
290 orf19.871 C2_03500W_A 1.2183 0.4063 
301 orf19.4784 CRP1 1.1956 0.4073 
306 orf19.6054 C1_00540C_A 1.1753 0.4104 
315 orf19.2024 C2_00990W_A 1.1524 0.4119 
317 orf19.918 CDR11 1.1521 0.4161 
355 orf19.740 HAP41 1.0953 0.4065 
363 orf19.5474 C3_00010C_A 1.0793 0.4081 
373 orf19.6514 CUP9 1.0667 0.4089 
375 orf19.7095 C7_00270W_A 1.0640 0.4128 
389 orf19.3867 RPL7 1.0450 0.4120 
405 orf19.5232 CSI2 1.0221 0.4104 
408 orf19.1416 COX11 1.0184 0.4136 
415 orf19.3195 HIP1 1.0059 0.4153 
416 orf19.3670 GAL1 1.0030 0.4193 
438 orf19.449 C1_05160C_A 0.9844 0.4153 
462 orf19.6937 PTR22 0.9548 0.4104 
468 orf19.674 C1_11280W_A 0.9483 0.4122 
471 orf19.6486 LDG3 0.9477 0.4152 
472 orf19.1971 TRY3 0.9474 0.4189 
480 orf19.4942 C1_13150W_A 0.9421 0.4200 
484 orf19.4783 C1_09240C_A 0.9391 0.4226 
517 orf19.4459 C1_03870C_A 0.9121 0.4141 
519 orf19.1736 CR_04680C_A 0.9104 0.4174 
529 orf19.4056 BRG1 0.9001 0.4175 
531 orf19.3618 YWP1 0.8988 0.4207 
534 orf19.3969 SFL2 0.8950 0.4235 
565 orf19.7374 CTA4 0.8713 0.4156 
569 orf19.2893 C4_06410W_A 0.8674 0.4179 
571 orf19.1662 C3_01850W_A 0.8659 0.4209 
605 orf19.1314 C4_03600C_A 0.8390 0.4118 
606 orf19.5992 WOR2 0.8387 0.4151 
608 orf19.938 C5_00510W_A 0.8386 0.4180 
630 orf19.7592 FAA4 0.8113 0.4133 
639 orf19.2752 ADR1 0.8048 0.4135 
651 orf19.7539 INO2 0.8011 0.4125 
652 orf19.3967 PFK1 0.8007 0.4157 
658 orf19.6548 ISU1 0.7951 0.4169 
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666 orf19.3895 CHT2 0.7864 0.4174 
670 orf19.4210 C6_00490W_A 0.7844 0.4193 
672 orf19.1957 CYC3 0.7839 0.4221 
675 orf19.6487 C7_02260W_A 0.7824 0.4244 
686 orf19.5284 CR_05420W_A 0.7745 0.4237 
691 orf19.2639 C5_03410C_A 0.7654 0.4252 
714 orf19.7306 CR_09100C_A 0.7531 0.4199 
724 orf19.3193 FCR3 0.7434 0.4194 
734 orf19.2892 C4_06420W_A 0.7377 0.4189 
742 orf19.1735 CR_04710W_A 0.7319 0.4192 
743 orf19.6781 ZFU2 0.7310 0.4221 
760 orf19.1742 HEM3 0.7235 0.4189 
768 orf19.1842 BUD5 0.7208 0.4191 
782 orf19.1718 ZCF8 0.7132 0.4170 
793 orf19.413.1 RPS27A 0.7090 0.4161 
828 orf19.4528 C1_01950C_A 0.6879 0.4060 
835 orf19.7521 REP1 0.6844 0.4064 
844 orf19.5906 ADE2 0.6799 0.4061 
846 orf19.6984 C3_05460W_A 0.6787 0.4084 
863 orf19.4167 C4_00750C_A 0.6698 0.4050 
895 orf19.3707 YHB1 0.6507 0.3959 
897 orf19.6599.1 CR_09640C_A 0.6501 0.3981 
912 orf19.5555 C6_02810C_A 0.6423 0.3953 
940 orf19.5312 MET4 0.6309 0.3876 
944 orf19.413 C1_05520W_A 0.6293 0.3890 
948 orf19.610 EFG1 0.6283 0.3903 
971 orf19.5626 C6_03370W_A 0.6154 0.3845 
981 orf19.118 FAD2 0.6115 0.3835 
1000 orf19.7027 C7_00880C_A 0.6017 0.3791 
1013 orf19.4166 ZCF21 0.5938 0.3769 
1017 orf19.3291 HMT1 0.5926 0.3781 
1024 orf19.868 ADAEC 0.5876 0.3782 
1026 orf19.1604 C2_09460C_A 0.5873 0.3801 
1040 orf19.721 CR_06450W_A 0.5806 0.3775 
1056 orf19.2825 DRE2 0.5683 0.3741 
1071 orf19.7539.1 CR_00040C_A 0.5628 0.3711 
1078 orf19.3369 MOH1 0.5601 0.3710 
1081 orf19.6734 TCC1 0.5593 0.3725 
1084 orf19.2751 C4_02510W_A 0.5586 0.3739 
1089 orf19.96 TOP1 0.5545 0.3746 
1124 orf19.7501 NAP1 0.5387 0.3639 
1129 orf19.568 SPE2 0.5347 0.3645 
1134 orf19.5994 RHB1 0.5315 0.3651 
1168 orf19.5754 C6_03800C_A 0.5173 0.3547 
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1211 orf19.1047 ERB1 0.4868 0.3408 
1216 orf19.2309 PET127 0.4852 0.3412 
1221 orf19.6817 FCR1 0.4841 0.3416 
1233 orf19.3706 CR_07780W_A 0.4753 0.3393 
1271 orf19.7502 CR_00310C_A 0.4529 0.3272 
1399 orf19.1285 C5_04050W_A 0.3691 0.2808 
1496 orf19.1601 RPL3 -0.3736 0.2461 
1567 orf19.6091 RIM8 -0.4230 0.2214 
1581 orf19.1605 PMS1 -0.4303 0.2182 
1585 orf19.1095 GLE2 -0.4323 0.2188 
1600 orf19.2961 C1_02720W_A -0.4415 0.2153 
1618 orf19.1313 CDR3 -0.4519 0.2107 
1648 orf19.5031 SSK1 -0.4651 0.2016 
1658 orf19.3282 BMT3 -0.4723 0.2000 
1666 orf19.2930 C1_02430C_A -0.4773 0.1993 
1675 orf19.1933 C5_01350W_A -0.4847 0.1982 
1716 orf19.3042 C1_03410W_A -0.5056 0.1851 
1724 orf19.1961 C5_01090C_A -0.5101 0.1845 
1727 orf19.4432 KSP1 -0.5124 0.1858 
1757 orf19.7149 C7_04240C_A -0.5236 0.1769 
1766 orf19.2737 C4_02620C_A -0.5281 0.1760 
1795 orf19.7380 C3_05990C_A -0.5410 0.1676 
1817 orf19.1317 OSH3 -0.5537 0.1618 
1820 orf19.3433 OYE23 -0.5552 0.1633 
1829 orf19.3794 CSR1 -0.5640 0.1625 
1842 orf19.2506 C3_01020W_A -0.5699 0.1602 
1846 orf19.342 BMT7 -0.5716 0.1613 
1864 orf19.5763 C6_03880W_A -0.5813 0.1572 
1881 orf19.6118 CR_07470W_A -0.5904 0.1535 
1893 orf19.5953 SFP1 -0.5949 0.1517 
1911 orf19.5384 CHS8 -0.6038 0.1477 
1919 orf19.332.1 C3_03340C_A -0.6062 0.1475 
1924 orf19.6798 SSN6 -0.6080 0.1483 
1934 orf19.4433 CPH1 -0.6125 0.1474 
1965 orf19.7053 GAC1 -0.6218 0.1385 
1973 orf19.6117 CR_07480W_A -0.6246 0.1384 
2011 orf19.7056 C7_00630C_A -0.6409 0.1269 
2024 orf19.5595 SHE3 -0.6492 0.1250 
2036 orf19.405 VCX1 -0.6548 0.1234 
2039 orf19.4456 GAP4 -0.6561 0.1253 
2072 orf19.3010.1 ECM33 -0.6787 0.1159 
2098 orf19.3999 C5_05070W_A -0.6929 0.1092 
2134 orf19.2724 C4_02740W_A -0.7093 0.0988 
2148 orf19.1223 DBF2 -0.7173 0.0967 
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2152 orf19.6512 EXO70 -0.7208 0.0985 
2157 orf19.2638 C5_03430W_A -0.7253 0.0998 
2192 orf19.7337 CR_09410W_A -0.7441 0.0899 
2195 orf19.333 FCY2 -0.7456 0.0921 
2247 orf19.4900 MNN12 -0.7687 0.0760 
2257 orf19.4346 C5_03140C_A -0.7731 0.0756 
2296 orf19.4341 C5_03120W_A -0.8019 0.0645 
2300 orf19.4899 GCA1 -0.8036 0.0665 
2317 orf19.691 GPD2 -0.8155 0.0637 
2321 orf19.6757 GCY1 -0.8170 0.0658 
2350 orf19.5268 MED10 -0.8366 0.0585 
2369 orf19.6800 POS5 -0.8546 0.0551 
2401 orf19.3180 C5_01920C_A -0.8766 0.0469 
2410 orf19.4245 C5_02370C_A -0.8863 0.0474 
2469 orf19.2184 C2_07980W_A -0.9428 0.0293 
2489 orf19.4943 PSA2 -0.9615 0.0259 
2492 orf19.1075 C6_04190C_A -0.9633 0.0289 
2511 orf19.1048 IFD6 -0.9756 0.0260 
2528 orf19.7563 BET2 -0.9932 0.0239 
2598 orf19.675 C1_11270W_A -1.0678 0.0021 
2641 orf19.467 WOR3 -1.1183 -0.0093 
2658 orf19.3767 PEP1 -1.1432 -0.0108 
2694 orf19.4867 SWE1 -1.2140 -0.0192 
2701 orf19.5716 SAP4 -1.2287 -0.0166 
2734 orf19.3283 CR_00710C_A -1.3219 -0.0234 
2736 orf19.6816 C3_06860C_A -1.3248 -0.0186 
2766 orf19.7078 C7_00420C_A -1.3949 -0.0240 
2784 orf19.6277 C1_06340W_A -1.4729 -0.0246 
2804 orf19.5285 PST3 -1.5662 -0.0256 
2818 orf19.6420 PGA13 -1.6448 -0.0240 
2843 orf19.535 RBR1 -1.8774 -0.0256 
2861 orf19.7077 C7_00430W_A -2.3018 -0.0230 
2869 orf19.5674 PGA10 -2.5161 -0.0157 










1 orf19.5741 ALS1 3.7669 0.0116 
4 orf19.4934 OP4 3.3214 0.0214 
5 orf19.4211 FET31 3.1690 0.0314 
7 orf19.5267 C1_11990W_A 3.1051 0.0409 
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8 orf19.4438 RME1 3.0969 0.0507 
13 orf19.849 MNN41 2.9716 0.0586 
15 orf19.7279.1 CR_08830W_A 2.8212 0.0672 
16 orf19.4921.1 C1_12910W_A 2.7644 0.0760 
18 orf19.7585 INO1 2.7086 0.0842 
21 orf19.5728 C6_03600C_A 2.6549 0.0919 
22 orf19.6715 C3_07720C_A 2.6148 0.1002 
23 orf19.1286 C5_04040C_A 2.6036 0.1085 
34 orf19.4673 BMT9 2.4314 0.1123 
37 orf19.6713 WOR4 2.4007 0.1192 
39 orf19.2023 HGT7 2.3851 0.1264 
50 orf19.2332 C1_10850W_A 2.2465 0.1296 
54 orf19.54 RHD1 2.2299 0.1356 
55 orf19.2725 C4_02730C_A 2.2163 0.1426 
59 orf19.6547 C7_01770W_A 2.1587 0.1483 
60 orf19.4884 WOR1 2.1534 0.1551 
62 orf19.2738 SUL2 2.1449 0.1616 
65 orf19.5933 C3_04730C_A 2.1167 0.1675 
69 orf19.218 BUD20 2.1019 0.1730 
80 orf19.2766 C4_02380W_A 1.9940 0.1755 
81 orf19.454 SFL1 1.9628 0.1817 
82 orf19.111 CAN2 1.9617 0.1880 
83 orf19.3674 GAL102 1.9457 0.1941 
86 orf19.6983 C3_05450C_A 1.9390 0.1995 
87 orf19.1350 C2_08330W_A 1.9373 0.2057 
92 orf19.4231 PTH2 1.8930 0.2102 
93 orf19.2356 CRZ2 1.8902 0.2162 
98 orf19.6687 C7_03550C_A 1.8746 0.2206 
99 orf19.4555 ALS4 1.8730 0.2265 
102 orf19.935 AGA1 1.8553 0.2316 
103 orf19.5625 C6_03360C_A 1.8474 0.2375 
104 orf19.258 C3_02660W_A 1.8340 0.2433 
116 orf19.7150 NRG1 1.7552 0.2447 
118 orf19.3668 HGT2 1.7445 0.2498 
127 orf19.5908 TEC1 1.6893 0.2521 
128 orf19.4936 C1_13090W_A 1.6835 0.2574 
130 orf19.2430 C1_06150W_A 1.6813 0.2624 
142 orf19.7054 C7_00650W_A 1.6351 0.2633 
144 orf19.4682 HGT17 1.6299 0.2681 
145 orf19.5302 PGA31 1.6212 0.2733 
146 orf19.1996 CHA1 1.6194 0.2784 
148 orf19.6488 C7_02250W_A 1.6081 0.2832 
154 orf19.4833 MLS1 1.5673 0.2862 
167 orf19.1224 FRP3 1.5343 0.2864 
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173 orf19.5114.1 C1_08350C_A 1.5195 0.2893 
176 orf19.3368 C4_03420C_A 1.4951 0.2933 
179 orf19.1105 C5_03910C_A 1.4741 0.2972 
186 orf19.5203 C1_04350C_A 1.4653 0.2996 
191 orf19.5288.1 CR_05330W_A 1.4527 0.3026 
209 orf19.3675 GAL7 1.3944 0.3005 
210 orf19.6736 C3_07550C_A 1.3852 0.3049 
225 orf19.450 C1_05150C_A 1.3508 0.3038 
229 orf19.5032 SIM1 1.3375 0.3069 
231 orf19.7436 AAF1 1.3322 0.3107 
240 orf19.1189 C6_00290W_A 1.3141 0.3118 
241 orf19.5475 C3_00020W_A 1.3109 0.3159 
243 orf19.1122 C5_03730W_A 1.3059 0.3197 
246 orf19.3795 AGP3 1.2958 0.3231 
249 orf19.4951 C1_13240W_A 1.2920 0.3264 
256 orf19.3711 CR_07820W_A 1.2840 0.3281 
257 orf19.4972 OFI1 1.2815 0.3322 
258 orf19.7151 C7_04220W_A 1.2797 0.3363 
264 orf19.2169 C2_08150W_A 1.2599 0.3384 
265 orf19.4394 CR_03510W_A 1.2583 0.3424 
271 orf19.3672 GAL10 1.2536 0.3444 
279 orf19.723 BCR1 1.2419 0.3456 
289 orf19.6343 FEN1 1.2191 0.3460 
290 orf19.871 C2_03500W_A 1.2183 0.3499 
292 orf19.4234 C5_02280C_A 1.2171 0.3534 
294 orf19.3656 COX15 1.2085 0.3568 
308 orf19.6169 ATO1 1.1735 0.3555 
309 orf19.2397.3 CR_03260W_A 1.1715 0.3593 
310 orf19.3337 C1_01510W_A 1.1671 0.3630 
313 orf19.4793 C1_09330W_A 1.1571 0.3659 
315 orf19.2024 C2_00990W_A 1.1524 0.3692 
321 orf19.986 GLY1 1.1498 0.3709 
326 orf19.85 GPX2 1.1465 0.3730 
328 orf19.6288 CR_07610C_A 1.1430 0.3762 
336 orf19.6555 C7_01690W_A 1.1259 0.3771 
354 orf19.84 CAN3 1.0956 0.3740 
355 orf19.740 HAP41 1.0953 0.3775 
363 orf19.5474 C3_00010C_A 1.0793 0.3782 
365 orf19.6530 C7_01910C_A 1.0781 0.3812 
373 orf19.6514 CUP9 1.0667 0.3819 
379 orf19.1978 GIT2 1.0578 0.3834 
380 orf19.6661 C5_03520W_A 1.0555 0.3867 
389 orf19.3867 RPL7 1.0450 0.3869 
394 orf19.4892 TPK1 1.0386 0.3887 
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405 orf19.5232 CSI2 1.0221 0.3881 
407 orf19.6529 CDC34 1.0202 0.3909 
408 orf19.1416 COX11 1.0184 0.3942 
416 orf19.3670 GAL1 1.0030 0.3946 
420 orf19.3653 FAT1 0.9995 0.3967 
421 orf19.7112 FRP2 0.9991 0.3998 
438 orf19.449 C1_05160C_A 0.9844 0.3968 
453 orf19.1756 GPD1 0.9626 0.3944 
462 orf19.6937 PTR22 0.9548 0.3944 
464 orf19.5636 RBT5 0.9526 0.3970 
467 orf19.3439 C6_01450C_A 0.9497 0.3992 
480 orf19.4942 C1_13150W_A 0.9421 0.3976 
482 orf19.3413 FGR37 0.9415 0.4002 
494 orf19.1687 C3_01560W_A 0.9292 0.3989 
505 orf19.1906 C2_00130W_A 0.9200 0.3980 
517 orf19.4459 C1_03870C_A 0.9121 0.3966 
529 orf19.4056 BRG1 0.9001 0.3952 
531 orf19.3618 YWP1 0.8988 0.3977 
534 orf19.3969 SFL2 0.8950 0.3998 
554 orf19.4856 LIP3 0.8759 0.3952 
567 orf19.2021 HGT8 0.8705 0.3933 
569 orf19.2893 C4_06410W_A 0.8674 0.3957 
588 orf19.2398 CR_03250C_A 0.8512 0.3915 
593 orf19.7314 CDG1 0.8470 0.3926 
605 orf19.1314 C4_03600C_A 0.8390 0.3910 
606 orf19.5992 WOR2 0.8387 0.3937 
608 orf19.938 C5_00510W_A 0.8386 0.3960 
625 orf19.4563 C4_02260C_A 0.8160 0.3924 
630 orf19.7592 FAA4 0.8113 0.3934 
651 orf19.7539 INO2 0.8011 0.3882 
652 orf19.3967 PFK1 0.8007 0.3908 
658 orf19.6548 ISU1 0.7951 0.3914 
670 orf19.4210 C6_00490W_A 0.7844 0.3896 
672 orf19.1957 CYC3 0.7839 0.3917 
674 orf19.7296 SLP3 0.7825 0.3938 
675 orf19.6487 C7_02260W_A 0.7824 0.3963 
677 orf19.3190 HAL9 0.7820 0.3984 
691 orf19.2639 C5_03410C_A 0.7654 0.3958 
693 orf19.4792 C1_09320C_A 0.7627 0.3978 
717 orf19.4941 TYE7 0.7516 0.3913 
721 orf19.1815 CR_07080W_A 0.7444 0.3925 
725 orf19.921 HMS1 0.7425 0.3937 
734 orf19.2892 C4_06420W_A 0.7377 0.3930 
740 orf19.908 FEN12 0.7328 0.3934 
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741 orf19.1727 PMC1 0.7324 0.3957 
743 orf19.6781 ZFU2 0.7310 0.3976 
768 orf19.1842 BUD5 0.7208 0.3907 
769 orf19.4393 CIT1 0.7193 0.3929 
782 orf19.1718 ZCF8 0.7132 0.3906 
785 orf19.7488 CR_00460C_A 0.7123 0.3921 
826 orf19.5635 PGA7 0.6885 0.3788 
828 orf19.4528 C1_01950C_A 0.6879 0.3806 
830 orf19.7084 DFI1 0.6877 0.3824 
844 orf19.5906 ADE2 0.6799 0.3795 
846 orf19.6984 C3_05460W_A 0.6787 0.3813 
849 orf19.1345 LIP8 0.6774 0.3827 
852 orf19.4936.1 C1_13100W_A 0.6750 0.3840 
863 orf19.4167 C4_00750C_A 0.6698 0.3823 
872 orf19.2198 FLC3 0.6670 0.3813 
895 orf19.3707 YHB1 0.6507 0.3749 
912 orf19.5555 C6_02810C_A 0.6423 0.3708 
916 orf19.4967 COX19 0.6401 0.3716 
940 orf19.5312 MET4 0.6309 0.3648 
945 orf19.6385 ACO1 0.6292 0.3652 
946 orf19.1562 C2_02390W_A 0.6284 0.3672 
948 orf19.610 EFG1 0.6283 0.3688 
964 orf19.3188 TAC1 0.6208 0.3650 
971 orf19.5626 C6_03370W_A 0.6154 0.3646 
981 orf19.118 FAD2 0.6115 0.3631 
1004 orf19.4235 PDE1 0.5995 0.3565 
1008 orf19.3278 GSY1 0.5973 0.3572 
1013 orf19.4166 ZCF21 0.5938 0.3576 
1024 orf19.868 ADAEC 0.5876 0.3556 
1040 orf19.721 CR_06450W_A 0.5806 0.3516 
1044 orf19.1264 CFL2 0.5783 0.3523 
1056 orf19.2825 DRE2 0.5683 0.3499 
1059 orf19.2199 PHO86 0.5673 0.3509 
1062 orf19.475 CR_03940W_A 0.5661 0.3519 
1071 orf19.7539.1 CR_00040C_A 0.5628 0.3506 
1078 orf19.3369 MOH1 0.5601 0.3501 
1081 orf19.6734 TCC1 0.5593 0.3511 
1082 orf19.474 CR_03930C_A 0.5589 0.3529 
1086 orf19.7341.1 CR_09460C_A 0.5566 0.3535 
1124 orf19.7501 NAP1 0.5387 0.3409 
1127 orf19.7312 ERG13 0.5359 0.3418 
1129 orf19.568 SPE2 0.5347 0.3431 
1130 orf19.732 CR_07170W_A 0.5343 0.3448 
1134 orf19.5994 RHB1 0.5315 0.3453 
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1136 orf19.2178.1 C2_08060W_A 0.5308 0.3466 
1143 orf19.3276 PWP2 0.5277 0.3460 
1216 orf19.2309 PET127 0.4852 0.3197 
1221 orf19.6817 FCR1 0.4841 0.3197 
1225 orf19.814 SSY1 0.4791 0.3201 
1271 orf19.7502 CR_00310C_A 0.4529 0.3041 
1305 orf19.5903 RAX1 0.4393 0.2928 
1330 orf19.2457 C1_05920W_A 0.4262 0.2849 
1374 orf19.4028 RER2 0.3886 0.2695 
1399 orf19.1285 C5_04050W_A 0.3691 0.2614 
1422 orf19.3206 CCT7 0.3424 0.2540 
1454 orf19.1777 C2_10050W_A -0.3269 0.2430 
1502 orf19.6840 C1_04470C_A -0.3775 0.2261 
1521 orf19.6873 RPS8A -0.3944 0.2204 
1526 orf19.4998 ROB1 -0.3985 0.2201 
1533 orf19.314 C3_03150W_A -0.4049 0.2190 
1564 orf19.5210 C2_05860C_A -0.4215 0.2088 
1568 orf19.6408 CR_08420W_A -0.4238 0.2090 
1585 orf19.1095 GLE2 -0.4323 0.2042 
1593 orf19.3334 RPS21 -0.4371 0.2029 
1600 orf19.2961 C1_02720W_A -0.4415 0.2019 
1648 orf19.5031 SSK1 -0.4651 0.1853 
1650 orf19.949 C5_00400C_A -0.4656 0.1863 
1666 orf19.2930 C1_02430C_A -0.4773 0.1821 
1685 orf19.3359 ARP8 -0.4915 0.1767 
1690 orf19.4997 KIS2 -0.4932 0.1767 
1706 orf19.90 C6_00890W_A -0.5019 0.1725 
1712 orf19.3340 SOD2 -0.5043 0.1722 
1724 orf19.1961 C5_01090C_A -0.5101 0.1695 
1757 orf19.7149 C7_04240C_A -0.5236 0.1588 
1766 orf19.2737 C4_02620C_A -0.5281 0.1574 
1795 orf19.7380 C3_05990C_A -0.5410 0.1483 
1799 orf19.2747 RGT1 -0.5428 0.1489 
1801 orf19.2765 PGA62 -0.5436 0.1502 
1805 orf19.4280 C5_02640W_A -0.5451 0.1508 
1815 orf19.733 CR_07160C_A -0.5513 0.1491 
1817 orf19.1317 OSH3 -0.5537 0.1504 
1826 orf19.7297 CR_09010C_A -0.5614 0.1491 
1829 orf19.3794 CSR1 -0.5640 0.1501 
1833 orf19.4403 VPS11 -0.5655 0.1508 
1846 orf19.342 BMT7 -0.5716 0.1480 
1911 orf19.5384 CHS8 -0.6038 0.1252 
1916 orf19.3325 C1_01360C_A -0.6051 0.1255 
1924 orf19.6798 SSN6 -0.6080 0.1248 
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1947 orf19.3002 RPS1 -0.6150 0.1182 
1951 orf19.3325.3 RPS21B -0.6157 0.1190 
1961 orf19.4907 C1_10360C_A -0.6207 0.1175 
1965 orf19.7053 GAC1 -0.6218 0.1183 
1985 orf19.7242 NCR1 -0.6295 0.1130 
1986 orf19.1998 C2_01260W_A -0.6300 0.1150 
2011 orf19.7056 C7_00630C_A -0.6409 0.1077 
2039 orf19.4456 GAP4 -0.6561 0.0994 
2064 orf19.6660 C5_03510C_A -0.6730 0.0923 
2072 orf19.3010.1 ECM33 -0.6787 0.0917 
2098 orf19.3999 C5_05070W_A -0.6929 0.0842 
2134 orf19.2724 C4_02740W_A -0.7093 0.0730 
2145 orf19.5211 IDP1 -0.7162 0.0714 
2148 orf19.1223 DBF2 -0.7173 0.0729 
2152 orf19.6512 EXO70 -0.7208 0.0740 
2157 orf19.2638 C5_03430W_A -0.7253 0.0748 
2171 orf19.3001 TEM1 -0.7323 0.0721 
2192 orf19.7337 CR_09410W_A -0.7441 0.0667 
2195 orf19.333 FCY2 -0.7456 0.0683 
2247 orf19.4900 MNN12 -0.7687 0.0511 
2279 orf19.4153 C5_01590W_A -0.7864 0.0416 
2296 orf19.4341 C5_03120W_A -0.8019 0.0379 
2300 orf19.4899 GCA1 -0.8036 0.0393 
2310 orf19.4858 VPS41 -0.8107 0.0384 
2350 orf19.5268 MED10 -0.8366 0.0260 
2351 orf19.1585 ZRT2 -0.8383 0.0287 
2369 orf19.6800 POS5 -0.8546 0.0248 
2383 orf19.3501 C6_02090C_A -0.8633 0.0225 
2387 orf19.6842 TUS1 -0.8656 0.0241 
2392 orf19.4831 MTS1 -0.8688 0.0254 
2396 orf19.3417 ACF2 -0.8713 0.0270 
2404 orf19.1570 ERG7 -0.8790 0.0270 
2410 orf19.4245 C5_02370C_A -0.8863 0.0279 
2433 orf19.6784 PGA32 -0.9057 0.0223 
2441 orf19.2848 CR_02910W_A -0.9119 0.0225 
2484 orf19.6168 C3_00910W_A -0.9551 0.0093 
2489 orf19.4943 PSA2 -0.9615 0.0108 
2509 orf19.395 ENO1 -0.9740 0.0066 
2523 orf19.2049 C2_00750W_A -0.9889 0.0047 
2528 orf19.7563 BET2 -0.9932 0.0063 
2537 orf19.3264.1 CR_00910W_A -1.0028 0.0064 
2549 orf19.860 BMT8 -1.0177 0.0054 
2556 orf19.3358 LSC1 -1.0240 0.0063 
2564 orf19.320 C3_03210W_A -1.0341 0.0069 
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2625 orf19.113 CIP1 -1.1047 -0.0128 
2641 orf19.467 WOR3 -1.1183 -0.0150 
2650 orf19.1447 C2_01420C_A -1.1370 -0.0145 
2681 orf19.3374 ECE1 -1.1833 -0.0223 
2694 orf19.4867 SWE1 -1.2140 -0.0231 
2701 orf19.5716 SAP4 -1.2287 -0.0215 
2725 orf19.5021 PDX1 -1.3069 -0.0263 
2754 orf19.656 DPP1 -1.3641 -0.0328 
2758 orf19.6084 C1_00190C_A -1.3713 -0.0296 
2766 orf19.7078 C7_00420C_A -1.3949 -0.0278 
2776 orf19.3207 CCN1 -1.4235 -0.0268 
2804 orf19.5285 PST3 -1.5662 -0.0322 
2806 orf19.2431 C1_06140C_A -1.5766 -0.0276 
2857 orf19.7111.1 SOD3 -2.2003 -0.0400 
2861 orf19.7077 C7_00430W_A -2.3018 -0.0338 
2862 orf19.4975 HYR1 -2.3065 -0.0265 
2868 orf19.3740 PGA23 -2.4731 -0.0206 
2870 orf19.7544 TLO1 -2.5977 -0.0127 










0 orf19.6993 GAP2 4.6048 0.0089 
1 orf19.5741 ALS1 3.7669 0.0161 
2 orf19.3904 MRV4 3.6966 0.0232 
4 orf19.4934 OP4 3.3214 0.0292 
5 orf19.4211 FET31 3.1690 0.0353 
8 orf19.4438 RME1 3.0969 0.0404 
9 orf19.3643 C6_00810C_A 3.0665 0.0463 
12 orf19.2849 AQY1 2.9932 0.0512 
13 orf19.849 MNN41 2.9716 0.0569 
14 orf19.3117 CSA2 2.9491 0.0626 
15 orf19.7279.1 CR_08830W_A 2.8212 0.0680 
21 orf19.5728 C6_03600C_A 2.6549 0.0710 
22 orf19.6715 C3_07720C_A 2.6148 0.0761 
23 orf19.1286 C5_04040C_A 2.6036 0.0811 
24 orf19.3906 MRV6 2.5814 0.0860 
25 orf19.5604 MDR1 2.5564 0.0909 
26 orf19.851 MNN42 2.5559 0.0959 
29 orf19.3905 MRV5 2.5187 0.0999 
30 orf19.4933 FAD3 2.4966 0.1047 
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34 orf19.4673 BMT9 2.4314 0.1081 
37 orf19.6713 WOR4 2.4007 0.1119 
39 orf19.2023 HGT7 2.3851 0.1160 
40 orf19.7218 RBE1 2.3719 0.1206 
46 orf19.1932 CFL4 2.2907 0.1229 
49 orf19.7094 HGT12 2.2631 0.1264 
50 orf19.2332 C1_10850W_A 2.2465 0.1307 
55 orf19.2725 C4_02730C_A 2.2163 0.1333 
56 orf19.3924 C5_04380C_A 2.1978 0.1375 
58 orf19.2460 C1_05890W_A 2.1801 0.1413 
60 orf19.4884 WOR1 2.1534 0.1450 
65 orf19.5933 C3_04730C_A 2.1167 0.1474 
67 orf19.1449 C2_01450C_A 2.1093 0.1511 
69 orf19.218 BUD20 2.1019 0.1547 
71 orf19.5735.3 C6_03670C_A 2.0931 0.1583 
76 orf19.2177 C2_08090W_A 2.0332 0.1605 
80 orf19.2766 C4_02380W_A 1.9940 0.1631 
81 orf19.454 SFL1 1.9628 0.1669 
84 orf19.936 C5_00530W_A 1.9408 0.1698 
85 orf19.6276 C1_06350W_A 1.9402 0.1735 
86 orf19.6983 C3_05450C_A 1.9390 0.1772 
87 orf19.1350 C2_08330W_A 1.9373 0.1809 
88 orf19.4568 ZCF25 1.9371 0.1847 
91 orf19.4773 AOX2 1.9058 0.1875 
92 orf19.4231 PTH2 1.8930 0.1911 
93 orf19.2356 CRZ2 1.8902 0.1948 
94 orf19.7566 CR_09920W_A 1.8869 0.1984 
98 orf19.6687 C7_03550C_A 1.8746 0.2007 
99 orf19.4555 ALS4 1.8730 0.2043 
102 orf19.935 AGA1 1.8553 0.2071 
103 orf19.5625 C6_03360C_A 1.8474 0.2106 
104 orf19.258 C3_02660W_A 1.8340 0.2142 
115 orf19.4551 CTN1 1.7587 0.2133 
116 orf19.7150 NRG1 1.7552 0.2167 
117 orf19.6518 C7_02010C_A 1.7499 0.2201 
118 orf19.3668 HGT2 1.7445 0.2234 
125 orf19.138 FIG1 1.6915 0.2242 
126 orf19.4063 GPT1 1.6901 0.2274 
127 orf19.5908 TEC1 1.6893 0.2307 
128 orf19.4936 C1_13090W_A 1.6835 0.2339 
130 orf19.2430 C1_06150W_A 1.6813 0.2367 
131 orf19.6844 ICL1 1.6773 0.2399 
132 orf19.6995 ATO6 1.6712 0.2432 
134 orf19.6574 ALK6 1.6654 0.2459 
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140 orf19.3548.1 WH11 1.6394 0.2470 
142 orf19.7054 C7_00650W_A 1.6351 0.2497 
145 orf19.5302 PGA31 1.6212 0.2520 
149 orf19.7514 PCK1 1.6074 0.2538 
152 orf19.6998 GTT1 1.5874 0.2560 
154 orf19.4833 MLS1 1.5673 0.2586 
157 orf19.5307 JEN2 1.5563 0.2608 
159 orf19.6997 ATO5 1.5554 0.2633 
164 orf19.5070 C1_07990C_A 1.5436 0.2646 
167 orf19.1224 FRP3 1.5343 0.2667 
168 orf19.1541 C2_02230C_A 1.5341 0.2697 
171 orf19.3432 C6_01520W_A 1.5218 0.2718 
176 orf19.3368 C4_03420C_A 1.4951 0.2730 
177 orf19.3218 C5_03940C_A 1.4817 0.2758 
193 orf19.204 C2_09000C_A 1.4504 0.2723 
199 orf19.2990 XOG1 1.4398 0.2730 
204 orf19.1497 ZCF6 1.4097 0.2740 
208 orf19.3440 FRP5 1.3962 0.2754 
210 orf19.6736 C3_07550C_A 1.3852 0.2777 
214 orf19.3209 FGR42 1.3727 0.2790 
215 orf19.6267 C1_06430C_A 1.3724 0.2817 
225 orf19.450 C1_05150C_A 1.3508 0.2805 
229 orf19.5032 SIM1 1.3375 0.2818 
231 orf19.7436 AAF1 1.3322 0.2840 
236 orf19.5975 TRY4 1.3208 0.2848 
237 orf19.7114 CSA1 1.3190 0.2874 
240 orf19.1189 C6_00290W_A 1.3141 0.2890 
244 orf19.1287 C5_04030W_A 1.3044 0.2903 
245 orf19.77.1 C6_04150W_A 1.3027 0.2928 
249 orf19.4951 C1_13240W_A 1.2920 0.2940 
253 orf19.2691 C4_03000C_A 1.2884 0.2952 
254 orf19.4567 C4_02230C_A 1.2867 0.2977 
256 orf19.3711 CR_07820W_A 1.2840 0.2998 
258 orf19.7151 C7_04220W_A 1.2797 0.3018 
263 orf19.385 GCV2 1.2606 0.3025 
264 orf19.2169 C2_08150W_A 1.2599 0.3050 
271 orf19.3672 GAL10 1.2536 0.3048 
279 orf19.723 BCR1 1.2419 0.3043 
280 orf19.3071 MIH1 1.2400 0.3067 
283 orf19.2781 C1_07640C_A 1.2380 0.3082 
285 orf19.272 FAA21 1.2320 0.3102 
286 orf19.4591 CAT2 1.2297 0.3125 
290 orf19.871 C2_03500W_A 1.2183 0.3136 
293 orf19.3733 IDP2 1.2096 0.3151 
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294 orf19.3656 COX15 1.2085 0.3174 
295 orf19.3049 C1_03470C_A 1.2055 0.3197 
301 orf19.4784 CRP1 1.1956 0.3199 
308 orf19.6169 ATO1 1.1735 0.3197 
309 orf19.2397.3 CR_03260W_A 1.1715 0.3219 
310 orf19.3337 C1_01510W_A 1.1671 0.3242 
313 orf19.4793 C1_09330W_A 1.1571 0.3256 
315 orf19.2024 C2_00990W_A 1.1524 0.3274 
322 orf19.7447 JEN1 1.1493 0.3270 
323 orf19.2618 MET2 1.1493 0.3293 
326 orf19.85 GPX2 1.1465 0.3306 
329 orf19.787.1 C4_03960W_A 1.1375 0.3320 
335 orf19.4689 PGA57 1.1259 0.3320 
336 orf19.6555 C7_01690W_A 1.1259 0.3342 
342 orf19.1599 C2_09410W_A 1.1128 0.3342 
345 orf19.3831 C4_04520W_A 1.1070 0.3355 
347 orf19.6996 MNN14 1.1027 0.3372 
352 orf19.2881 MNN4 1.0963 0.3376 
354 orf19.84 CAN3 1.0956 0.3393 
358 orf19.7444 C3_06550C_A 1.0906 0.3402 
373 orf19.6514 CUP9 1.0667 0.3363 
375 orf19.7095 C7_00270W_A 1.0640 0.3380 
379 orf19.1978 GIT2 1.0578 0.3387 
380 orf19.6661 C5_03520W_A 1.0555 0.3408 
389 orf19.3867 RPL7 1.0450 0.3394 
394 orf19.4892 TPK1 1.0386 0.3397 
400 orf19.1152 C1_11670W_A 1.0299 0.3396 
408 orf19.1416 COX11 1.0184 0.3386 
413 orf19.6520 C7_02000C_A 1.0105 0.3389 
415 orf19.3195 HIP1 1.0059 0.3404 
416 orf19.3670 GAL1 1.0030 0.3423 
420 orf19.3653 FAT1 0.9995 0.3430 
421 orf19.7112 FRP2 0.9991 0.3449 
429 orf19.787 C4_03950C_A 0.9902 0.3439 
433 orf19.3116 EXM2 0.9862 0.3445 
434 orf19.1868 RNR22 0.9851 0.3464 
438 orf19.449 C1_05160C_A 0.9844 0.3470 
450 orf19.2020 HGT6 0.9702 0.3443 
451 orf19.7231 FTR2 0.9694 0.3461 
455 orf19.5094 BUL1 0.9611 0.3467 
462 orf19.6937 PTR22 0.9548 0.3460 
463 orf19.1581 C2_02560W_A 0.9534 0.3479 
464 orf19.5636 RBT5 0.9526 0.3497 
467 orf19.3439 C6_01450C_A 0.9497 0.3507 
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468 orf19.674 C1_11280W_A 0.9483 0.3525 
474 orf19.4910 FGR41 0.9459 0.3522 
480 orf19.4942 C1_13150W_A 0.9421 0.3519 
482 orf19.3413 FGR37 0.9415 0.3533 
484 orf19.4783 C1_09240C_A 0.9391 0.3547 
485 orf19.6254 ANT1 0.9376 0.3565 
494 orf19.1687 C3_01560W_A 0.9292 0.3549 
505 orf19.1906 C2_00130W_A 0.9200 0.3525 
509 orf19.968 PGA14 0.9144 0.3530 
517 orf19.4459 C1_03870C_A 0.9121 0.3518 
519 orf19.1736 CR_04680C_A 0.9104 0.3531 
520 orf19.6017 C1_00880W_A 0.9077 0.3549 
529 orf19.4056 BRG1 0.9001 0.3533 
531 orf19.3618 YWP1 0.8988 0.3546 
534 orf19.3969 SFL2 0.8950 0.3554 
542 orf19.1543 OPI1 0.8881 0.3542 
545 orf19.4716 GDH3 0.8862 0.3551 
567 orf19.2021 HGT8 0.8705 0.3479 
569 orf19.2893 C4_06410W_A 0.8674 0.3492 
570 orf19.3954.1 C5_04690C_A 0.8667 0.3508 
588 orf19.2398 CR_03250C_A 0.8512 0.3453 
599 orf19.173 CR_02510W_A 0.8419 0.3427 
603 orf19.4658 C4_01290W_A 0.8397 0.3431 
606 orf19.5992 WOR2 0.8387 0.3439 
608 orf19.938 C5_00510W_A 0.8386 0.3451 
609 orf19.3040 EHT1 0.8371 0.3467 
613 orf19.6686 ENP2 0.8327 0.3470 
617 orf19.4768 C1_09110W_A 0.8266 0.3473 
630 orf19.7592 FAA4 0.8113 0.3438 
638 orf19.5079 CDR4 0.8049 0.3424 
644 orf19.6928 SAP9 0.8038 0.3419 
651 orf19.7539 INO2 0.8011 0.3409 
652 orf19.3967 PFK1 0.8007 0.3425 
666 orf19.3895 CHT2 0.7864 0.3385 
670 orf19.4210 C6_00490W_A 0.7844 0.3387 
672 orf19.1957 CYC3 0.7839 0.3398 
692 orf19.6948 CCC1 0.7648 0.3333 
693 orf19.4792 C1_09320C_A 0.7627 0.3348 
697 orf19.7446 OPI3 0.7606 0.3350 
698 orf19.2072 C2_00550W_A 0.7590 0.3364 
705 orf19.1252 YME1 0.7556 0.3354 
708 orf19.1233 ADE4 0.7546 0.3360 
717 orf19.4941 TYE7 0.7516 0.3341 
718 orf19.5959 NOP14 0.7472 0.3355 
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721 orf19.1815 CR_07080W_A 0.7444 0.3361 
724 orf19.3193 FCR3 0.7434 0.3367 
725 orf19.921 HMS1 0.7425 0.3381 
731 orf19.6886 C2_05750W_A 0.7392 0.3374 
734 orf19.2892 C4_06420W_A 0.7377 0.3380 
740 orf19.908 FEN12 0.7328 0.3373 
743 orf19.6781 ZFU2 0.7310 0.3379 
764 orf19.1150 C1_11690W_A 0.7228 0.3309 
769 orf19.4393 CIT1 0.7193 0.3306 
782 orf19.1718 ZCF8 0.7132 0.3269 
785 orf19.7488 CR_00460C_A 0.7123 0.3274 
786 orf19.4769 IPT1 0.7122 0.3288 
790 orf19.1837 TBP1 0.7097 0.3289 
791 orf19.3370 DOT4 0.7095 0.3303 
793 orf19.413.1 RPS27A 0.7090 0.3312 
794 orf19.2073 C2_00540W_A 0.7088 0.3326 
800 orf19.5672 MEP2 0.7055 0.3318 
801 orf19.7565 GNP3 0.7050 0.3332 
802 orf19.6311 CR_04820W_A 0.7049 0.3345 
826 orf19.5635 PGA7 0.6885 0.3262 
828 orf19.4528 C1_01950C_A 0.6879 0.3271 
830 orf19.7084 DFI1 0.6877 0.3280 
844 orf19.5906 ADE2 0.6799 0.3238 
846 orf19.6984 C3_05460W_A 0.6787 0.3247 
849 orf19.1345 LIP8 0.6774 0.3252 
860 orf19.6852 C1_04580C_A 0.6704 0.3223 
863 orf19.4167 C4_00750C_A 0.6698 0.3227 
877 orf19.3682 CWH8 0.6637 0.3185 
884 orf19.5449 C3_00210C_A 0.6595 0.3173 
890 orf19.2459 C1_05900W_A 0.6547 0.3164 
895 orf19.3707 YHB1 0.6507 0.3160 
898 orf19.6143 CR_07250C_A 0.6483 0.3164 
912 orf19.5555 C6_02810C_A 0.6423 0.3122 
940 orf19.5312 MET4 0.6309 0.3020 
944 orf19.413 C1_05520W_A 0.6293 0.3020 
946 orf19.1562 C2_02390W_A 0.6284 0.3028 
948 orf19.610 EFG1 0.6283 0.3035 
971 orf19.5626 C6_03370W_A 0.6154 0.2955 
973 orf19.6066 C1_00410C_A 0.6139 0.2962 
974 orf19.4118 CNT 0.6136 0.2974 
998 orf19.3544 C2_05130W_A 0.6020 0.2889 
1000 orf19.7027 C7_00880C_A 0.6017 0.2896 
1005 orf19.5291 C4_04180C_A 0.5995 0.2891 
1013 orf19.4166 ZCF21 0.5938 0.2873 
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1019 orf19.4174 C4_00680W_A 0.5892 0.2863 
1024 orf19.868 ADAEC 0.5876 0.2858 
1026 orf19.1604 C2_09460C_A 0.5873 0.2865 
1040 orf19.721 CR_06450W_A 0.5806 0.2821 
1051 orf19.7551 ALO1 0.5703 0.2790 
1056 orf19.2825 DRE2 0.5683 0.2784 
1062 orf19.475 CR_03940W_A 0.5661 0.2774 
1067 orf19.1424 C4_04250W_A 0.5648 0.2768 
1068 orf19.7396 C3_06140W_A 0.5646 0.2779 
1071 orf19.7539.1 CR_00040C_A 0.5628 0.2782 
1073 orf19.1886 RCL1 0.5625 0.2788 
1078 orf19.3369 MOH1 0.5601 0.2782 
1081 orf19.6734 TCC1 0.5593 0.2785 
1082 orf19.474 CR_03930C_A 0.5589 0.2795 
1083 orf19.969 C5_00260W_A 0.5589 0.2806 
1086 orf19.7341.1 CR_09460C_A 0.5566 0.2808 
1105 orf19.1944 GPR1 0.5479 0.2743 
1121 orf19.2876 CBF1 0.5415 0.2691 
1124 orf19.7501 NAP1 0.5387 0.2692 
1126 orf19.4274 PUT1 0.5375 0.2699 
1129 orf19.568 SPE2 0.5347 0.2700 
1134 orf19.5994 RHB1 0.5315 0.2694 
1136 orf19.2178.1 C2_08060W_A 0.5308 0.2700 
1151 orf19.1767 C2_10140W_A 0.5258 0.2651 
1166 orf19.6747 C3_07430W_A 0.5179 0.2602 
1168 orf19.5754 C6_03800C_A 0.5173 0.2608 
1179 orf19.1426 C4_04240C_A 0.5114 0.2576 
1203 orf19.4600 C4_01930C_A 0.4923 0.2489 
1205 orf19.2604 CR_02030C_A 0.4915 0.2494 
1206 orf19.6994 BAT22 0.4909 0.2503 
1216 orf19.2309 PET127 0.4852 0.2475 
1218 orf19.5550 MRT4 0.4850 0.2480 
1221 orf19.6817 FCR1 0.4841 0.2481 
1225 orf19.814 SSY1 0.4791 0.2477 
1233 orf19.3706 CR_07780W_A 0.4753 0.2457 
1248 orf19.7397 C3_06150W_A 0.4675 0.2407 
1271 orf19.7502 CR_00310C_A 0.4529 0.2323 
1295 orf19.386 SAM4 0.4444 0.2235 
1305 orf19.5903 RAX1 0.4393 0.2206 
1316 orf19.3666 C1_02090C_A 0.4348 0.2172 
1328 orf19.1280 SUI1 0.4268 0.2134 
1330 orf19.2457 C1_05920W_A 0.4262 0.2138 
1344 orf19.1770 CYC1 0.4172 0.2091 
1358 orf19.4851 TFA1 0.4056 0.2045 
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1369 orf19.7382 CAM1 0.3971 0.2010 
1395 orf19.5861 KRE9 0.3722 0.1912 
1399 orf19.1285 C5_04050W_A 0.3691 0.1907 
1403 orf19.5563 RNH1 0.3650 0.1901 
1404 orf19.7667 IAH1 0.3645 0.1908 
1435 orf19.1279 CDS1 0.3237 0.1788 
1453 orf19.4380.1 CR_03620C_A -0.3267 0.1723 
1456 orf19.6094 VPS53 -0.3291 0.1721 
1461 orf19.5671 C4_00420C_A -0.3409 0.1711 
1466 orf19.1991 C2_01340W_A -0.3453 0.1700 
1472 orf19.4308 HSL1 -0.3497 0.1686 
1478 orf19.1891 APR1 -0.3562 0.1672 
1480 orf19.3813 C4_04670C_A -0.3580 0.1675 
1489 orf19.1836 APN2 -0.3683 0.1648 
1496 orf19.1601 RPL3 -0.3736 0.1630 
1502 orf19.6840 C1_04470C_A -0.3775 0.1616 
1511 orf19.1064 ACS2 -0.3837 0.1590 
1521 orf19.6873 RPS8A -0.3944 0.1560 
1522 orf19.1793 C4_05350W_A -0.3951 0.1567 
1525 orf19.657 SAM2 -0.3979 0.1567 
1526 orf19.4998 ROB1 -0.3985 0.1574 
1536 orf19.3158 C3_01190C_A -0.4074 0.1544 
1564 orf19.5210 C2_05860C_A -0.4215 0.1439 
1568 orf19.6408 CR_08420W_A -0.4238 0.1434 
1576 orf19.2423 ZCF11 -0.4276 0.1413 
1581 orf19.1605 PMS1 -0.4303 0.1405 
1591 orf19.6092 KEL1 -0.4368 0.1375 
1592 orf19.3744 CEX1 -0.4369 0.1383 
1593 orf19.3334 RPS21 -0.4371 0.1392 
1600 orf19.2961 C1_02720W_A -0.4415 0.1375 
1603 orf19.3469 C6_02280W_A -0.4451 0.1375 
1613 orf19.6259 C1_06540C_A -0.4493 0.1346 
1616 orf19.5450 ETR1 -0.4506 0.1346 
1618 orf19.1313 CDR3 -0.4519 0.1351 
1630 orf19.2175 C2_08100W_A -0.4560 0.1313 
1647 orf19.302 C3_03060W_A -0.4643 0.1255 
1648 orf19.5031 SSK1 -0.4651 0.1264 
1652 orf19.7625 PGA1 -0.4676 0.1260 
1658 orf19.3282 BMT3 -0.4723 0.1248 
1661 orf19.139 TRA1 -0.4731 0.1249 
1666 orf19.2930 C1_02430C_A -0.4773 0.1241 
1675 orf19.1933 C5_01350W_A -0.4847 0.1217 
1676 orf19.4381 VTC3 -0.4850 0.1226 
1685 orf19.3359 ARP8 -0.4915 0.1202 
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1688 orf19.3087.1 C4_07170C_A -0.4924 0.1203 
1690 orf19.4997 KIS2 -0.4932 0.1209 
1700 orf19.6197 DHH1 -0.4987 0.1180 
1712 orf19.3340 SOD2 -0.5043 0.1144 
1721 orf19.6027 C1_00790W_A -0.5088 0.1120 
1722 orf19.2474 PRC3 -0.5094 0.1130 
1724 orf19.1961 C5_01090C_A -0.5101 0.1135 
1733 orf19.3572.3 C2_05410W_A -0.5153 0.1112 
1741 orf19.1334 C7_03410C_A -0.5182 0.1092 
1750 orf19.5015 MYO2 -0.5204 0.1069 
1757 orf19.7149 C7_04240C_A -0.5236 0.1053 
1759 orf19.5337 UBC15 -0.5240 0.1059 
1768 orf19.6146 CLG1 -0.5285 0.1036 
1795 orf19.7380 C3_05990C_A -0.5410 0.0937 
1799 orf19.2747 RGT1 -0.5428 0.0935 
1801 orf19.2765 PGA62 -0.5436 0.0941 
1805 orf19.4280 C5_02640W_A -0.5451 0.0939 
1810 orf19.1926 SEF2 -0.5475 0.0932 
1812 orf19.2515 C3_01130C_A -0.5487 0.0939 
1814 orf19.931 C5_00580W_A -0.5511 0.0945 
1820 orf19.3433 OYE23 -0.5552 0.0935 
1828 orf19.2613 ECM4 -0.5638 0.0916 
1833 orf19.4403 VPS11 -0.5655 0.0910 
1834 orf19.779 HAT1 -0.5656 0.0921 
1838 orf19.1186 C6_00270W_A -0.5689 0.0920 
1842 orf19.2506 C3_01020W_A -0.5699 0.0918 
1845 orf19.1994 C2_01310W_A -0.5712 0.0920 
1850 orf19.4911 C1_10410W_A -0.5728 0.0915 
1893 orf19.5953 SFP1 -0.5949 0.0749 
1900 orf19.3667 C1_02100W_A -0.5992 0.0736 
1901 orf19.1120 FAV2 -0.5994 0.0747 
1911 orf19.5384 CHS8 -0.6038 0.0721 
1912 orf19.493 RPL15A -0.6044 0.0733 
1914 orf19.3727 PHO112 -0.6047 0.0740 
1916 orf19.3325 C1_01360C_A -0.6051 0.0748 
1924 orf19.6798 SSN6 -0.6080 0.0730 
1944 orf19.6196 C1_07080W_A -0.6147 0.0662 
1951 orf19.3325.3 RPS21B -0.6157 0.0648 
1960 orf19.3823 ZDS1 -0.6205 0.0627 
1961 orf19.4907 C1_10360C_A -0.6207 0.0639 
1964 orf19.3840 SAK1 -0.6215 0.0642 
1965 orf19.7053 GAC1 -0.6218 0.0654 
1978 orf19.5265 KIP4 -0.6268 0.0616 
1985 orf19.7242 NCR1 -0.6295 0.0603 
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1990 orf19.4772 SSU81 -0.6316 0.0598 
2007 orf19.1451 SRB9 -0.6401 0.0543 
2011 orf19.7056 C7_00630C_A -0.6409 0.0543 
2029 orf19.290 KRE5 -0.6520 0.0484 
2031 orf19.382 TEF2 -0.6522 0.0492 
2039 orf19.4456 GAP4 -0.6561 0.0475 
2053 orf19.5141 C7_03140W_A -0.6645 0.0433 
2064 orf19.6660 C5_03510C_A -0.6730 0.0404 
2072 orf19.3010.1 ECM33 -0.6787 0.0388 
2074 orf19.6760 MDS3 -0.6798 0.0397 
2076 orf19.348 SKN2 -0.6814 0.0406 
2082 orf19.5334 ZSF1 -0.6847 0.0398 
2093 orf19.2280 ZCF10 -0.6900 0.0369 
2098 orf19.3999 C5_05070W_A -0.6929 0.0365 
2113 orf19.6255 C1_06560W_A -0.6996 0.0320 
2119 orf19.1723 C3_01280W_A -0.7032 0.0313 
2134 orf19.2724 C4_02740W_A -0.7093 0.0267 
2145 orf19.5211 IDP1 -0.7162 0.0239 
2148 orf19.1223 DBF2 -0.7173 0.0244 
2152 orf19.6512 EXO70 -0.7208 0.0246 
2155 orf19.2158 NAG3 -0.7250 0.0251 
2157 orf19.2638 C5_03430W_A -0.7253 0.0261 
2164 orf19.3281 CR_00750C_A -0.7287 0.0250 
2166 orf19.5338 GAL4 -0.7298 0.0260 
2172 orf19.1330 C7_03460W_A -0.7331 0.0253 
2182 orf19.3156 C3_01180C_A -0.7407 0.0229 
2188 orf19.4979 KNS1 -0.7426 0.0222 
2192 orf19.7337 CR_09410W_A -0.7441 0.0224 
2215 orf19.5927 RPS15 -0.7529 0.0146 
2216 orf19.1995 MNN24 -0.7530 0.0160 
2219 orf19.5376 C3_00790W_A -0.7557 0.0167 
2233 orf19.1760 RAS1 -0.7643 0.0127 
2247 orf19.4900 MNN12 -0.7687 0.0087 
2271 orf19.5506 PLC1 -0.7826 0.0005 
2287 orf19.5078 OFR1 -0.7950 -0.0043 
2292 orf19.7610 PTP3 -0.7979 -0.0044 
2300 orf19.4899 GCA1 -0.8036 -0.0058 
2315 orf19.6658 C5_03490C_A -0.8135 -0.0101 
2317 orf19.691 GPD2 -0.8155 -0.0090 
2346 orf19.1331 HSM3 -0.8341 -0.0192 
2347 orf19.1368 C2_09820W_A -0.8347 -0.0176 
2351 orf19.1585 ZRT2 -0.8383 -0.0172 
2363 orf19.1409.1 C4_04390W_A -0.8458 -0.0202 
2365 orf19.6349 RVS162 -0.8493 -0.0190 
 245 
 
2369 orf19.6800 POS5 -0.8546 -0.0186 
2371 orf19.6078 POL93 -0.8557 -0.0174 
2383 orf19.3501 C6_02090C_A -0.8633 -0.0203 
2387 orf19.6842 TUS1 -0.8656 -0.0199 
2392 orf19.4831 MTS1 -0.8688 -0.0200 
2394 orf19.3225 CWH43 -0.8703 -0.0187 
2409 orf19.4391 CR_03480W_A -0.8853 -0.0229 
2410 orf19.4245 C5_02370C_A -0.8863 -0.0212 
2414 orf19.3149 LSP1 -0.8914 -0.0207 
2417 orf19.6028 HGC1 -0.8928 -0.0199 
2429 orf19.1212 C6_04100W_A -0.9020 -0.0227 
2434 orf19.31 C2_06550W_A -0.9065 -0.0227 
2435 orf19.1825 C1_06250W_A -0.9073 -0.0209 
2448 orf19.4774 AOX1 -0.9207 -0.0242 
2450 orf19.3839 SAP10 -0.9220 -0.0229 
2465 orf19.1930 CFL5 -0.9393 -0.0269 
2472 orf19.2551 MET6 -0.9462 -0.0276 
2478 orf19.6763 SLK19 -0.9516 -0.0279 
2481 orf19.7668 MAL2 -0.9534 -0.0269 
2484 orf19.6168 C3_00910W_A -0.9551 -0.0259 
2487 orf19.1747 KIP2 -0.9596 -0.0249 
2491 orf19.7350 RCT1 -0.9633 -0.0243 
2492 orf19.1075 C6_04190C_A -0.9633 -0.0225 
2494 orf19.5209 C2_05850C_A -0.9650 -0.0210 
2498 orf19.2767 PGA59 -0.9671 -0.0204 
2506 orf19.2163 C6_04650W_A -0.9739 -0.0215 
2509 orf19.395 ENO1 -0.9740 -0.0205 
2528 orf19.7563 BET2 -0.9932 -0.0261 
2531 orf19.6592 CR_09700W_A -0.9951 -0.0251 
2532 orf19.5142 DFR1 -0.9958 -0.0232 
2563 orf19.2190 VRP1 -1.0340 -0.0338 
2594 orf19.3572 C2_05400W_A -1.0653 -0.0443 
2598 orf19.675 C1_11270W_A -1.0678 -0.0436 
2604 orf19.7324 THI13 -1.0714 -0.0436 
2607 orf19.2172 ARA1 -1.0785 -0.0424 
2613 orf19.7323 CBP1 -1.0888 -0.0424 
2623 orf19.2451 PGA45 -1.1021 -0.0440 
2636 orf19.6594 PLB3 -1.1133 -0.0469 
2641 orf19.467 WOR3 -1.1183 -0.0465 
2642 orf19.1522 C2_02050C_A -1.1228 -0.0443 
2648 orf19.6229 CAT1 -1.1311 -0.0442 
2649 orf19.854 UGA11 -1.1368 -0.0421 
2659 orf19.4980 HSP70 -1.1449 -0.0436 
2666 orf19.4651 PGA53 -1.1527 -0.0439 
 246 
 
2681 orf19.3374 ECE1 -1.1833 -0.0476 
2682 orf19.6081 PHR2 -1.1904 -0.0453 
2687 orf19.251 GLX3 -1.2052 -0.0446 
2694 orf19.4867 SWE1 -1.2140 -0.0448 
2695 orf19.301 PGA18 -1.2171 -0.0425 
2696 orf19.3802 PMT6 -1.2175 -0.0401 
2702 orf19.1321 HWP1 -1.2354 -0.0399 
2705 orf19.1505 C2_01930C_A -1.2441 -0.0383 
2716 orf19.4906 C1_10350C_A -1.2763 -0.0401 
2721 orf19.6527 C7_01940C_A -1.2939 -0.0392 
2723 orf19.2202 C2_07790C_A -1.3015 -0.0372 
2725 orf19.5021 PDX1 -1.3069 -0.0351 
2729 orf19.6191 TLO8 -1.3148 -0.0338 
2736 orf19.6816 C3_06860C_A -1.3248 -0.0338 
2745 orf19.7504 CR_00290W_A -1.3445 -0.0346 
2754 orf19.656 DPP1 -1.3641 -0.0353 
2755 orf19.7436.1 ECM15 -1.3659 -0.0327 
2758 orf19.6084 C1_00190C_A -1.3713 -0.0309 
2766 orf19.7078 C7_00420C_A -1.3949 -0.0311 
2784 orf19.6277 C1_06340W_A -1.4729 -0.0354 
2787 orf19.4652 C4_01350W_A -1.4873 -0.0334 
2791 orf19.5454 DAL1 -1.5048 -0.0318 
2796 orf19.6350 C1_12720C_A -1.5284 -0.0305 
2801 orf19.6313 MNT4 -1.5540 -0.0292 
2806 orf19.2431 C1_06140C_A -1.5766 -0.0279 
2814 orf19.4064 GPI7 -1.6003 -0.0277 
2817 orf19.1539 C2_02220C_A -1.6348 -0.0254 
2818 orf19.6420 PGA13 -1.6448 -0.0223 
2819 orf19.2837 ALG5 -1.6502 -0.0191 
2820 orf19.3908 MRV8 -1.6621 -0.0159 
2826 orf19.2425 HGT18 -1.7046 -0.0147 
2828 orf19.2467 PRN1 -1.7191 -0.0118 
2834 orf19.1153 GAD1 -1.7752 -0.0105 
2844 orf19.7550 IFA14 -1.9115 -0.0106 
2857 orf19.7111.1 SOD3 -2.2003 -0.0115 
2861 orf19.7077 C7_00430W_A -2.3018 -0.0083 
2865 orf19.7017 YOX1 -2.3578 -0.0050 














1 orf19.5741 ALS1 3.7669 0.0198 
5 orf19.4211 FET31 3.1690 0.0356 
8 orf19.4438 RME1 3.0969 0.0515 
13 orf19.849 MNN41 2.9716 0.0659 
22 orf19.6715 C3_07720C_A 2.6148 0.0770 
23 orf19.1286 C5_04040C_A 2.6036 0.0909 
26 orf19.851 MNN42 2.5559 0.1038 
37 orf19.6713 WOR4 2.4007 0.1130 
39 orf19.2023 HGT7 2.3851 0.1254 
41 orf19.97 CAN1 2.3381 0.1375 
46 orf19.1932 CFL4 2.2907 0.1483 
50 orf19.2332 C1_10850W_A 2.2465 0.1592 
54 orf19.54 RHD1 2.2299 0.1701 
55 orf19.2725 C4_02730C_A 2.2163 0.1819 
59 orf19.6547 C7_01770W_A 2.1587 0.1924 
60 orf19.4884 WOR1 2.1534 0.2039 
65 orf19.5933 C3_04730C_A 2.1167 0.2137 
81 orf19.454 SFL1 1.9628 0.2187 
86 orf19.6983 C3_05450C_A 1.9390 0.2276 
92 orf19.4231 PTH2 1.8930 0.2359 
93 orf19.2356 CRZ2 1.8902 0.2460 
99 orf19.4555 ALS4 1.8730 0.2542 
102 orf19.935 AGA1 1.8553 0.2634 
103 orf19.5625 C6_03360C_A 1.8474 0.2733 
104 orf19.258 C3_02660W_A 1.8340 0.2831 
116 orf19.7150 NRG1 1.7552 0.2884 
118 orf19.3668 HGT2 1.7445 0.2974 
127 orf19.5908 TEC1 1.6893 0.3035 
128 orf19.4936 C1_13090W_A 1.6835 0.3125 
136 orf19.3182 GIS2 1.6607 0.3188 
142 orf19.7054 C7_00650W_A 1.6351 0.3257 
145 orf19.5302 PGA31 1.6212 0.3336 
148 orf19.6488 C7_02250W_A 1.6081 0.3415 
157 orf19.5307 JEN2 1.5563 0.3469 
210 orf19.6736 C3_07550C_A 1.3852 0.3350 
214 orf19.3209 FGR42 1.3727 0.3413 
225 orf19.450 C1_05150C_A 1.3508 0.3448 
231 orf19.7436 AAF1 1.3322 0.3501 
240 orf19.1189 C6_00290W_A 1.3141 0.3542 
244 orf19.1287 C5_04030W_A 1.3044 0.3600 
245 orf19.77.1 C6_04150W_A 1.3027 0.3670 
 248 
 
258 orf19.7151 C7_04220W_A 1.2797 0.3694 
271 orf19.3672 GAL10 1.2536 0.3717 
279 orf19.723 BCR1 1.2419 0.3758 
290 orf19.871 C2_03500W_A 1.2183 0.3786 
310 orf19.3337 C1_01510W_A 1.1671 0.3778 
315 orf19.2024 C2_00990W_A 1.1524 0.3825 
326 orf19.85 GPX2 1.1465 0.3849 
352 orf19.2881 MNN4 1.0963 0.3816 
354 orf19.84 CAN3 1.0956 0.3871 
355 orf19.740 HAP41 1.0953 0.3929 
369 orf19.2652 TEF4 1.0727 0.3939 
373 orf19.6514 CUP9 1.0667 0.3985 
389 orf19.3867 RPL7 1.0450 0.3985 
405 orf19.5232 CSI2 1.0221 0.3984 
406 orf19.2062 SOD4 1.0219 0.4039 
415 orf19.3195 HIP1 1.0059 0.4063 
416 orf19.3670 GAL1 1.0030 0.4117 
438 orf19.449 C1_05160C_A 0.9844 0.4092 
462 orf19.6937 PTR22 0.9548 0.4058 
464 orf19.5636 RBT5 0.9526 0.4106 
480 orf19.4942 C1_13150W_A 0.9421 0.4100 
517 orf19.4459 C1_03870C_A 0.9121 0.4016 
519 orf19.1736 CR_04680C_A 0.9104 0.4061 
529 orf19.4056 BRG1 0.9001 0.4076 
531 orf19.3618 YWP1 0.8988 0.4121 
534 orf19.3969 SFL2 0.8950 0.4161 
569 orf19.2893 C4_06410W_A 0.8674 0.4082 
606 orf19.5992 WOR2 0.8387 0.3994 
608 orf19.938 C5_00510W_A 0.8386 0.4035 
630 orf19.7592 FAA4 0.8113 0.4001 
651 orf19.7539 INO2 0.8011 0.3970 
652 orf19.3967 PFK1 0.8007 0.4012 
658 orf19.6548 ISU1 0.7951 0.4036 
666 orf19.3895 CHT2 0.7864 0.4053 
670 orf19.4210 C6_00490W_A 0.7844 0.4084 
672 orf19.1957 CYC3 0.7839 0.4122 
675 orf19.6487 C7_02260W_A 0.7824 0.4156 
724 orf19.3193 FCR3 0.7434 0.4019 
734 orf19.2892 C4_06420W_A 0.7377 0.4025 
740 orf19.908 FEN12 0.7328 0.4046 
742 orf19.1735 CR_04710W_A 0.7319 0.4081 
743 orf19.6781 ZFU2 0.7310 0.4120 
768 orf19.1842 BUD5 0.7208 0.4070 
802 orf19.6311 CR_04820W_A 0.7049 0.3986 
 249 
 
826 orf19.5635 PGA7 0.6885 0.3938 
828 orf19.4528 C1_01950C_A 0.6879 0.3971 
844 orf19.5906 ADE2 0.6799 0.3952 
846 orf19.6984 C3_05460W_A 0.6787 0.3984 
852 orf19.4936.1 C1_13100W_A 0.6750 0.4002 
863 orf19.4167 C4_00750C_A 0.6698 0.4001 
884 orf19.5449 C3_00210C_A 0.6595 0.3962 
895 orf19.3707 YHB1 0.6507 0.3960 
911 orf19.76 SPB1 0.6423 0.3939 
940 orf19.5312 MET4 0.6309 0.3869 
948 orf19.610 EFG1 0.6283 0.3877 
971 orf19.5626 C6_03370W_A 0.6154 0.3829 
1000 orf19.7027 C7_00880C_A 0.6017 0.3757 
1013 orf19.4166 ZCF21 0.5938 0.3745 
1024 orf19.868 ADAEC 0.5876 0.3739 
1026 orf19.1604 C2_09460C_A 0.5873 0.3767 
1040 orf19.721 CR_06450W_A 0.5806 0.3750 
1056 orf19.2825 DRE2 0.5683 0.3725 
1066 orf19.3981 MAL31 0.5652 0.3722 
1071 orf19.7539.1 CR_00040C_A 0.5628 0.3737 
1081 orf19.6734 TCC1 0.5593 0.3734 
1089 orf19.96 TOP1 0.5545 0.3738 
1105 orf19.1944 GPR1 0.5479 0.3712 
1124 orf19.7501 NAP1 0.5387 0.3674 
1129 orf19.568 SPE2 0.5347 0.3688 
1134 orf19.5994 RHB1 0.5315 0.3701 
1136 orf19.2178.1 C2_08060W_A 0.5308 0.3726 
1168 orf19.5754 C6_03800C_A 0.5173 0.3639 
1176 orf19.6973 C3_05360C_A 0.5129 0.3641 
1192 orf19.2653 C5_03260C_A 0.4987 0.3612 
1221 orf19.6817 FCR1 0.4841 0.3534 
1225 orf19.814 SSY1 0.4791 0.3549 
1271 orf19.7502 CR_00310C_A 0.4529 0.3407 
1305 orf19.5903 RAX1 0.4393 0.3308 
1319 orf19.6071 NAA25 0.4337 0.3284 
1496 orf19.1601 RPL3 -0.3736 0.2653 
1521 orf19.6873 RPS8A -0.3944 0.2585 
1522 orf19.1793 C4_05350W_A -0.3951 0.2606 
1567 orf19.6091 RIM8 -0.4230 0.2466 
1581 orf19.1605 PMS1 -0.4303 0.2441 
1666 orf19.2930 C1_02430C_A -0.4773 0.2156 
1675 orf19.1933 C5_01350W_A -0.4847 0.2153 
1704 orf19.2992 RPP1A -0.5005 0.2076 
1712 orf19.3340 SOD2 -0.5043 0.2077 
 250 
 
1724 orf19.1961 C5_01090C_A -0.5101 0.2064 
1749 orf19.6415.1 CR_08480C_A -0.5204 0.2003 
1757 orf19.7149 C7_04240C_A -0.5236 0.2005 
1768 orf19.6146 CLG1 -0.5285 0.1996 
1795 orf19.7380 C3_05990C_A -0.5410 0.1929 
1820 orf19.3433 OYE23 -0.5552 0.1870 
1829 orf19.3794 CSR1 -0.5640 0.1871 
1833 orf19.4403 VPS11 -0.5655 0.1890 
1842 orf19.2506 C3_01020W_A -0.5699 0.1891 
1846 orf19.342 BMT7 -0.5716 0.1911 
1911 orf19.5384 CHS8 -0.6038 0.1706 
1924 orf19.6798 SSN6 -0.6080 0.1694 
1968 orf19.6147 CR_07230W_A -0.6232 0.1569 
2011 orf19.7056 C7_00630C_A -0.6409 0.1448 
2021 orf19.2994.1 RPS16A -0.6462 0.1449 
2036 orf19.405 VCX1 -0.6548 0.1432 
2039 orf19.4456 GAP4 -0.6561 0.1460 
2072 orf19.3010.1 ECM33 -0.6787 0.1378 
2098 orf19.3999 C5_05070W_A -0.6929 0.1323 
2115 orf19.6872 C2_05590C_A -0.7002 0.1301 
2152 orf19.6512 EXO70 -0.7208 0.1207 
2157 orf19.2638 C5_03430W_A -0.7253 0.1231 
2192 orf19.7337 CR_09410W_A -0.7441 0.1145 
2195 orf19.333 FCY2 -0.7456 0.1177 
2247 orf19.4900 MNN12 -0.7687 0.1030 
2300 orf19.4899 GCA1 -0.8036 0.0881 
2369 orf19.6800 POS5 -0.8546 0.0675 
2401 orf19.3180 C5_01920C_A -0.8766 0.0607 
2434 orf19.31 C2_06550W_A -0.9065 0.0538 
2489 orf19.4943 PSA2 -0.9615 0.0390 
2498 orf19.2767 PGA59 -0.9671 0.0412 
2528 orf19.7563 BET2 -0.9932 0.0358 
2641 orf19.467 WOR3 -1.1183 0.0003 
2694 orf19.4867 SWE1 -1.2140 -0.0124 
2758 orf19.6084 C1_00190C_A -1.3713 -0.0283 
2766 orf19.7078 C7_00420C_A -1.3949 -0.0234 
2785 orf19.2768 AMS1 -1.4783 -0.0222 
2786 orf19.3982 C5_04940W_A -1.4788 -0.0143 
2843 orf19.535 RBR1 -1.8774 -0.0249 
2861 orf19.7077 C7_00430W_A -2.3018 -0.0189 












1 orf19.5741 ALS1 3.7668 0.1152 
11 orf19.4216 C5_02110W_A 3.0229 0.2047 
17 orf19.3160 HSP12 2.7155 0.2863 
51 orf19.6001 SAP3 2.2455 0.3435 
60 orf19.4884 WOR1 2.1534 0.4068 
99 orf19.4555 ALS4 1.8730 0.4509 
127 orf19.5908 TEC1 1.6893 0.4932 
189 orf19.1097 ALS2 1.4598 0.5166 
231 orf19.7436 AAF1 1.3322 0.5431 
531 orf19.3618 YWP1 0.8988 0.4658 
558 orf19.4257 INT1 0.8747 0.4835 
644 orf19.6928 SAP9 0.8038 0.4783 
805 orf19.1665 MNT1 0.7032 0.4438 
948 orf19.610 EFG1 0.6283 0.4132 
1174 orf19.5714 SAP1 0.5140 0.3501 
1285 orf19.1671 UTR2 0.4467 0.3252 
2015 orf19.1133 MSB1 -0.6427 0.0892 
2072 orf19.3010.1 ECM33 -0.6787 0.0904 
2239 orf19.548 CDC10 -0.7654 0.0556 
2294 orf19.6109 TUP1 -0.8013 0.0612 
2450 orf19.3839 SAP10 -0.9220 0.0352 
2686 orf19.4477 CSH1 -1.2046 -0.0103 
2701 orf19.5716 SAP4 -1.2287 0.0224 










0 orf19.6993 GAP2 4.6048 0.0272 
3 orf19.4335 TNA1 3.3619 0.0463 
12 orf19.2849 AQY1 2.9932 0.0610 
25 orf19.5604 MDR1 2.5564 0.0717 
39 orf19.2023 HGT7 2.3851 0.0810 
41 orf19.97 CAN1 2.3381 0.0944 
44 orf19.2810 AAP1 2.3154 0.1074 
45 orf19.3120 C4_06910W_A 2.3040 0.1210 
49 orf19.7094 HGT12 2.2631 0.1332 
52 orf19.7093 HGT13 2.2362 0.1457 
 252 
 
62 orf19.2738 SUL2 2.1449 0.1550 
73 orf19.7071 FGR2 2.0821 0.1636 
82 orf19.111 CAN2 1.9617 0.1723 
94 orf19.7566 CR_09920W_A 1.8869 0.1794 
106 orf19.4304 GAP1 1.8272 0.1861 
108 orf19.3122 ARR3 1.8229 0.1965 
111 orf19.1587 HGT20 1.7944 0.2064 
118 orf19.3668 HGT2 1.7445 0.2144 
126 orf19.4063 GPT1 1.6901 0.2218 
139 orf19.3455 C6_02150C_A 1.6417 0.2271 
144 orf19.4682 HGT17 1.6299 0.2353 
151 orf19.1867 C2_07580W_A 1.5932 0.2425 
155 orf19.2006.1 COX17 1.5667 0.2506 
157 orf19.5307 JEN2 1.5563 0.2594 
165 orf19.6570 NUP 1.5424 0.2659 
184 orf19.3931 SFC1 1.4671 0.2680 
203 orf19.700 SEO1 1.4102 0.2697 
221 orf19.28 C2_06520C_A 1.3566 0.2714 
246 orf19.3795 AGP3 1.2958 0.2702 
278 orf19.23 RTA3 1.2449 0.2661 
281 orf19.150 TIM17 1.2399 0.2727 
301 orf19.4784 CRP1 1.1956 0.2727 
304 orf19.5859 DAL8 1.1868 0.2790 
305 orf19.1386 C2_09680W_A 1.1759 0.2860 
314 orf19.1855 CR_06790C_A 1.1564 0.2898 
317 orf19.918 CDR11 1.1521 0.2959 
322 orf19.7447 JEN1 1.1493 0.3012 
330 orf19.5121 OPT5 1.1367 0.3053 
334 orf19.6532 C7_01880C_A 1.1270 0.3109 
354 orf19.84 CAN3 1.0956 0.3104 
362 orf19.1352 TIM22 1.0800 0.3142 
372 orf19.4940 C1_13130C_A 1.0685 0.3171 
379 orf19.1978 GIT2 1.0578 0.3212 
399 orf19.5280 MUP1 1.0304 0.3203 
415 orf19.3195 HIP1 1.0059 0.3207 
420 orf19.3653 FAT1 0.9995 0.3251 
424 orf19.5870 CTP1 0.9956 0.3299 
441 orf19.5444 TIM44 0.9812 0.3297 
450 orf19.2020 HGT6 0.9702 0.3325 
451 orf19.7231 FTR2 0.9694 0.3383 
462 orf19.6937 PTR22 0.9548 0.3402 
483 orf19.5915 DUR35 0.9406 0.3384 
485 orf19.6254 ANT1 0.9376 0.3435 
504 orf19.309 DAL5 0.9209 0.3423 
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528 orf19.1393 C2_09610W_A 0.9008 0.3392 
561 orf19.6956 DAL9 0.8726 0.3325 
567 orf19.2021 HGT8 0.8705 0.3358 
568 orf19.804 C2_04180C_A 0.8678 0.3409 
579 orf19.6578 C7_01510W_A 0.8589 0.3423 
615 orf19.2754 TIM13 0.8302 0.3343 
635 orf19.5143 TIM54 0.8087 0.3321 
638 orf19.5079 CDR4 0.8049 0.3361 
655 orf19.2178 MRS4 0.7982 0.3349 
667 orf19.5958 CDR2 0.7855 0.3355 
671 orf19.1403 C2_09510C_A 0.7842 0.3390 
698 orf19.2072 C2_00550W_A 0.7590 0.3339 
703 orf19.5962 HGT4 0.7558 0.3369 
726 orf19.7500 PXA1 0.7418 0.3332 
733 orf19.1361 TIM23 0.7378 0.3353 
737 orf19.2117 LEU5 0.7345 0.3385 
741 orf19.1727 PMC1 0.7324 0.3418 
748 orf19.4447 YMC1 0.7284 0.3439 
754 orf19.941 SEC14 0.7263 0.3463 
765 orf19.4583 C4_02080W_A 0.7224 0.3469 
767 orf19.3700 TOM70 0.7212 0.3508 
772 orf19.3234.1 SFT1 0.7184 0.3535 
779 orf19.3526 ITR1 0.7151 0.3555 
800 orf19.5672 MEP2 0.7055 0.3523 
801 orf19.7565 GNP3 0.7050 0.3565 
804 orf19.24 RTA2 0.7041 0.3599 
832 orf19.6531.1 TOM7 0.6863 0.3540 
853 orf19.4779 C1_09210C_A 0.6749 0.3506 
858 orf19.2851 CR_02940C_A 0.6720 0.3531 
872 orf19.2198 FLC3 0.6670 0.3522 
875 orf19.7327 PHO88 0.6659 0.3554 
915 orf19.4720 CTR2 0.6402 0.3448 
916 orf19.4967 COX19 0.6401 0.3486 
936 orf19.5599 MDL2 0.6316 0.3453 
941 orf19.5720 C6_03540W_A 0.6297 0.3476 
974 orf19.4118 CNT 0.6136 0.3394 
989 orf19.3663 PHO91 0.6071 0.3378 
991 orf19.6696 TIM9 0.6052 0.3410 
997 orf19.1804 CR_04920W_A 0.6022 0.3427 
1019 orf19.4174 C4_00680W_A 0.5892 0.3385 
1023 orf19.2337 ALP1 0.5888 0.3408 
1066 orf19.3981 MAL31 0.5652 0.3287 
1084 orf19.2751 C4_02510W_A 0.5586 0.3257 
1115 orf19.3696 TOM22 0.5433 0.3179 
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1242 orf19.3227 FTH2 0.4721 0.2742 
1263 orf19.6209 C1_06980C_A 0.4553 0.2695 
1272 orf19.6263 C1_06510C_A 0.4523 0.2692 
1292 orf19.2633 HGT14 0.4453 0.2648 
1325 orf19.3031 SEC62 0.4271 0.2555 
1407 orf19.1027 PDR16 0.3576 0.2278 
1425 orf19.2597 MRS2 0.3368 0.2235 
1430 orf19.3900 C5_04170W_A 0.3313 0.2240 
1446 orf19.6478 YCF1 -0.3083 0.2203 
1494 orf19.1376 SSO2 -0.3734 0.2051 
1514 orf19.3212 MID1 -0.3856 0.2004 
1528 orf19.388 CAF16 -0.3992 0.1980 
1546 orf19.5875 VAM3 -0.4110 0.1941 
1554 orf19.1680 TFP1 -0.4179 0.1940 
1570 orf19.3579 ATP4 -0.4249 0.1910 
1618 orf19.1313 CDR3 -0.4519 0.1763 
1699 orf19.2746 EMP70 -0.4987 0.1497 
1730 orf19.1538 TLG2 -0.5139 0.1417 
1745 orf19.2895 VMA8 -0.5188 0.1396 
1792 orf19.7089 PMR1 -0.5400 0.1258 
1798 orf19.1534 C2_02180W_A -0.5426 0.1272 
1809 orf19.1182 C6_00240C_A -0.5468 0.1267 
1877 orf19.5526 SEC20 -0.5880 0.1055 
1897 orf19.2599 CRC1 -0.5979 0.1020 
1929 orf19.2644 QCR2 -0.6107 0.0942 
1933 orf19.459 ADP1 -0.6124 0.0967 
1992 orf19.5880 C3_04360W_A -0.6325 0.0790 
2008 orf19.4954 C1_13280C_A -0.6405 0.0773 
2011 orf19.7056 C7_00630C_A -0.6409 0.0803 
2036 orf19.405 VCX1 -0.6548 0.0753 
2039 orf19.4456 GAP4 -0.6561 0.0785 
2055 orf19.7354 LAC1 -0.6662 0.0769 
2083 orf19.7483 CRM1 -0.6851 0.0710 
2086 orf19.5052 C1_07820W_A -0.6879 0.0743 
2092 orf19.645.1 VMA13 -0.6896 0.0765 
2111 orf19.1866 VMA10 -0.6993 0.0740 
2118 orf19.6634 VMA2 -0.7022 0.0759 
2143 orf19.30 SPF1 -0.7144 0.0713 
2155 orf19.2158 NAG3 -0.7250 0.0715 
2187 orf19.7086 C7_00340C_A -0.7426 0.0645 
2195 orf19.333 FCY2 -0.7456 0.0663 
2208 orf19.6656 C5_03480C_A -0.7507 0.0663 
2288 orf19.7578 CR_10020C_A -0.7960 0.0419 
2303 orf19.337 VTI1 -0.8058 0.0415 
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2351 orf19.1585 ZRT2 -0.8383 0.0291 
2361 orf19.2598 VMA4 -0.8448 0.0307 
2366 orf19.1614 MEP1 -0.8508 0.0343 
2424 orf19.4733 YMC2 -0.8997 0.0186 
2436 orf19.1979 GIT3 -0.9088 0.0199 
2461 orf19.5926 ARG11 -0.9352 0.0166 
2464 orf19.479.2 SEC22 -0.9387 0.0214 
2475 orf19.806 VMA7 -0.9495 0.0233 
2560 orf19.3249 LAG1 -1.0289 -0.0016 
2567 orf19.4655 OPT6 -1.0420 0.0023 
2582 orf19.4384 HXT5 -1.0530 0.0034 
2627 orf19.2397 CR_03270W_A -1.1058 -0.0063 
2633 orf19.2587 HNM3 -1.1091 -0.0016 
2656 orf19.4690 C4_00990W_A -1.1405 -0.0030 
2677 orf19.5428 C3_00390W_A -1.1787 -0.0034 
2704 orf19.644 HGT9 -1.2417 -0.0057 
2807 orf19.3646 CTR1 -1.5788 -0.0340 
2812 orf19.5017 DUR32 -1.5890 -0.0261 
2816 orf19.4449 CCS1 -1.6287 -0.0176 
2826 orf19.2425 HGT18 -1.7046 -0.0108 
2859 orf19.7331 FCY24 -2.2699 -0.0092 
2866 orf19.1395 C2_09590C_A -2.4346 0.0030 
 
 
AMINO ACID TRANSPORT_BIO  
Rank in 
Gene List 




0 orf19.6993 GAP2 4.6048 0.1824 
41 orf19.97 CAN1 2.3381 0.2610 
44 orf19.2810 AAP1 2.3154 0.3521 
82 orf19.111 CAN2 1.9617 0.4168 
94 orf19.7566 CR_09920W_A 1.8869 0.4877 
106 orf19.4304 GAP1 1.8272 0.5563 
126 orf19.4063 GPT1 1.6901 0.6166 
246 orf19.3795 AGP3 1.2958 0.6263 
354 orf19.84 CAN3 1.0956 0.6323 
372 orf19.4940 C1_13130C_A 1.0685 0.6686 
399 orf19.5280 MUP1 1.0304 0.7004 
415 orf19.3195 HIP1 1.0059 0.7350 
801 orf19.7565 GNP3 0.7050 0.6282 
1023 orf19.2337 ALP1 0.5888 0.5742 
1134 orf19.5994 RHB1 0.5315 0.5567 
2011 orf19.7056 C7_00630C_A -0.6409 0.2756 
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2039 orf19.4456 GAP4 -0.6561 0.2922 
 
CARBOHYDRATE TRANSPORTER ACTIVITY_MOL  
Rank in 
Gene List 




39 orf19.2023 HGT7 2.3851 0.0994 
49 orf19.7094 HGT12 2.2631 0.2035 
52 orf19.7093 HGT13 2.2362 0.3088 
111 orf19.1587 HGT20 1.7944 0.3736 
118 orf19.3668 HGT2 1.7445 0.4541 
144 orf19.4682 HGT17 1.6299 0.5226 
450 orf19.2020 HGT6 0.9702 0.4619 
567 orf19.2021 HGT8 0.8705 0.4626 
703 orf19.5962 HGT4 0.7558 0.4512 
779 orf19.3526 ITR1 0.7151 0.4589 
1066 orf19.3981 MAL31 0.5652 0.3856 
1292 orf19.2633 HGT14 0.4453 0.3280 
2155 orf19.2158 NAG3 -0.7250 0.0609 
2582 orf19.4384 HXT5 -1.0530 -0.0382 
2704 orf19.644 HGT9 -1.2417 -0.0217 










0 orf19.6993 GAP2 4.6048 0.0318 
3 orf19.4335 TNA1 3.3619 0.0542 
18 orf19.7585 INO1 2.7086 0.0678 
25 orf19.5604 MDR1 2.5564 0.0833 
32 orf19.2701 C4_02930W_A 2.4462 0.0979 
36 orf19.699 CR_06650C_A 2.4119 0.1135 
38 orf19.670.2 C1_11320C_A 2.3900 0.1296 
48 orf19.2809 CTN3 2.2853 0.1421 
67 orf19.1449 C2_01450C_A 2.1093 0.1501 
82 orf19.111 CAN2 1.9617 0.1585 
83 orf19.3674 GAL102 1.9457 0.1720 
94 orf19.7566 CR_09920W_A 1.8869 0.1813 
96 orf19.5069 C1_07980C_A 1.8814 0.1940 
101 orf19.1438 C4_03340C_A 1.8594 0.2053 
115 orf19.4551 CTN1 1.7587 0.2127 
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118 orf19.3668 HGT2 1.7445 0.2240 
131 orf19.6844 ICL1 1.6773 0.2312 
140 orf19.3548.1 WH11 1.6394 0.2396 
144 orf19.4682 HGT17 1.6299 0.2498 
154 orf19.4833 MLS1 1.5673 0.2573 
157 orf19.5307 JEN2 1.5563 0.2673 
167 orf19.1224 FRP3 1.5343 0.2746 
169 orf19.4539 C1_01840C_A 1.5256 0.2848 
172 orf19.4445 C1_07220W_A 1.5197 0.2946 
175 orf19.4506 LYS22 1.5066 0.3042 
184 orf19.3931 SFC1 1.4671 0.3114 
196 orf19.4041 PEX4 1.4462 0.3174 
209 orf19.3675 GAL7 1.3944 0.3227 
215 orf19.6267 C1_06430C_A 1.3724 0.3303 
236 orf19.5975 TRY4 1.3208 0.3322 
271 orf19.3672 GAL10 1.2536 0.3285 
278 orf19.23 RTA3 1.2449 0.3349 
285 orf19.272 FAA21 1.2320 0.3412 
286 orf19.4591 CAT2 1.2297 0.3497 
293 orf19.3733 IDP2 1.2096 0.3558 
308 orf19.6169 ATO1 1.1735 0.3588 
340 orf19.6306 CR_04870C_A 1.1171 0.3553 
355 orf19.740 HAP41 1.0953 0.3578 
369 orf19.2652 TEF4 1.0727 0.3604 
416 orf19.3670 GAL1 1.0030 0.3506 
438 orf19.449 C1_05160C_A 0.9844 0.3498 
455 orf19.5094 BUL1 0.9611 0.3506 
464 orf19.5636 RBT5 0.9526 0.3543 
485 orf19.6254 ANT1 0.9376 0.3535 
500 orf19.3684 C1_02270C_A 0.9253 0.3548 
545 orf19.4716 GDH3 0.8862 0.3449 
619 orf19.6838 C1_04460C_A 0.8236 0.3241 
636 orf19.4894 C1_10240C_A 0.8084 0.3239 
644 orf19.6928 SAP9 0.8038 0.3269 
656 orf19.3661 C1_02040C_A 0.7964 0.3284 
662 orf19.638 FDH1 0.7929 0.3320 
674 orf19.7296 SLP3 0.7825 0.3334 
682 orf19.7469 ARG1 0.7771 0.3362 
703 orf19.5962 HGT4 0.7558 0.3342 
704 orf19.278 C3_02870C_A 0.7557 0.3394 
726 orf19.7500 PXA1 0.7418 0.3369 
741 orf19.1727 PMC1 0.7324 0.3368 
779 orf19.3526 ITR1 0.7151 0.3283 
781 orf19.1704 FOX3 0.7134 0.3329 
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802 orf19.6311 CR_04820W_A 0.7049 0.3305 
804 orf19.24 RTA2 0.7041 0.3350 
806 orf19.6445 ECI1 0.7032 0.3395 
807 orf19.5215 TES15 0.7027 0.3443 
822 orf19.5806 ALD5 0.6926 0.3440 
826 orf19.5635 PGA7 0.6885 0.3477 
890 orf19.2459 C1_05900W_A 0.6547 0.3293 
898 orf19.6143 CR_07250C_A 0.6483 0.3312 
998 orf19.3544 C2_05130W_A 0.6020 0.2994 
1018 orf19.1288 FOX2 0.5924 0.2966 
1066 orf19.3981 MAL31 0.5652 0.2835 
1075 orf19.1800 C4_05440C_A 0.5613 0.2844 
1078 orf19.3369 MOH1 0.5601 0.2876 
1125 orf19.1652 POX1-3 0.5383 0.2746 
1126 orf19.4274 PUT1 0.5375 0.2783 
1130 orf19.732 CR_07170W_A 0.5343 0.2809 
1167 orf19.4504 C2_04480W_A 0.5177 0.2714 
1178 orf19.2887 C4_06470W_A 0.5114 0.2713 
1288 orf19.7520 POT1 0.4463 0.2348 
1299 orf19.3770 ARG8 0.4428 0.2342 
1502 orf19.6840 C1_04470C_A -0.3775 0.1634 
1658 orf19.3282 BMT3 -0.4723 0.1104 
1739 orf19.2909 ERG26 -0.5168 0.0849 
1812 orf19.2515 C3_01130C_A -0.5487 0.0626 
1840 orf19.4476 C1_04010C_A -0.5694 0.0567 
1841 orf19.260 SLD1 -0.5694 0.0606 
1870 orf19.1631 ERG6 -0.5853 0.0545 
1874 orf19.192 C2_04750W_A -0.5875 0.0574 
1896 orf19.1237 ARO9 -0.5971 0.0539 
1973 orf19.6117 CR_07480W_A -0.6246 0.0306 
2000 orf19.4706 C4_00860C_A -0.6382 0.0256 
2042 orf19.1985 CR_07700W_A -0.6587 0.0153 
2044 orf19.2030 C2_00940W_A -0.6589 0.0194 
2068 orf19.7448 LYS9 -0.6746 0.0157 
2158 orf19.5645 MET15 -0.7261 -0.0116 
2188 orf19.4979 KNS1 -0.7426 -0.0170 
2218 orf19.4135 PRC2 -0.7538 -0.0223 
2321 orf19.6757 GCY1 -0.8170 -0.0537 
2491 orf19.7350 RCT1 -0.9633 -0.1084 
2504 orf19.3615 C2_08620W_A -0.9711 -0.1061 
2548 orf19.5379 ERG4 -1.0173 -0.1147 
2571 orf19.5525 C6_02560W_A -1.0454 -0.1155 
2582 orf19.4384 HXT5 -1.0530 -0.1118 
2587 orf19.428 C1_05370C_A -1.0558 -0.1060 
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2598 orf19.675 C1_11270W_A -1.0678 -0.1023 
2648 orf19.6229 CAT1 -1.1311 -0.1123 
2671 orf19.5614 C6_03260W_A -1.1642 -0.1122 
2682 orf19.6081 PHR2 -1.1904 -0.1077 
2686 orf19.4477 CSH1 -1.2046 -0.1004 
2687 orf19.251 GLX3 -1.2052 -0.0921 
2692 orf19.1344 C7_03310W_A -1.2123 -0.0852 
2709 orf19.6139 FRE7 -1.2508 -0.0824 
2728 orf19.2496 ATO2 -1.3134 -0.0799 
2745 orf19.7504 CR_00290W_A -1.3445 -0.0764 
2756 orf19.677 CHO1 -1.3670 -0.0706 
2796 orf19.6350 C1_12720C_A -1.5284 -0.0743 
2810 orf19.3932 C5_04470C_A -1.5870 -0.0680 
2813 orf19.4255 ECM331 -1.5893 -0.0578 
2854 orf19.4082 DDR48 -2.1597 -0.0574 
2857 orf19.7111.1 SOD3 -2.2003 -0.0430 
2863 orf19.3210 C5_04010C_A -2.3082 -0.0289 
2874 orf19.1691 C3_01540W_A -4.7146 0.0000 
 
 
Gene sets with genes enriched in the downregulated group of differentially expressed genes 
These gene sets are for pathways which the GSEA concluded are significantly downregulated 
within 5% CO2 biofilms. The rank in gene list refers to the position of the gene in the overall 
list of significantly differentially expressed genes in this study ranked with regards to log2 fold 
change. The running enrichment score is a running tally as a quantitative measure of how 
much each gene contributes to the overall gene set/pathway being downregulated as 
measured via GSEA. Genes which cause the running enrichment score to increase, known as 
the leading edge subset (green – subsequent to the lowest enrichment score), are those which 














146 orf19.1996 CHA1 1.6194 -0.0158 
694 orf19.3478 NIP7 0.7620 -0.1914 
880 orf19.5025 MET3 0.6624 -0.2419 
1848 orf19.4666 C4_01230C_A -0.5718 -0.5694 
2039 orf19.4456 GAP4 -0.6561 -0.6218 
2224 orf19.7127 TLO16 -0.7578 -0.6699 
2292 orf19.7610 PTP3 -0.7979 -0.6759 
2309 orf19.2769 C4_02340W_A -0.8076 -0.6638 
2371 orf19.6078 POL93 -0.8557 -0.6665 
2529 orf19.2903 AGO1 -0.9934 -0.6803 
2625 orf19.113 CIP1 -1.1047 -0.6894 
2675 orf19.3844 MRP8 -1.1741 -0.6809 
2681 orf19.3374 ECE1 -1.1833 -0.6567 
2691 orf19.2060 SOD5 -1.2121 -0.6333 
2701 orf19.5716 SAP4 -1.2287 -0.6095 
2702 orf19.1321 HWP1 -1.2354 -0.5824 
2774 orf19.2274 C2_07180W_A -1.4185 -0.5762 
2788 orf19.3150 GRE2 -1.4957 -0.5479 
2799 orf19.4054 CTA24 -1.5406 -0.5176 
2808 orf19.2241 PST1 -1.5798 -0.4858 
2811 orf19.125 EBP1 -1.5887 -0.4516 
2815 orf19.3074 TLO10 -1.6051 -0.4175 
2829 orf19.2685 PGA54 -1.7209 -0.3843 
2833 orf19.6021 IHD2 -1.7682 -0.3465 
2850 orf19.6601.1 YKE2 -2.0442 -0.3073 
2854 orf19.4082 DDR48 -2.1597 -0.2610 
2864 orf19.3460 C6_02200C_A -2.3208 -0.2132 
2869 orf19.5674 PGA10 -2.5161 -0.1594 
2870 orf19.7544 TLO1 -2.5977 -0.1024 










402 orf19.6770 C3_07280C_A 1.0229 -0.1265 
558 orf19.4257 INT1 0.8747 -0.1671 
770 orf19.3115 C4_06940C_A 0.7191 -0.2304 
776 orf19.712 KIP1 0.7156 -0.2201 
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896 orf19.670 SMT3 0.6502 -0.2516 
1029 orf19.3295 C1_01070C_A 0.5854 -0.2889 
1048 orf19.7450 C3_06610W_A 0.5722 -0.2857 
1201 orf19.2925 C1_02380C_A 0.4943 -0.3317 
1285 orf19.1671 UTR2 0.4467 -0.3538 
1422 orf19.3206 CCT7 0.3424 -0.3966 
1465 orf19.4927 BNI1 -0.3449 -0.4058 
1472 orf19.4308 HSL1 -0.3497 -0.4020 
1499 orf19.2911 SEC3 -0.3755 -0.4050 
1516 orf19.7201 SLA2 -0.3884 -0.4041 
1563 orf19.2519 CR_01360W_A -0.4213 -0.4135 
1607 orf19.4184 C4_00590C_A -0.4463 -0.4213 
1646 orf19.7537 BNR1 -0.4643 -0.4270 
1663 orf19.3647 SEC8 -0.4737 -0.4247 
1681 orf19.5007 ACT1 -0.4870 -0.4225 
1750 orf19.5015 MYO2 -0.5204 -0.4381 
1780 orf19.4557 C6_04120C_A -0.5361 -0.4394 
1784 orf19.1474 SLA1 -0.5389 -0.4313 
1791 orf19.3251 ARC19 -0.5400 -0.4243 
1836 orf19.4203 C6_00560W_A -0.5675 -0.4304 
1855 orf19.564 KAR3 -0.5771 -0.4271 
1861 orf19.6598 WAL1 -0.5799 -0.4191 
1880 orf19.5463 SEC6 -0.5893 -0.4155 
1895 orf19.7377 ASE1 -0.5961 -0.4105 
1900 orf19.3667 C1_02100W_A -0.5992 -0.4017 
1915 orf19.3013 CDC12 -0.6048 -0.3965 
1917 orf19.6151 ARC15 -0.6057 -0.3866 
1978 orf19.5265 KIP4 -0.6268 -0.3975 
1980 orf19.7293 MPS1 -0.6269 -0.3872 
1981 orf19.1698 C3_01510W_A -0.6269 -0.3766 
2002 orf19.3919 C5_04320C_A -0.6391 -0.3729 
2006 orf19.3680 SEP1 -0.6400 -0.3632 
2024 orf19.5595 SHE3 -0.6492 -0.3583 
2060 orf19.1418 SEC15 -0.6684 -0.3595 
2085 orf19.5544 SAC6 -0.6878 -0.3564 
2088 orf19.5691 CDC11 -0.6891 -0.3455 
2110 orf19.6479 SEC1 -0.6991 -0.3411 
2148 orf19.1223 DBF2 -0.7173 -0.3422 
2152 orf19.6512 EXO70 -0.7208 -0.3311 
2171 orf19.3001 TEM1 -0.7323 -0.3251 
2226 orf19.6414.3 TPM2 -0.7599 -0.3316 
2227 orf19.7292 ARP2 -0.7602 -0.3187 
2235 orf19.3269 GSL2 -0.7648 -0.3083 
2239 orf19.548 CDC10 -0.7654 -0.2964 
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2252 orf19.3873 ARC40 -0.7714 -0.2876 
2256 orf19.505 SRV2 -0.7728 -0.2756 
2283 orf19.2289 ARP3 -0.7895 -0.2716 
2311 orf19.953.1 COF1 -0.8111 -0.2675 
2313 orf19.2480.1 AUT7 -0.8121 -0.2541 
2320 orf19.4395 CR_03520C_A -0.8165 -0.2424 
2332 orf19.3976 C5_04890C_A -0.8273 -0.2324 
2336 orf19.7308 TUB1 -0.8291 -0.2194 
2356 orf19.2642 C5_03370C_A -0.8402 -0.2120 
2365 orf19.6349 RVS162 -0.8493 -0.2004 
2400 orf19.1220 RVS167 -0.8758 -0.1978 
2407 orf19.6148 CR_07220C_A -0.8816 -0.1850 
2457 orf19.6536 IQG1 -0.9316 -0.1868 
2473 orf19.5664 HOF1 -0.9463 -0.1761 
2484 orf19.6168 C3_00910W_A -0.9551 -0.1635 
2487 orf19.1747 KIP2 -0.9596 -0.1480 
2499 orf19.486 NIP100 -0.9673 -0.1355 
2517 orf19.2416.1 MLC1 -0.9818 -0.1250 
2519 orf19.3086 SEC10 -0.9840 -0.1087 
2547 orf19.6034 TUB2 -1.0160 -0.1012 
2550 orf19.2641 ARP1 -1.0180 -0.0847 
2563 orf19.2190 VRP1 -1.0340 -0.0714 
2570 orf19.1055 CDC3 -1.0434 -0.0559 
2578 orf19.2699 ABP1 -1.0507 -0.0406 
2600 orf19.6010 CDC5 -1.0694 -0.0300 
2632 orf19.2228 C2_06770W_A -1.1086 -0.0224 
2673 orf19.4837 DAM1 -1.1666 -0.0169 
2693 orf19.7079 C7_00410C_A -1.2125 -0.0032 
2698 orf19.5827 BUB2 -1.2221 0.0161 
2744 orf19.676 C1_11250W_A -1.3444 0.0227 










194 orf19.2133 LIP4 1.4493 -0.0522 
438 orf19.449 C1_05160C_A 0.9844 -0.1277 
495 orf19.7394 GDA1 0.9279 -0.1365 
499 orf19.1880 HEM15 0.9255 -0.1263 
519 orf19.1736 CR_04680C_A 0.9104 -0.1220 
624 orf19.2302 C1_11140W_A 0.8169 -0.1495 
629 orf19.1888 C2_07430C_A 0.8144 -0.1410 
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727 orf19.4959 C1_13320C_A 0.7415 -0.1669 
729 orf19.3694 C1_02370C_A 0.7402 -0.1582 
795 orf19.5551 MIF2 0.7086 -0.1729 
799 orf19.2347 MNN2 0.7060 -0.1654 
975 orf19.7564 DPB2 0.6134 -0.2209 
1054 orf19.1666 C3_01800C_A 0.5686 -0.2421 
1197 orf19.7083 DCC1 0.4972 -0.2872 
1270 orf19.3715 ASF1 0.4536 -0.3076 
1405 orf19.4603 ARL1 0.3596 -0.3514 
1437 orf19.926 EXO1 0.3202 -0.3587 
1454 orf19.1777 C2_10050W_A -0.3269 -0.3605 
1460 orf19.5147 LMO1 -0.3392 -0.3581 
1463 orf19.5089 TERT -0.3417 -0.3547 
1472 orf19.4308 HSL1 -0.3497 -0.3533 
1492 orf19.4105 CSM3 -0.3709 -0.3556 
1518 orf19.2216 PDS5 -0.3915 -0.3598 
1524 orf19.7224 C1_14170W_A -0.3977 -0.3567 
1569 orf19.5804 HYU1 -0.4241 -0.3674 
1581 orf19.1605 PMS1 -0.4303 -0.3661 
1643 orf19.1390 PMI1 -0.4633 -0.3824 
1703 orf19.7186 CLB4 -0.5005 -0.3976 
1742 orf19.7106 VPS70 -0.5184 -0.4049 
1758 orf19.652 CR_05010W_A -0.5240 -0.4039 
1783 orf19.7065 PSF3 -0.5377 -0.4060 
1803 orf19.771 LPG20 -0.5448 -0.4062 
1811 orf19.7631 SLD5 -0.5479 -0.4020 
1876 orf19.658 GIN1 -0.5877 -0.4178 
1900 orf19.3667 C1_02100W_A -0.5992 -0.4188 
1908 orf19.4136 YBL053 -0.6030 -0.4140 
1937 orf19.3319 C1_01300W_A -0.6131 -0.4165 
1943 orf19.3266 CR_00880W_A -0.6147 -0.4108 
1959 orf19.3322 DUT1 -0.6198 -0.4086 
1977 orf19.4945 MSH6 -0.6250 -0.4071 
2003 orf19.6049 C1_00570C_A -0.6392 -0.4083 
2005 orf19.1208 C4_03990C_A -0.6397 -0.4009 
2022 orf19.6671 LAP4 -0.6465 -0.3987 
2024 orf19.5595 SHE3 -0.6492 -0.3911 
2042 orf19.1985 CR_07700W_A -0.6587 -0.3892 
2045 orf19.4712 FGR6-3 -0.6599 -0.3818 
2047 orf19.6434 PEX19 -0.6610 -0.3741 
2057 orf19.1889 C2_07420W_A -0.6673 -0.3692 
2070 orf19.7634 MCD1 -0.6771 -0.3652 
2091 orf19.262 SMC3 -0.6895 -0.3640 
2096 orf19.7632 CR_10530W_A -0.6922 -0.3570 
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2107 orf19.4616 POL30 -0.6973 -0.3521 
2121 orf19.5775 C6_03990C_A -0.7036 -0.3481 
2122 orf19.6670 CAC2 -0.7039 -0.3395 
2123 orf19.2267 RFA2 -0.7042 -0.3309 
2167 orf19.7425 C3_06400C_A -0.7301 -0.3375 
2222 orf19.7409 ERV25 -0.7568 -0.3477 
2237 orf19.5191 FGR6-1 -0.7650 -0.3434 
2238 orf19.3239 CTF18 -0.7652 -0.3340 
2239 orf19.548 CDC10 -0.7654 -0.3247 
2257 orf19.4346 C5_03140C_A -0.7731 -0.3213 
2276 orf19.1340 C7_03350C_A -0.7857 -0.3182 
2282 orf19.7494 MMS22 -0.7892 -0.3103 
2285 orf19.4162 MLH1 -0.7916 -0.3014 
2288 orf19.7578 CR_10020C_A -0.7960 -0.2924 
2293 orf19.3581 C2_05510C_A -0.7981 -0.2840 
2312 orf19.5041 C4_03860C_A -0.8118 -0.2806 
2314 orf19.1823 C1_06270W_A -0.8134 -0.2710 
2322 orf19.5622 GLC3 -0.8172 -0.2635 
2364 orf19.1427 C4_04230W_A -0.8491 -0.2679 
2380 orf19.6813 C3_06880W_A -0.8617 -0.2628 
2383 orf19.3501 C6_02090C_A -0.8633 -0.2529 
2384 orf19.5841 C2_02660W_A -0.8644 -0.2424 
2408 orf19.3296 C1_01080W_A -0.8844 -0.2398 
2435 orf19.1825 C1_06250W_A -0.9073 -0.2381 
2444 orf19.687 C6_01960W_A -0.9151 -0.2298 
2471 orf19.2093 RFA1 -0.9454 -0.2276 
2479 orf19.338 C3_03410C_A -0.9523 -0.2185 
2485 orf19.2029 RFC5 -0.9578 -0.2086 
2486 orf19.2863 CR_03000C_A -0.9590 -0.1968 
2503 orf19.4830 C1_09670C_A -0.9706 -0.1907 
2535 orf19.3490 FGR6-4 -1.0024 -0.1896 
2539 orf19.727 CR_06380C_A -1.0036 -0.1784 
2540 orf19.6247 C1_06630W_A -1.0064 -0.1661 
2575 orf19.4664 NAT4 -1.0485 -0.1656 
2581 orf19.3649 C6_00760W_A -1.0528 -0.1545 
2584 orf19.5579 C6_03000C_A -1.0548 -0.1423 
2626 orf19.7453 C3_06640W_A -1.1051 -0.1436 
2630 orf19.2657 C5_03210C_A -1.1067 -0.1311 
2634 orf19.3093 MSH2 -1.1103 -0.1186 
2653 orf19.1738 UGP1 -1.1394 -0.1111 
2694 orf19.4867 SWE1 -1.2140 -0.1107 
2708 orf19.403 PCL2 -1.2505 -0.1001 
2762 orf19.244 DCG1 -1.3790 -0.1023 
2776 orf19.3207 CCN1 -1.4235 -0.0896 
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2808 orf19.2241 PST1 -1.5798 -0.0814 
2813 orf19.4255 ECM331 -1.5893 -0.0634 
2851 orf19.2649 PCL1 -2.0641 -0.0515 
2865 orf19.7017 YOX1 -2.3578 -0.0274 
2868 orf19.3740 PGA23 -2.4731 0.0022 
 
 
 
